id	sid	tid	token	lemma	pos
iajs-3010	1	1	ihjpas	ihjpas	PROPN
iajs-3010	1	2	.	.	PUNCT
iajs-3010	2	1	36(2)2023	36(2)2023	NUM
iajs-3010	2	2	33	33	NUM
iajs-3010	2	3	this	this	DET
iajs-3010	2	4	work	work	NOUN
iajs-3010	2	5	is	be	AUX
iajs-3010	2	6	licensed	license	VERB
iajs-3010	2	7	under	under	ADP
iajs-3010	2	8	a	a	DET
iajs-3010	2	9	creative	creative	ADJ
iajs-3010	2	10	commons	common	NOUN
iajs-3010	2	11	attribution	attribution	NOUN
iajs-3010	2	12	4.0	4.0	NUM
iajs-3010	2	13	international	international	ADJ
iajs-3010	2	14	license	license	NOUN
iajs-3010	2	15	.	.	PUNCT
iajs-3010	3	1	abstract	abstract	ADV
iajs-3010	3	2	a	a	DET
iajs-3010	3	3	skin	skin	NOUN
iajs-3010	3	4	condition	condition	NOUN
iajs-3010	3	5	known	know	VERB
iajs-3010	3	6	as	as	ADP
iajs-3010	3	7	chronic	chronic	ADJ
iajs-3010	3	8	spontaneous	spontaneous	ADJ
iajs-3010	3	9	urticaria	urticaria	NOUN
iajs-3010	3	10	(	(	PUNCT
iajs-3010	3	11	csu	csu	PROPN
iajs-3010	3	12	)	)	PUNCT
iajs-3010	3	13	,	,	PUNCT
iajs-3010	3	14	which	which	PRON
iajs-3010	3	15	lacks	lack	VERB
iajs-3010	3	16	an	an	DET
iajs-3010	3	17	obvious	obvious	ADJ
iajs-3010	3	18	triggering	trigger	VERB
iajs-3010	3	19	factor	factor	NOUN
iajs-3010	3	20	,	,	PUNCT
iajs-3010	3	21	is	be	AUX
iajs-3010	3	22	characterized	characterize	VERB
iajs-3010	3	23	by	by	ADP
iajs-3010	3	24	recurrent	recurrent	ADJ
iajs-3010	3	25	transient	transient	ADJ
iajs-3010	3	26	wheals	wheal	NOUN
iajs-3010	3	27	,	,	PUNCT
iajs-3010	3	28	angioedema	angioedema	VERB
iajs-3010	3	29	,	,	PUNCT
iajs-3010	3	30	or	or	CCONJ
iajs-3010	3	31	both	both	PRON
iajs-3010	3	32	for	for	ADP
iajs-3010	3	33	longer	long	ADJ
iajs-3010	3	34	than	than	ADP
iajs-3010	3	35	six	six	NUM
iajs-3010	3	36	weeks	week	NOUN
iajs-3010	3	37	.	.	PUNCT
iajs-3010	4	1	the	the	DET
iajs-3010	4	2	current	current	ADJ
iajs-3010	4	3	study	study	NOUN
iajs-3010	4	4	was	be	AUX
iajs-3010	4	5	focused	focus	VERB
iajs-3010	4	6	to	to	PART
iajs-3010	4	7	study	study	VERB
iajs-3010	4	8	compared	compare	VERB
iajs-3010	4	9	and	and	CCONJ
iajs-3010	4	10	diagnosis	diagnosis	NOUN
iajs-3010	4	11	csu	csu	VERB
iajs-3010	4	12	by	by	ADP
iajs-3010	4	13	using	use	VERB
iajs-3010	4	14	heamatological	heamatological	ADJ
iajs-3010	4	15	and	and	CCONJ
iajs-3010	4	16	immunological	immunological	ADJ
iajs-3010	4	17	parameters	parameter	NOUN
iajs-3010	4	18	as	as	ADP
iajs-3010	4	19	(	(	PUNCT
iajs-3010	4	20	white	white	ADJ
iajs-3010	4	21	blood	blood	NOUN
iajs-3010	4	22	cell	cell	NOUN
iajs-3010	4	23	count	count	NOUN
iajs-3010	4	24	,	,	PUNCT
iajs-3010	4	25	eosinophils	eosinophil	NOUN
iajs-3010	4	26	(	(	PUNCT
iajs-3010	4	27	eo	eo	NOUN
iajs-3010	4	28	)	)	PUNCT
iajs-3010	4	29	,	,	PUNCT
iajs-3010	4	30	il-6	il-6	NUM
iajs-3010	4	31	and	and	CCONJ
iajs-3010	4	32	total	total	NOUN
iajs-3010	4	33	-	-	PUNCT
iajs-3010	4	34	ige	ige	NOUN
iajs-3010	4	35	,	,	PUNCT
iajs-3010	4	36	in	in	ADP
iajs-3010	4	37	chronic	chronic	ADJ
iajs-3010	4	38	urticaria	urticaria	NOUN
iajs-3010	4	39	patients	patient	NOUN
iajs-3010	4	40	were	be	AUX
iajs-3010	4	41	clinically	clinically	ADV
iajs-3010	4	42	diagnosed	diagnose	VERB
iajs-3010	4	43	by	by	ADP
iajs-3010	4	44	dermatologists	dermatologist	NOUN
iajs-3010	4	45	in	in	ADP
iajs-3010	4	46	specialized	specialized	ADJ
iajs-3010	4	47	center	center	NOUN
iajs-3010	4	48	of	of	ADP
iajs-3010	4	49	allergy	allergy	NOUN
iajs-3010	4	50	in	in	ADP
iajs-3010	4	51	baghdad	baghdad	PROPN
iajs-3010	4	52	/	/	SYM
iajs-3010	4	53	al	al	PROPN
iajs-3010	4	54	-	-	PUNCT
iajs-3010	4	55	rusafa	rusafa	PROPN
iajs-3010	4	56	with	with	ADP
iajs-3010	4	57	age	age	NOUN
iajs-3010	4	58	ranged	range	VERB
iajs-3010	4	59	between	between	ADP
iajs-3010	4	60	(	(	PUNCT
iajs-3010	4	61	11	11	NUM
iajs-3010	4	62	-	-	SYM
iajs-3010	4	63	60	60	NUM
iajs-3010	4	64	)	)	PUNCT
iajs-3010	4	65	,	,	PUNCT
iajs-3010	4	66	as	as	ADV
iajs-3010	4	67	well	well	ADV
iajs-3010	4	68	as	as	ADP
iajs-3010	4	69	a	a	DET
iajs-3010	4	70	control	control	NOUN
iajs-3010	4	71	group	group	NOUN
iajs-3010	4	72	included	include	VERB
iajs-3010	4	73	40	40	NUM
iajs-3010	4	74	with	with	ADP
iajs-3010	4	75	age	age	NOUN
iajs-3010	4	76	ranged	range	VERB
iajs-3010	4	77	between	between	ADP
iajs-3010	4	78	(	(	PUNCT
iajs-3010	4	79	11	11	NUM
iajs-3010	4	80	-	-	SYM
iajs-3010	4	81	60	60	NUM
iajs-3010	4	82	)	)	PUNCT
iajs-3010	4	83	.	.	PUNCT
iajs-3010	5	1	the	the	DET
iajs-3010	5	2	results	result	NOUN
iajs-3010	5	3	of	of	ADP
iajs-3010	5	4	demographic	demographic	ADJ
iajs-3010	5	5	and	and	CCONJ
iajs-3010	5	6	clinical	clinical	ADJ
iajs-3010	5	7	characteristics	characteristic	NOUN
iajs-3010	5	8	displayed	display	VERB
iajs-3010	5	9	the	the	DET
iajs-3010	5	10	rate	rate	NOUN
iajs-3010	5	11	of	of	ADP
iajs-3010	5	12	female	female	ADJ
iajs-3010	5	13	patients	patient	NOUN
iajs-3010	5	14	was	be	AUX
iajs-3010	5	15	higher	high	ADJ
iajs-3010	5	16	than	than	ADP
iajs-3010	5	17	male	male	NOUN
iajs-3010	5	18	which	which	PRON
iajs-3010	5	19	represented	represent	VERB
iajs-3010	5	20	by	by	ADP
iajs-3010	5	21	56.3	56.3	NUM
iajs-3010	5	22	and	and	CCONJ
iajs-3010	5	23	43.8	43.8	NUM
iajs-3010	5	24	%	%	NOUN
iajs-3010	5	25	respectively	respectively	ADV
iajs-3010	5	26	.	.	PUNCT
iajs-3010	6	1	the	the	DET
iajs-3010	6	2	results	result	NOUN
iajs-3010	6	3	showed	show	VERB
iajs-3010	6	4	there	there	PRON
iajs-3010	6	5	was	be	VERB
iajs-3010	6	6	highly	highly	ADV
iajs-3010	6	7	significant	significant	ADJ
iajs-3010	6	8	differences	difference	NOUN
iajs-3010	6	9	between	between	ADP
iajs-3010	6	10	the	the	DET
iajs-3010	6	11	patients	patient	NOUN
iajs-3010	6	12	and	and	CCONJ
iajs-3010	6	13	the	the	DET
iajs-3010	6	14	control	control	NOUN
iajs-3010	6	15	in	in	ADP
iajs-3010	6	16	wbc	wbc	PROPN
iajs-3010	6	17	,	,	PUNCT
iajs-3010	6	18	total	total	ADJ
iajs-3010	6	19	-	-	PUNCT
iajs-3010	6	20	ige	ige	NOUN
iajs-3010	6	21	,	,	PUNCT
iajs-3010	6	22	il-6	il-6	PRON
iajs-3010	6	23	the	the	DET
iajs-3010	6	24	results	result	NOUN
iajs-3010	6	25	showed	show	VERB
iajs-3010	6	26	eo	eo	PROPN
iajs-3010	6	27	was	be	AUX
iajs-3010	6	28	higher	high	ADJ
iajs-3010	6	29	than	than	ADP
iajs-3010	6	30	control	control	NOUN
iajs-3010	6	31	but	but	CCONJ
iajs-3010	6	32	no	no	DET
iajs-3010	6	33	significant	significant	ADJ
iajs-3010	6	34	difference	difference	NOUN
iajs-3010	6	35	at	at	ADP
iajs-3010	6	36	p	p	NOUN
iajs-3010	6	37	≤	≤	NUM
iajs-3010	6	38	0.05	0.05	NUM
iajs-3010	6	39	.	.	PUNCT
iajs-3010	7	1	the	the	DET
iajs-3010	7	2	eosinophils	eosinophil	NOUN
iajs-3010	7	3	percentage	percentage	NOUN
iajs-3010	7	4	was	be	AUX
iajs-3010	7	5	high	high	ADJ
iajs-3010	7	6	in	in	ADP
iajs-3010	7	7	age	age	NOUN
iajs-3010	7	8	51	51	NUM
iajs-3010	7	9	-	-	SYM
iajs-3010	7	10	60	60	NUM
iajs-3010	7	11	and	and	CCONJ
iajs-3010	7	12	21	21	NUM
iajs-3010	7	13	-	-	SYM
iajs-3010	7	14	30	30	NUM
iajs-3010	7	15	year	year	NOUN
iajs-3010	7	16	while	while	SCONJ
iajs-3010	7	17	those	those	PRON
iajs-3010	7	18	with	with	ADP
iajs-3010	7	19	age	age	NOUN
iajs-3010	7	20	41	41	NUM
iajs-3010	7	21	-	-	SYM
iajs-3010	7	22	50	50	NUM
iajs-3010	7	23	and	and	CCONJ
iajs-3010	7	24	51	51	NUM
iajs-3010	7	25	-	-	SYM
iajs-3010	7	26	60	60	NUM
iajs-3010	7	27	year	year	NOUN
iajs-3010	7	28	had	have	VERB
iajs-3010	7	29	highest	high	ADJ
iajs-3010	7	30	,	,	PUNCT
iajs-3010	7	31	totalige	totalige	NOUN
iajs-3010	7	32	level	level	NOUN
iajs-3010	7	33	211.7	211.7	NUM
iajs-3010	7	34	±38.96	±38.96	NOUN
iajs-3010	7	35	iu	iu	PROPN
iajs-3010	7	36	/	/	SYM
iajs-3010	7	37	ml	ml	NOUN
iajs-3010	7	38	,	,	PUNCT
iajs-3010	7	39	211.69	211.69	NUM
iajs-3010	7	40	±38.71iu	±38.71iu	VERB
iajs-3010	7	41	/	/	SYM
iajs-3010	7	42	ml	ml	X
iajs-3010	7	43	respectively	respectively	ADV
iajs-3010	7	44	but	but	CCONJ
iajs-3010	7	45	il-6	il-6	NUM
iajs-3010	7	46	level	level	NOUN
iajs-3010	7	47	was	be	AUX
iajs-3010	7	48	highest	high	ADJ
iajs-3010	7	49	26.4	26.4	NUM
iajs-3010	7	50	±1.77	±1.77	NOUN
iajs-3010	7	51	pg	pg	NOUN
iajs-3010	7	52	/	/	SYM
iajs-3010	7	53	ml	ml	X
iajs-3010	7	54	in	in	ADP
iajs-3010	7	55	patients	patient	NOUN
iajs-3010	7	56	with	with	ADP
iajs-3010	7	57	age	age	NOUN
iajs-3010	7	58	group	group	NOUN
iajs-3010	7	59	21	21	NUM
iajs-3010	7	60	-	-	SYM
iajs-3010	7	61	30	30	NUM
iajs-3010	7	62	year	year	NOUN
iajs-3010	7	63	.	.	PUNCT
iajs-3010	8	1	wbc	wbc	PROPN
iajs-3010	8	2	count	count	NOUN
iajs-3010	8	3	in	in	ADP
iajs-3010	8	4	age	age	NOUN
iajs-3010	8	5	41	41	NUM
iajs-3010	8	6	-	-	SYM
iajs-3010	8	7	50	50	NUM
iajs-3010	8	8	and	and	CCONJ
iajs-3010	8	9	51	51	NUM
iajs-3010	8	10	-	-	SYM
iajs-3010	8	11	60	60	NUM
iajs-3010	8	12	year	year	NOUN
iajs-3010	8	13	showed	show	VERB
iajs-3010	8	14	highest	high	ADJ
iajs-3010	8	15	count	count	NOUN
iajs-3010	8	16	9.2	9.2	NUM
iajs-3010	8	17	±1.34	±1.34	NOUN
iajs-3010	8	18	cell	cell	NOUN
iajs-3010	8	19	/	/	SYM
iajs-3010	8	20	cm³blood	cm³blood	NOUN
iajs-3010	8	21	,	,	PUNCT
iajs-3010	8	22	9.3±1.21	9.3±1.21	NUM
iajs-3010	8	23	cell	cell	NOUN
iajs-3010	8	24	/	/	SYM
iajs-3010	8	25	cm³blood	cm³blood	NOUN
iajs-3010	8	26	respectively	respectively	ADV
iajs-3010	8	27	.	.	PUNCT
iajs-3010	9	1	in	in	ADP
iajs-3010	9	2	same	same	ADJ
iajs-3010	9	3	time	time	NOUN
iajs-3010	9	4	doi.org/10.30526/36.2.3010	doi.org/10.30526/36.2.3010	NOUN
iajs-3010	9	5	article	article	NOUN
iajs-3010	9	6	history	history	NOUN
iajs-3010	9	7	:	:	PUNCT
iajs-3010	9	8	received	receive	VERB
iajs-3010	9	9	12	12	NUM
iajs-3010	9	10	september	september	PROPN
iajs-3010	9	11	2022	2022	NUM
iajs-3010	9	12	,	,	PUNCT
iajs-3010	9	13	accepted	accept	VERB
iajs-3010	9	14	23	23	NUM
iajs-3010	9	15	october2022	october2022	PROPN
iajs-3010	9	16	,	,	PUNCT
iajs-3010	9	17	published	publish	VERB
iajs-3010	9	18	in	in	ADP
iajs-3010	9	19	april	april	PROPN
iajs-3010	9	20	2023	2023	NUM
iajs-3010	9	21	.	.	PUNCT
iajs-3010	10	1	ibn	ibn	PROPN
iajs-3010	10	2	al	al	PROPN
iajs-3010	10	3	-	-	PUNCT
iajs-3010	10	4	haitham	haitham	PROPN
iajs-3010	10	5	journal	journal	PROPN
iajs-3010	10	6	for	for	ADP
iajs-3010	10	7	pure	pure	ADJ
iajs-3010	10	8	and	and	CCONJ
iajs-3010	10	9	applied	applied	ADJ
iajs-3010	10	10	sciences	sciences	PROPN
iajs-3010	10	11	journal	journal	PROPN
iajs-3010	10	12	homepage	homepage	NOUN
iajs-3010	10	13	:	:	PUNCT
iajs-3010	10	14	jih.uobaghdad.edu.iq	jih.uobaghdad.edu.iq	NOUN
iajs-3010	10	15	evaluation	evaluation	NOUN
iajs-3010	10	16	of	of	ADP
iajs-3010	10	17	il-6	il-6	NUM
iajs-3010	10	18	and	and	CCONJ
iajs-3010	10	19	ige	ige	PROPN
iajs-3010	10	20	levels	level	NOUN
iajs-3010	10	21	in	in	ADP
iajs-3010	10	22	iraqi	iraqi	ADJ
iajs-3010	10	23	patients	patient	NOUN
iajs-3010	10	24	with	with	ADP
iajs-3010	10	25	chronic	chronic	ADJ
iajs-3010	10	26	spontaneous	spontaneous	ADJ
iajs-3010	10	27	urticaria	urticaria	NOUN
iajs-3010	10	28	(	(	PUNCT
iajs-3010	10	29	csu	csu	PROPN
iajs-3010	10	30	)	)	PUNCT
iajs-3010	10	31	in	in	ADP
iajs-3010	10	32	baghdad	baghdad	PROPN
iajs-3010	10	33	,	,	PUNCT
iajs-3010	10	34	iraq	iraq	PROPN
iajs-3010	10	35	.	.	PUNCT
iajs-3010	11	1	riyam	riyam	PROPN
iajs-3010	11	2	ahmed	ahmed	PROPN
iajs-3010	11	3	saber	saber	PROPN
iajs-3010	11	4	al	al	PROPN
iajs-3010	11	5	-	-	PUNCT
iajs-3010	11	6	sofy	sofy	PROPN
iajs-3010	11	7	department	department	PROPN
iajs-3010	11	8	of	of	ADP
iajs-3010	11	9	biology	biology	NOUN
iajs-3010	11	10	,	,	PUNCT
iajs-3010	11	11	college	college	NOUN
iajs-3010	11	12	of	of	ADP
iajs-3010	11	13	science	science	NOUN
iajs-3010	11	14	for	for	ADP
iajs-3010	11	15	women	woman	NOUN
iajs-3010	11	16	,	,	PUNCT
iajs-3010	11	17	university	university	NOUN
iajs-3010	11	18	of	of	ADP
iajs-3010	11	19	baghdad	baghdad	PROPN
iajs-3010	11	20	,	,	PUNCT
iajs-3010	11	21	iraq	iraq	PROPN
iajs-3010	11	22	.	.	PUNCT
iajs-3010	12	1	rayam.ahmed1202a@csw.uobaghdad.edu.iq	rayam.ahmed1202a@csw.uobaghdad.edu.iq	ADJ
iajs-3010	12	2	talib	talib	PROPN
iajs-3010	12	3	abdullah	abdullah	PROPN
iajs-3010	12	4	hussein	hussein	PROPN
iajs-3010	12	5	department	department	PROPN
iajs-3010	12	6	of	of	ADP
iajs-3010	12	7	biology	biology	NOUN
iajs-3010	12	8	,	,	PUNCT
iajs-3010	12	9	college	college	NOUN
iajs-3010	12	10	of	of	ADP
iajs-3010	12	11	science	science	NOUN
iajs-3010	12	12	for	for	ADP
iajs-3010	12	13	women	woman	NOUN
iajs-3010	12	14	,	,	PUNCT
iajs-3010	12	15	university	university	NOUN
iajs-3010	12	16	of	of	ADP
iajs-3010	12	17	baghdad	baghdad	PROPN
iajs-3010	12	18	,	,	PUNCT
iajs-3010	12	19	iraq	iraq	PROPN
iajs-3010	12	20	.	.	PUNCT
iajs-3010	13	1	talibah_bio@csw.uobaghdad.edu.iq	talibah_bio@csw.uobaghdad.edu.iq	NOUN
iajs-3010	13	2	suaad	suaad	NOUN
iajs-3010	13	3	almas	almas	PROPN
iajs-3010	13	4	.	.	PUNCT
iajs-3010	14	1	brakhas	brakhas	PROPN
iajs-3010	14	2	department	department	PROPN
iajs-3010	14	3	of	of	ADP
iajs-3010	14	4	immunology	immunology	NOUN
iajs-3010	14	5	–	–	PUNCT
iajs-3010	14	6	allergy	allergy	NOUN
iajs-3010	14	7	specialized	specialized	ADJ
iajs-3010	14	8	center	center	NOUN
iajs-3010	14	9	,	,	PUNCT
iajs-3010	14	10	baghdad	baghdad	PROPN
iajs-3010	14	11	/	/	SYM
iajs-3010	14	12	iraq	iraq	PROPN
iajs-3010	14	13	.	.	PUNCT
iajs-3010	15	1	su_azimmune@yahoo.com	su_azimmune@yahoo.com	PROPN
iajs-3010	15	2	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
iajs-3010	15	3	mailto:rayam.ahmed1202a@csw.uobaghdad.edu.iq	mailto:rayam.ahmed1202a@csw.uobaghdad.edu.iq	NOUN
iajs-3010	15	4	mailto:talibah_bio@csw.uobaghdad.edu.iq	mailto:talibah_bio@csw.uobaghdad.edu.iq	NOUN
iajs-3010	15	5	mailto:su_azimmune@yahoo.com	mailto:su_azimmune@yahoo.com	NOUN
iajs-3010	15	6	ihjpas	ihjpa	VERB
iajs-3010	15	7	.	.	PUNCT
iajs-3010	16	1	36(2)2023	36(2)2023	NUM
iajs-3010	16	2	34	34	NUM
iajs-3010	16	3	the	the	DET
iajs-3010	16	4	values	value	NOUN
iajs-3010	16	5	of	of	ADP
iajs-3010	16	6	parameters	parameter	NOUN
iajs-3010	16	7	were	be	AUX
iajs-3010	16	8	various	various	ADJ
iajs-3010	16	9	between	between	ADP
iajs-3010	16	10	patients	patient	NOUN
iajs-3010	16	11	without	without	ADP
iajs-3010	16	12	treatment	treatment	NOUN
iajs-3010	16	13	and	and	CCONJ
iajs-3010	16	14	in	in	ADP
iajs-3010	16	15	patients	patient	NOUN
iajs-3010	16	16	who	who	PRON
iajs-3010	16	17	undergoes	undergo	VERB
iajs-3010	16	18	into	into	ADP
iajs-3010	16	19	treatment	treatment	NOUN
iajs-3010	16	20	,	,	PUNCT
iajs-3010	16	21	finally	finally	ADV
iajs-3010	16	22	the	the	DET
iajs-3010	16	23	roc	roc	PROPN
iajs-3010	16	24	showed	show	VERB
iajs-3010	16	25	the	the	DET
iajs-3010	16	26	il-6	il-6	NOUN
iajs-3010	16	27	and	and	CCONJ
iajs-3010	16	28	total	total	NOUN
iajs-3010	16	29	-	-	PUNCT
iajs-3010	16	30	ige	ige	PROPN
iajs-3010	16	31	were	be	AUX
iajs-3010	16	32	discriminated	discriminate	VERB
iajs-3010	16	33	as	as	ADP
iajs-3010	16	34	accurate	accurate	ADJ
iajs-3010	16	35	biomarkers	biomarker	NOUN
iajs-3010	16	36	for	for	ADP
iajs-3010	16	37	csu	csu	PROPN
iajs-3010	16	38	.	.	PUNCT
iajs-3010	17	1	keywords	keyword	NOUN
iajs-3010	17	2	:	:	PUNCT
iajs-3010	17	3	wbc	wbc	ADJ
iajs-3010	17	4	,	,	PUNCT
iajs-3010	17	5	eosinophils	eosinophil	VERB
iajs-3010	17	6	(	(	PUNCT
iajs-3010	17	7	eo	eo	NOUN
iajs-3010	17	8	)	)	PUNCT
iajs-3010	17	9	,	,	PUNCT
iajs-3010	17	10	il-6	il-6	NUM
iajs-3010	17	11	and	and	CCONJ
iajs-3010	17	12	total	total	NOUN
iajs-3010	17	13	-	-	PUNCT
iajs-3010	17	14	ige	ige	NOUN
iajs-3010	17	15	,	,	PUNCT
iajs-3010	17	16	cus	cus	NOUN
iajs-3010	17	17	and	and	CCONJ
iajs-3010	17	18	age	age	NOUN
iajs-3010	17	19	.	.	PUNCT
iajs-3010	18	1	1.introduction	1.introduction	NUM
iajs-3010	18	2	chronic	chronic	ADJ
iajs-3010	18	3	urticaria	urticaria	NOUN
iajs-3010	18	4	(	(	PUNCT
iajs-3010	18	5	cu	cu	PROPN
iajs-3010	18	6	)	)	PUNCT
iajs-3010	18	7	is	be	AUX
iajs-3010	18	8	the	the	DET
iajs-3010	18	9	occurrence	occurrence	NOUN
iajs-3010	18	10	of	of	ADP
iajs-3010	18	11	symptoms	symptom	NOUN
iajs-3010	18	12	for	for	ADP
iajs-3010	18	13	more	more	ADJ
iajs-3010	18	14	than	than	ADP
iajs-3010	18	15	6	6	NUM
iajs-3010	18	16	weeks	week	NOUN
iajs-3010	18	17	[	[	X
iajs-3010	18	18	1]the	1]the	DET
iajs-3010	18	19	chronic	chronic	ADJ
iajs-3010	18	20	urticaria	urticaria	NOUN
iajs-3010	18	21	is	be	AUX
iajs-3010	18	22	classified	classify	VERB
iajs-3010	18	23	into	into	ADP
iajs-3010	18	24	two	two	NUM
iajs-3010	18	25	subclasses	subclass	NOUN
iajs-3010	18	26	,	,	PUNCT
iajs-3010	18	27	the	the	DET
iajs-3010	18	28	first	first	ADJ
iajs-3010	18	29	class	class	NOUN
iajs-3010	18	30	is	be	AUX
iajs-3010	18	31	chronic	chronic	ADJ
iajs-3010	18	32	inducible	inducible	ADJ
iajs-3010	18	33	urticaria	urticaria	NOUN
iajs-3010	18	34	(	(	PUNCT
iajs-3010	18	35	cindu	cindu	NOUN
iajs-3010	18	36	)	)	PUNCT
iajs-3010	18	37	,	,	PUNCT
iajs-3010	18	38	while	while	SCONJ
iajs-3010	18	39	the	the	DET
iajs-3010	18	40	second	second	ADJ
iajs-3010	18	41	one	one	NOUN
iajs-3010	18	42	is	be	AUX
iajs-3010	18	43	chronic	chronic	ADJ
iajs-3010	18	44	spontaneous	spontaneous	ADJ
iajs-3010	18	45	urticaria	urticaria	NOUN
iajs-3010	18	46	(	(	PUNCT
iajs-3010	18	47	csu	csu	PROPN
iajs-3010	18	48	)	)	PUNCT
iajs-3010	18	49	is	be	AUX
iajs-3010	18	50	marked	mark	VERB
iajs-3010	18	51	by	by	ADP
iajs-3010	18	52	angioedema	angioedema	NOUN
iajs-3010	18	53	and	and	CCONJ
iajs-3010	18	54	the	the	DET
iajs-3010	18	55	appearance	appearance	NOUN
iajs-3010	18	56	of	of	ADP
iajs-3010	18	57	wheals	wheal	NOUN
iajs-3010	18	58	for	for	ADP
iajs-3010	18	59	more	more	ADJ
iajs-3010	18	60	than	than	ADP
iajs-3010	18	61	six	six	NUM
iajs-3010	18	62	weeks	week	NOUN
iajs-3010	18	63	in	in	ADP
iajs-3010	18	64	both	both	DET
iajs-3010	18	65	adults	adult	NOUN
iajs-3010	18	66	and	and	CCONJ
iajs-3010	18	67	children	child	NOUN
iajs-3010	18	68	.	.	PUNCT
iajs-3010	19	1	this	this	DET
iajs-3010	19	2	subtype	subtype	NOUN
iajs-3010	19	3	is	be	AUX
iajs-3010	19	4	appear	appear	VERB
iajs-3010	19	5	spontaneously	spontaneously	ADV
iajs-3010	19	6	without	without	ADP
iajs-3010	19	7	unknown	unknown	ADJ
iajs-3010	19	8	causes	cause	NOUN
iajs-3010	19	9	[	[	X
iajs-3010	19	10	2].there	2].there	NUM
iajs-3010	19	11	are	be	VERB
iajs-3010	19	12	many	many	ADJ
iajs-3010	19	13	mechanisms	mechanism	NOUN
iajs-3010	19	14	that	that	PRON
iajs-3010	19	15	may	may	AUX
iajs-3010	19	16	be	be	AUX
iajs-3010	19	17	contributed	contribute	VERB
iajs-3010	19	18	to	to	ADP
iajs-3010	19	19	the	the	DET
iajs-3010	19	20	pathogenesis	pathogenesis	NOUN
iajs-3010	19	21	of	of	ADP
iajs-3010	19	22	csu	csu	PROPN
iajs-3010	19	23	such	such	ADJ
iajs-3010	19	24	as	as	ADP
iajs-3010	19	25	infections	infection	NOUN
iajs-3010	19	26	,	,	PUNCT
iajs-3010	19	27	food	food	NOUN
iajs-3010	19	28	allergy	allergy	NOUN
iajs-3010	19	29	,	,	PUNCT
iajs-3010	19	30	coagulation	coagulation	NOUN
iajs-3010	19	31	cascade	cascade	NOUN
iajs-3010	19	32	and	and	CCONJ
iajs-3010	19	33	autoimmunity	autoimmunity	NOUN
iajs-3010	20	1	[	[	X
iajs-3010	20	2	3	3	NUM
iajs-3010	20	3	]	]	PUNCT
iajs-3010	20	4	.	.	PUNCT
iajs-3010	21	1	in	in	ADP
iajs-3010	21	2	csu	csu	PROPN
iajs-3010	21	3	type	type	NOUN
iajs-3010	21	4	i	i	PRON
iajs-3010	21	5	hypersensitivity	hypersensitivity	NOUN
iajs-3010	21	6	(	(	PUNCT
iajs-3010	21	7	also	also	ADV
iajs-3010	21	8	define	define	VERB
iajs-3010	21	9	autoallergy	autoallergy	NOUN
iajs-3010	21	10	,	,	PUNCT
iajs-3010	21	11	hypersensitivity	hypersensitivity	NOUN
iajs-3010	21	12	of	of	ADP
iajs-3010	21	13	type	type	NOUN
iajs-3010	21	14	i	i	PRON
iajs-3010	21	15	is	be	AUX
iajs-3010	21	16	also	also	ADV
iajs-3010	21	17	known	know	VERB
iajs-3010	21	18	as	as	ADP
iajs-3010	21	19	anaphylactic	anaphylactic	ADJ
iajs-3010	21	20	hypersensitivity	hypersensitivity	NOUN
iajs-3010	21	21	or	or	CCONJ
iajs-3010	21	22	acute	acute	ADJ
iajs-3010	21	23	hypersensitivity	hypersensitivity	NOUN
iajs-3010	21	24	[	[	X
iajs-3010	21	25	4	4	NUM
iajs-3010	21	26	]	]	PUNCT
iajs-3010	21	27	is	be	AUX
iajs-3010	21	28	involved	involve	VERB
iajs-3010	21	29	when	when	SCONJ
iajs-3010	21	30	antigen	antigen	NOUN
iajs-3010	21	31	crosslink	crosslink	VERB
iajs-3010	21	32	the	the	DET
iajs-3010	21	33	immunoglobulin	immunoglobulin	NOUN
iajs-3010	21	34	e	e	PROPN
iajs-3010	21	35	(	(	PUNCT
iajs-3010	21	36	ige	ige	PROPN
iajs-3010	21	37	)	)	PUNCT
iajs-3010	21	38	on	on	ADP
iajs-3010	21	39	mast	mast	NOUN
iajs-3010	21	40	cells	cell	NOUN
iajs-3010	21	41	and	and	CCONJ
iajs-3010	21	42	basophils	basophil	NOUN
iajs-3010	21	43	to	to	PART
iajs-3010	21	44	take	take	VERB
iajs-3010	21	45	out	out	ADP
iajs-3010	21	46	the	the	DET
iajs-3010	21	47	vasoactive	vasoactive	ADJ
iajs-3010	21	48	mediatorss	mediatorss	NOUN
iajs-3010	22	1	[	[	X
iajs-3010	22	2	5	5	NUM
iajs-3010	22	3	]	]	PUNCT
iajs-3010	22	4	.	.	PUNCT
iajs-3010	23	1	ige	ige	PROPN
iajs-3010	23	2	have	have	VERB
iajs-3010	23	3	a	a	DET
iajs-3010	23	4	roles	role	NOUN
iajs-3010	23	5	in	in	ADP
iajs-3010	23	6	allergic	allergic	ADJ
iajs-3010	23	7	reactions	reaction	NOUN
iajs-3010	23	8	,	,	PUNCT
iajs-3010	23	9	and	and	CCONJ
iajs-3010	23	10	its	its	PRON
iajs-3010	23	11	strong	strong	ADJ
iajs-3010	23	12	effecting	effecting	NOUN
iajs-3010	23	13	function	function	NOUN
iajs-3010	23	14	activated	activate	VERB
iajs-3010	23	15	when	when	SCONJ
iajs-3010	23	16	this	this	PRON
iajs-3010	23	17	antibodies	antibodie	VERB
iajs-3010	23	18	bind	bind	VERB
iajs-3010	23	19	to	to	ADP
iajs-3010	23	20	fc	fc	PROPN
iajs-3010	23	21	receptors	receptor	NOUN
iajs-3010	23	22	fcεri	fcεri	ADJ
iajs-3010	23	23	and	and	CCONJ
iajs-3010	23	24	fcεrii	fcεrii	ADJ
iajs-3010	23	25	/	/	SYM
iajs-3010	24	1	cd23	cd23	PROPN
iajs-3010	24	2	[	[	X
iajs-3010	24	3	6	6	NUM
iajs-3010	24	4	]	]	PUNCT
iajs-3010	24	5	.	.	PUNCT
iajs-3010	25	1	increased	increase	VERB
iajs-3010	25	2	serum	serum	NOUN
iajs-3010	25	3	levels	level	NOUN
iajs-3010	25	4	of	of	ADP
iajs-3010	25	5	igm	igm	PROPN
iajs-3010	25	6	-	-	PUNCT
iajs-3010	25	7	antifcεriα	antifcεriα	PROPN
iajs-3010	25	8	are	be	AUX
iajs-3010	25	9	common	common	ADJ
iajs-3010	25	10	in	in	ADP
iajs-3010	25	11	patients	patient	NOUN
iajs-3010	25	12	with	with	ADP
iajs-3010	25	13	csu	csu	PROPN
iajs-3010	25	14	and	and	CCONJ
iajs-3010	25	15	linked	link	VERB
iajs-3010	25	16	to	to	ADP
iajs-3010	25	17	features	feature	NOUN
iajs-3010	25	18	of	of	ADP
iajs-3010	25	19	autoimmunity	autoimmunity	NOUN
iajs-3010	25	20	[	[	X
iajs-3010	25	21	7	7	NUM
iajs-3010	25	22	]	]	PUNCT
iajs-3010	25	23	.	.	PUNCT
iajs-3010	26	1	interleukin	interleukin	NOUN
iajs-3010	26	2	6	6	NUM
iajs-3010	26	3	is	be	AUX
iajs-3010	26	4	pro	pro	ADJ
iajs-3010	26	5	-	-	ADJ
iajs-3010	26	6	inflammatory	inflammatory	ADJ
iajs-3010	26	7	cytokines	cytokine	NOUN
iajs-3010	26	8	,	,	PUNCT
iajs-3010	26	9	which	which	PRON
iajs-3010	26	10	deregulated	deregulate	VERB
iajs-3010	26	11	with	with	ADP
iajs-3010	26	12	auto	auto	NOUN
iajs-3010	26	13	-	-	PUNCT
iajs-3010	26	14	immune	immune	ADJ
iajs-3010	26	15	disorders	disorder	NOUN
iajs-3010	26	16	and	and	CCONJ
iajs-3010	26	17	chronic	chronic	ADJ
iajs-3010	26	18	inflammations	inflammation	NOUN
iajs-3010	26	19	[	[	X
iajs-3010	26	20	8	8	NUM
iajs-3010	26	21	]	]	PUNCT
iajs-3010	26	22	.	.	PUNCT
iajs-3010	27	1	currently	currently	ADV
iajs-3010	27	2	,	,	PUNCT
iajs-3010	27	3	alasandagutti	alasandagutti	VERB
iajs-3010	27	4	et	et	PROPN
iajs-3010	27	5	al	al	PROPN
iajs-3010	27	6	.	.	PROPN
iajs-3010	27	7	,[9	,[9	PROPN
iajs-3010	27	8	]	]	PUNCT
iajs-3010	27	9	who	who	PRON
iajs-3010	27	10	reported	report	VERB
iajs-3010	27	11	that	that	SCONJ
iajs-3010	27	12	family	family	NOUN
iajs-3010	27	13	of	of	ADP
iajs-3010	27	14	il-6	il-6	NOUN
iajs-3010	27	15	plays	play	VERB
iajs-3010	27	16	a	a	DET
iajs-3010	27	17	vital	vital	ADJ
iajs-3010	27	18	role	role	NOUN
iajs-3010	27	19	in	in	ADP
iajs-3010	27	20	csu	csu	PROPN
iajs-3010	27	21	pathogenesis	pathogenesis	NOUN
iajs-3010	27	22	.	.	PUNCT
iajs-3010	28	1	the	the	DET
iajs-3010	28	2	aim	aim	NOUN
iajs-3010	28	3	of	of	ADP
iajs-3010	28	4	the	the	DET
iajs-3010	28	5	study	study	NOUN
iajs-3010	28	6	was	be	AUX
iajs-3010	28	7	evaluate	evaluate	NOUN
iajs-3010	28	8	of	of	ADP
iajs-3010	28	9	il-6	il-6	NUM
iajs-3010	28	10	and	and	CCONJ
iajs-3010	28	11	totalige	totalige	NOUN
iajs-3010	28	12	in	in	ADP
iajs-3010	28	13	chronic	chronic	ADJ
iajs-3010	28	14	spontaneous	spontaneous	ADJ
iajs-3010	28	15	urticaria	urticaria	NOUN
iajs-3010	28	16	(	(	PUNCT
iajs-3010	28	17	cus	cus	NOUN
iajs-3010	28	18	)	)	PUNCT
iajs-3010	28	19	patients	patient	NOUN
iajs-3010	28	20	.	.	PUNCT
iajs-3010	29	1	2.material	2.material	NUM
iajs-3010	29	2	and	and	CCONJ
iajs-3010	29	3	methods	method	NOUN
iajs-3010	29	4	patient	patient	ADJ
iajs-3010	29	5	diagnosis	diagnosis	NOUN
iajs-3010	29	6	eighty	eighty	NUM
iajs-3010	29	7	patients	patient	NOUN
iajs-3010	29	8	with	with	ADP
iajs-3010	29	9	chronic	chronic	ADJ
iajs-3010	29	10	urticaria	urticaria	NOUN
iajs-3010	29	11	diagnosed	diagnose	VERB
iajs-3010	29	12	by	by	ADP
iajs-3010	29	13	dermatologists	dermatologist	NOUN
iajs-3010	29	14	in	in	ADP
iajs-3010	29	15	the	the	DET
iajs-3010	29	16	specialized	specialized	ADJ
iajs-3010	29	17	center	center	NOUN
iajs-3010	29	18	of	of	ADP
iajs-3010	29	19	allergy	allergy	NOUN
iajs-3010	29	20	in	in	ADP
iajs-3010	29	21	baghdad	baghdad	PROPN
iajs-3010	29	22	/	/	SYM
iajs-3010	29	23	al	al	PROPN
iajs-3010	29	24	-	-	PUNCT
iajs-3010	29	25	rusafa	rusafa	PROPN
iajs-3010	29	26	and	and	CCONJ
iajs-3010	29	27	forty	forty	NUM
iajs-3010	29	28	healthy	healthy	ADJ
iajs-3010	29	29	control	control	NOUN
iajs-3010	29	30	samples	sample	NOUN
iajs-3010	29	31	was	be	AUX
iajs-3010	29	32	involved	involve	VERB
iajs-3010	29	33	in	in	ADP
iajs-3010	29	34	the	the	DET
iajs-3010	29	35	study	study	NOUN
iajs-3010	29	36	from	from	ADP
iajs-3010	29	37	november	november	PROPN
iajs-3010	29	38	2021	2021	NUM
iajs-3010	29	39	to	to	ADP
iajs-3010	29	40	april	april	PROPN
iajs-3010	29	41	2022	2022	NUM
iajs-3010	29	42	,	,	PUNCT
iajs-3010	29	43	divided	divide	VERB
iajs-3010	29	44	patients	patient	NOUN
iajs-3010	29	45	into	into	ADP
iajs-3010	29	46	pre	pre	ADJ
iajs-3010	29	47	-	-	NOUN
iajs-3010	29	48	treatment	treatment	NOUN
iajs-3010	29	49	and	and	CCONJ
iajs-3010	29	50	post	post	ADJ
iajs-3010	29	51	-	-	ADJ
iajs-3010	29	52	treatment	treatment	ADJ
iajs-3010	29	53	patients	patient	NOUN
iajs-3010	29	54	.	.	PUNCT
iajs-3010	30	1	all	all	DET
iajs-3010	30	2	patients	patient	NOUN
iajs-3010	30	3	and	and	CCONJ
iajs-3010	30	4	controls	control	VERB
iajs-3010	30	5	samples	sample	NOUN
iajs-3010	30	6	underwent	undergo	VERB
iajs-3010	30	7	basic	basic	ADJ
iajs-3010	30	8	laboratory	laboratory	NOUN
iajs-3010	30	9	tests	test	NOUN
iajs-3010	30	10	in	in	ADP
iajs-3010	30	11	addition	addition	NOUN
iajs-3010	30	12	to	to	ADP
iajs-3010	30	13	evaluation	evaluation	VERB
iajs-3010	30	14	the	the	DET
iajs-3010	30	15	levels	level	NOUN
iajs-3010	30	16	of	of	ADP
iajs-3010	30	17	total	total	ADJ
iajs-3010	30	18	ige	ige	PROPN
iajs-3010	30	19	and	and	CCONJ
iajs-3010	30	20	il-6	il-6	NOUN
iajs-3010	30	21	in	in	ADP
iajs-3010	30	22	their	their	PRON
iajs-3010	30	23	serum	serum	NOUN
iajs-3010	30	24	.	.	PUNCT
iajs-3010	31	1	collection	collection	NOUN
iajs-3010	31	2	blood	blood	NOUN
iajs-3010	31	3	samples	sample	VERB
iajs-3010	31	4	eight	eight	NUM
iajs-3010	31	5	ml	ml	NOUN
iajs-3010	31	6	of	of	ADP
iajs-3010	31	7	venous	venous	ADJ
iajs-3010	31	8	blood	blood	NOUN
iajs-3010	31	9	were	be	AUX
iajs-3010	31	10	drawn	draw	VERB
iajs-3010	31	11	from	from	ADP
iajs-3010	31	12	each	each	DET
iajs-3010	31	13	subject	subject	NOUN
iajs-3010	31	14	using	use	VERB
iajs-3010	31	15	10	10	NUM
iajs-3010	31	16	ml	ml	ADV
iajs-3010	31	17	disposable	disposable	ADJ
iajs-3010	31	18	plastic	plastic	ADJ
iajs-3010	31	19	syringes	syrinx	NOUN
iajs-3010	31	20	in	in	ADP
iajs-3010	31	21	sterile	sterile	ADJ
iajs-3010	31	22	conditions	condition	NOUN
iajs-3010	31	23	.	.	PUNCT
iajs-3010	32	1	(	(	PUNCT
iajs-3010	32	2	2ml	2ml	NOUN
iajs-3010	32	3	)	)	PUNCT
iajs-3010	32	4	of	of	ADP
iajs-3010	32	5	blood	blood	NOUN
iajs-3010	32	6	was	be	AUX
iajs-3010	32	7	collected	collect	VERB
iajs-3010	32	8	in	in	ADP
iajs-3010	32	9	edta	edta	NOUN
iajs-3010	32	10	tube	tube	NOUN
iajs-3010	32	11	for	for	ADP
iajs-3010	32	12	hematological	hematological	ADJ
iajs-3010	32	13	assay	assay	PROPN
iajs-3010	32	14	beckman	beckman	PROPN
iajs-3010	32	15	analyzer	analyzer	PROPN
iajs-3010	32	16	counter	counter	PROPN
iajs-3010	32	17	.	.	PUNCT
iajs-3010	33	1	in	in	ADP
iajs-3010	33	2	the	the	DET
iajs-3010	33	3	gel	gel	NOUN
iajs-3010	33	4	tube	tube	NOUN
iajs-3010	33	5	,	,	PUNCT
iajs-3010	33	6	6	6	NUM
iajs-3010	33	7	ml	ml	NOUN
iajs-3010	33	8	of	of	ADP
iajs-3010	33	9	blood	blood	NOUN
iajs-3010	33	10	was	be	AUX
iajs-3010	33	11	obtained	obtain	VERB
iajs-3010	33	12	and	and	CCONJ
iajs-3010	33	13	allowed	allow	VERB
iajs-3010	33	14	to	to	PART
iajs-3010	33	15	coagulate	coagulate	VERB
iajs-3010	33	16	at	at	ADP
iajs-3010	33	17	room	room	NOUN
iajs-3010	33	18	ihjpas	ihjpas	PROPN
iajs-3010	33	19	.	.	PUNCT
iajs-3010	34	1	36(2)2023	36(2)2023	NUM
iajs-3010	34	2	35	35	NUM
iajs-3010	34	3	temperature	temperature	NOUN
iajs-3010	34	4	(	(	PUNCT
iajs-3010	34	5	20	20	NUM
iajs-3010	34	6	-	-	SYM
iajs-3010	34	7	25	25	NUM
iajs-3010	34	8	°	°	PROPN
iajs-3010	34	9	c	c	NOUN
iajs-3010	34	10	)	)	PUNCT
iajs-3010	34	11	.	.	PUNCT
iajs-3010	35	1	after	after	ADP
iajs-3010	35	2	blood	blood	NOUN
iajs-3010	35	3	clotting	clotting	NOUN
iajs-3010	35	4	,	,	PUNCT
iajs-3010	35	5	centrifuged	centrifuge	VERB
iajs-3010	35	6	at	at	ADP
iajs-3010	35	7	3000	3000	NUM
iajs-3010	35	8	rpm	rpm	NOUN
iajs-3010	35	9	for	for	ADP
iajs-3010	35	10	5	5	NUM
iajs-3010	35	11	minutes	minute	NOUN
iajs-3010	35	12	to	to	PART
iajs-3010	35	13	obtain	obtain	VERB
iajs-3010	35	14	serum	serum	NOUN
iajs-3010	35	15	before	before	ADP
iajs-3010	35	16	being	be	AUX
iajs-3010	35	17	separated	separate	VERB
iajs-3010	35	18	into	into	ADP
iajs-3010	35	19	equal	equal	ADJ
iajs-3010	35	20	parts	part	NOUN
iajs-3010	35	21	into	into	ADP
iajs-3010	35	22	3	3	NUM
iajs-3010	35	23	sterile	sterile	ADJ
iajs-3010	35	24	eppendrof	eppendrof	ADJ
iajs-3010	35	25	tubes	tube	NOUN
iajs-3010	35	26	which	which	PRON
iajs-3010	35	27	tightly	tightly	ADV
iajs-3010	35	28	closed	close	VERB
iajs-3010	35	29	and	and	CCONJ
iajs-3010	35	30	stored	store	VERB
iajs-3010	35	31	at-20	at-20	ADV
iajs-3010	35	32	°	°	ADP
iajs-3010	35	33	c	c	NOUN
iajs-3010	35	34	for	for	ADP
iajs-3010	35	35	immunological	immunological	ADJ
iajs-3010	35	36	testing	testing	NOUN
iajs-3010	35	37	of	of	ADP
iajs-3010	35	38	total	total	NOUN
iajs-3010	35	39	-	-	PUNCT
iajs-3010	35	40	ige	ige	NOUN
iajs-3010	35	41	(	(	PUNCT
iajs-3010	35	42	euroimmun	euroimmun	PROPN
iajs-3010	35	43	,	,	PUNCT
iajs-3010	35	44	germany	germany	PROPN
iajs-3010	35	45	)	)	PUNCT
iajs-3010	35	46	,	,	PUNCT
iajs-3010	35	47	il-6	il-6	PRON
iajs-3010	35	48	(	(	PUNCT
iajs-3010	35	49	mybiosource	mybiosource	PROPN
iajs-3010	35	50	,	,	PUNCT
iajs-3010	35	51	usa	usa	PROPN
iajs-3010	35	52	)	)	PUNCT
iajs-3010	35	53	by	by	ADP
iajs-3010	35	54	using	use	VERB
iajs-3010	35	55	elisa	elisa	NOUN
iajs-3010	35	56	technique	technique	NOUN
iajs-3010	35	57	.	.	PUNCT
iajs-3010	36	1	statistical	statistical	ADJ
iajs-3010	36	2	analysis	analysis	NOUN
iajs-3010	36	3	the	the	DET
iajs-3010	36	4	data	datum	NOUN
iajs-3010	36	5	was	be	AUX
iajs-3010	36	6	analyzed	analyze	VERB
iajs-3010	36	7	using	use	VERB
iajs-3010	36	8	spss	spss	ADJ
iajs-3010	36	9	statistical	statistical	ADJ
iajs-3010	36	10	approach	approach	NOUN
iajs-3010	36	11	(	(	PUNCT
iajs-3010	36	12	statistical	statistical	ADJ
iajs-3010	36	13	package	package	NOUN
iajs-3010	36	14	for	for	ADP
iajs-3010	36	15	the	the	DET
iajs-3010	36	16	social	social	ADJ
iajs-3010	36	17	sciences	science	NOUN
iajs-3010	36	18	)	)	PUNCT
iajs-3010	36	19	version-26	version-26	PROPN
iajs-3010	36	20	.	.	PUNCT
iajs-3010	37	1	for	for	ADP
iajs-3010	37	2	quantitative	quantitative	ADJ
iajs-3010	37	3	variables	variable	NOUN
iajs-3010	37	4	,	,	PUNCT
iajs-3010	37	5	tested	test	VERB
iajs-3010	37	6	had	have	AUX
iajs-3010	37	7	been	be	AUX
iajs-3010	37	8	data	datum	NOUN
iajs-3010	37	9	for	for	ADP
iajs-3010	37	10	normality	normality	NOUN
iajs-3010	37	11	(	(	PUNCT
iajs-3010	37	12	shapiro	shapiro	NOUN
iajs-3010	37	13	-	-	PUNCT
iajs-3010	37	14	wilk	wilk	PROPN
iajs-3010	37	15	and	and	CCONJ
iajs-3010	37	16	kolmogorov	kolmogorov	ADJ
iajs-3010	37	17	-	-	PUNCT
iajs-3010	37	18	smirnov	smirnov	ADJ
iajs-3010	37	19	tests	test	NOUN
iajs-3010	37	20	)	)	PUNCT
iajs-3010	37	21	,	,	PUNCT
iajs-3010	37	22	and	and	CCONJ
iajs-3010	37	23	the	the	DET
iajs-3010	37	24	levels	level	NOUN
iajs-3010	37	25	have	have	AUX
iajs-3010	37	26	given	give	VERB
iajs-3010	37	27	as	as	ADP
iajs-3010	37	28	,	,	PUNCT
iajs-3010	37	29	(	(	PUNCT
iajs-3010	37	30	mean	mean	NOUN
iajs-3010	37	31	±	±	NUM
iajs-3010	37	32	stander	stander	NOUN
iajs-3010	37	33	error	error	NOUN
iajs-3010	37	34	(	(	PUNCT
iajs-3010	37	35	.	.	PUNCT
iajs-3010	38	1	significant	significant	ADJ
iajs-3010	38	2	differences	difference	NOUN
iajs-3010	38	3	between	between	ADP
iajs-3010	38	4	medians	median	NOUN
iajs-3010	38	5	were	be	AUX
iajs-3010	38	6	assessed	assess	VERB
iajs-3010	38	7	by	by	ADP
iajs-3010	38	8	the	the	DET
iajs-3010	38	9	nonparametric	nonparametric	NOUN
iajs-3010	38	10	tests	test	NOUN
iajs-3010	38	11	(	(	PUNCT
iajs-3010	38	12	mann	mann	PROPN
iajs-3010	38	13	-	-	PUNCT
iajs-3010	38	14	whitney	whitney	PROPN
iajs-3010	38	15	and	and	CCONJ
iajs-3010	38	16	kruskal	kruskal	PROPN
iajs-3010	38	17	-	-	PUNCT
iajs-3010	38	18	wallis	wallis	PROPN
iajs-3010	38	19	)	)	PUNCT
iajs-3010	38	20	probability	probability	NOUN
iajs-3010	38	21	value	value	NOUN
iajs-3010	38	22	<	<	X
iajs-3010	38	23	0.05	0.05	NUM
iajs-3010	38	24	roc	roc	PROPN
iajs-3010	38	25	curve	curve	NOUN
iajs-3010	38	26	(	(	PUNCT
iajs-3010	38	27	receiver	receiver	ADV
iajs-3010	38	28	operating	operate	VERB
iajs-3010	38	29	characteristic	characteristic	ADJ
iajs-3010	38	30	curve	curve	NOUN
iajs-3010	38	31	)	)	PUNCT
iajs-3010	38	32	,	,	PUNCT
iajs-3010	38	33	this	this	DET
iajs-3010	38	34	graph	graph	NOUN
iajs-3010	38	35	was	be	AUX
iajs-3010	38	36	used	use	VERB
iajs-3010	38	37	to	to	PART
iajs-3010	38	38	discriminate	discriminate	VERB
iajs-3010	38	39	whether	whether	SCONJ
iajs-3010	38	40	all	all	PRON
iajs-3010	38	41	immunological	immunological	ADJ
iajs-3010	38	42	and	and	CCONJ
iajs-3010	38	43	hematological	hematological	ADJ
iajs-3010	38	44	are	be	AUX
iajs-3010	38	45	biomarkers	biomarker	NOUN
iajs-3010	38	46	or	or	CCONJ
iajs-3010	38	47	not	not	PART
iajs-3010	38	48	.	.	PUNCT
iajs-3010	39	1	3.results	3.results	NUM
iajs-3010	39	2	and	and	CCONJ
iajs-3010	39	3	discussion	discussion	NOUN
iajs-3010	39	4	demographic	demographic	ADJ
iajs-3010	39	5	characteristics	characteristic	NOUN
iajs-3010	39	6	of	of	ADP
iajs-3010	39	7	study	study	NOUN
iajs-3010	39	8	:	:	PUNCT
iajs-3010	39	9	the	the	DET
iajs-3010	39	10	results	result	NOUN
iajs-3010	39	11	of	of	ADP
iajs-3010	39	12	demographic	demographic	ADJ
iajs-3010	39	13	and	and	CCONJ
iajs-3010	39	14	clinical	clinical	ADJ
iajs-3010	39	15	characteristics	characteristic	NOUN
iajs-3010	39	16	showed	show	VERB
iajs-3010	39	17	the	the	DET
iajs-3010	39	18	rate	rate	NOUN
iajs-3010	39	19	of	of	ADP
iajs-3010	39	20	female	female	ADJ
iajs-3010	39	21	patients	patient	NOUN
iajs-3010	39	22	was	be	AUX
iajs-3010	39	23	higher	high	ADJ
iajs-3010	39	24	than	than	ADP
iajs-3010	39	25	male	male	NOUN
iajs-3010	39	26	which	which	PRON
iajs-3010	39	27	represented	represent	VERB
iajs-3010	39	28	by	by	ADP
iajs-3010	39	29	56.3	56.3	NUM
iajs-3010	39	30	and	and	CCONJ
iajs-3010	39	31	43.8	43.8	NUM
iajs-3010	39	32	%	%	NOUN
iajs-3010	39	33	respectively	respectively	ADV
iajs-3010	39	34	,	,	PUNCT
iajs-3010	39	35	also	also	ADV
iajs-3010	39	36	showed	show	VERB
iajs-3010	39	37	20	20	NUM
iajs-3010	39	38	%	%	NOUN
iajs-3010	39	39	of	of	ADP
iajs-3010	39	40	patients	patient	NOUN
iajs-3010	39	41	were	be	AUX
iajs-3010	39	42	smoking	smoke	VERB
iajs-3010	39	43	.	.	PUNCT
iajs-3010	40	1	finally	finally	ADV
iajs-3010	40	2	,	,	PUNCT
iajs-3010	40	3	the	the	DET
iajs-3010	40	4	mean	mean	ADJ
iajs-3010	40	5	ages	age	NOUN
iajs-3010	40	6	of	of	ADP
iajs-3010	40	7	,	,	PUNCT
iajs-3010	40	8	patients	patient	NOUN
iajs-3010	40	9	34.8±1.5	34.8±1.5	NUM
iajs-3010	40	10	as	as	ADP
iajs-3010	40	11	in	in	ADP
iajs-3010	40	12	table	table	NOUN
iajs-3010	40	13	1	1	NUM
iajs-3010	40	14	.	.	PUNCT
iajs-3010	40	15	table	table	NOUN
iajs-3010	40	16	1	1	NUM
iajs-3010	40	17	.	.	PUNCT
iajs-3010	40	18	demographic	demographic	ADJ
iajs-3010	40	19	and	and	CCONJ
iajs-3010	40	20	clinical	clinical	ADJ
iajs-3010	40	21	characteristics	characteristic	NOUN
iajs-3010	40	22	of	of	ADP
iajs-3010	40	23	the	the	DET
iajs-3010	40	24	participants	participant	NOUN
iajs-3010	40	25	.	.	PUNCT
iajs-3010	41	1	demographic	demographic	ADJ
iajs-3010	41	2	characteristics	characteristic	NOUN
iajs-3010	41	3	patients	patient	NOUN
iajs-3010	41	4	n	n	PROPN
iajs-3010	41	5	(	(	PUNCT
iajs-3010	41	6	%	%	INTJ
iajs-3010	41	7	)	)	PUNCT
iajs-3010	41	8	controls	control	VERB
iajs-3010	41	9	n	n	PROPN
iajs-3010	41	10	(	(	PUNCT
iajs-3010	41	11	%	%	INTJ
iajs-3010	41	12	)	)	PUNCT
iajs-3010	41	13	groups	group	NOUN
iajs-3010	41	14	80	80	NUM
iajs-3010	41	15	(	(	PUNCT
iajs-3010	41	16	50	50	NUM
iajs-3010	41	17	%	%	NOUN
iajs-3010	41	18	)	)	PUNCT
iajs-3010	41	19	40	40	NUM
iajs-3010	41	20	(	(	PUNCT
iajs-3010	41	21	50	50	NUM
iajs-3010	41	22	%	%	NOUN
iajs-3010	41	23	)	)	PUNCT
iajs-3010	41	24	gender	gender	NOUN
iajs-3010	41	25	:	:	PUNCT
iajs-3010	41	26	male	male	ADJ
iajs-3010	41	27	female	female	NOUN
iajs-3010	41	28	35	35	NUM
iajs-3010	41	29	(	(	PUNCT
iajs-3010	41	30	43.8	43.8	NUM
iajs-3010	41	31	%	%	NOUN
iajs-3010	41	32	)	)	PUNCT
iajs-3010	41	33	45	45	NUM
iajs-3010	41	34	(	(	PUNCT
iajs-3010	41	35	56.3	56.3	NUM
iajs-3010	41	36	%	%	NOUN
iajs-3010	41	37	)	)	PUNCT
iajs-3010	41	38	24	24	NUM
iajs-3010	41	39	(	(	PUNCT
iajs-3010	41	40	60	60	NUM
iajs-3010	41	41	%	%	NOUN
iajs-3010	41	42	)	)	PUNCT
iajs-3010	41	43	16	16	NUM
iajs-3010	41	44	(	(	PUNCT
iajs-3010	41	45	40	40	NUM
iajs-3010	41	46	%	%	NOUN
iajs-3010	41	47	)	)	PUNCT
iajs-3010	41	48	treatment	treatment	NOUN
iajs-3010	41	49	:	:	PUNCT
iajs-3010	42	1	yes	yes	INTJ
iajs-3010	42	2	no	no	INTJ
iajs-3010	43	1	58	58	NUM
iajs-3010	43	2	(	(	PUNCT
iajs-3010	43	3	72.5	72.5	NUM
iajs-3010	43	4	%	%	NOUN
iajs-3010	43	5	)	)	PUNCT
iajs-3010	43	6	22	22	NUM
iajs-3010	43	7	(	(	PUNCT
iajs-3010	43	8	27.5	27.5	NUM
iajs-3010	43	9	%	%	NOUN
iajs-3010	43	10	)	)	PUNCT
iajs-3010	43	11	0	0	NUM
iajs-3010	44	1	(	(	PUNCT
iajs-3010	44	2	0	0	NUM
iajs-3010	44	3	%	%	NOUN
iajs-3010	44	4	)	)	PUNCT
iajs-3010	44	5	40	40	NUM
iajs-3010	44	6	(	(	PUNCT
iajs-3010	44	7	100	100	NUM
iajs-3010	44	8	%	%	NOUN
iajs-3010	44	9	)	)	PUNCT
iajs-3010	44	10	smoke	smoke	NOUN
iajs-3010	44	11	:	:	PUNCT
iajs-3010	45	1	no	no	INTJ
iajs-3010	45	2	yes	yes	INTJ
iajs-3010	45	3	64	64	NUM
iajs-3010	45	4	(	(	PUNCT
iajs-3010	45	5	80	80	NUM
iajs-3010	45	6	%	%	NOUN
iajs-3010	45	7	)	)	PUNCT
iajs-3010	45	8	16	16	NUM
iajs-3010	45	9	(	(	PUNCT
iajs-3010	45	10	20	20	NUM
iajs-3010	45	11	%	%	NOUN
iajs-3010	45	12	)	)	PUNCT
iajs-3010	45	13	40	40	NUM
iajs-3010	45	14	(	(	PUNCT
iajs-3010	45	15	100	100	NUM
iajs-3010	45	16	)	)	PUNCT
iajs-3010	45	17	0	0	NUM
iajs-3010	46	1	(	(	PUNCT
iajs-3010	46	2	0	0	NUM
iajs-3010	46	3	%	%	NOUN
iajs-3010	46	4	)	)	PUNCT
iajs-3010	46	5	age	age	NOUN
iajs-3010	46	6	(	(	PUNCT
iajs-3010	46	7	mean±	mean±	PROPN
iajs-3010	46	8	s.e	s.e	PROPN
iajs-3010	46	9	.	.	PROPN
iajs-3010	46	10	)	)	PUNCT
iajs-3010	47	1	34.8±1.5	34.8±1.5	NUM
iajs-3010	47	2	34.65±2.25	34.65±2.25	NOUN
iajs-3010	47	3	this	this	DET
iajs-3010	47	4	findings	finding	NOUN
iajs-3010	47	5	were	be	AUX
iajs-3010	47	6	similar	similar	ADJ
iajs-3010	47	7	with	with	ADP
iajs-3010	47	8	uysal	uysal	PROPN
iajs-3010	47	9	et	et	PROPN
iajs-3010	47	10	al	al	PROPN
iajs-3010	47	11	.	.	PUNCT
iajs-3010	48	1	[	[	X
iajs-3010	48	2	10	10	NUM
iajs-3010	48	3	]	]	PUNCT
iajs-3010	48	4	who	who	PRON
iajs-3010	48	5	revealed	reveal	VERB
iajs-3010	48	6	,	,	PUNCT
iajs-3010	48	7	the	the	DET
iajs-3010	48	8	19	19	NUM
iajs-3010	48	9	%	%	NOUN
iajs-3010	48	10	of	of	ADP
iajs-3010	48	11	patients	patient	NOUN
iajs-3010	48	12	were	be	AUX
iajs-3010	48	13	smoking	smoke	VERB
iajs-3010	48	14	and	and	CCONJ
iajs-3010	48	15	the	the	DET
iajs-3010	48	16	female	female	NOUN
iajs-3010	48	17	was	be	AUX
iajs-3010	48	18	high	high	ADJ
iajs-3010	48	19	than	than	ADP
iajs-3010	48	20	male	male	ADJ
iajs-3010	48	21	24/7	24/7	NOUN
iajs-3010	48	22	and	and	CCONJ
iajs-3010	48	23	age	age	NOUN
iajs-3010	48	24	mean	mean	VERB
iajs-3010	48	25	47.19	47.19	NUM
iajs-3010	48	26	,	,	PUNCT
iajs-3010	48	27	also	also	ADV
iajs-3010	48	28	the	the	DET
iajs-3010	48	29	results	result	NOUN
iajs-3010	48	30	agreed	agree	VERB
iajs-3010	48	31	with	with	ADP
iajs-3010	48	32	hatif	hatif	PROPN
iajs-3010	48	33	et	et	PROPN
iajs-3010	48	34	al	al	PROPN
iajs-3010	48	35	.	.	PUNCT
iajs-3010	49	1	[	[	X
iajs-3010	49	2	11	11	NUM
iajs-3010	49	3	]	]	PUNCT
iajs-3010	49	4	that	that	PRON
iajs-3010	49	5	found	find	VERB
iajs-3010	49	6	the	the	DET
iajs-3010	49	7	female	female	ADJ
iajs-3010	49	8	patients	patient	NOUN
iajs-3010	49	9	were	be	AUX
iajs-3010	49	10	higher	high	ADJ
iajs-3010	49	11	than	than	ADP
iajs-3010	49	12	male	male	NOUN
iajs-3010	49	13	maurer	maurer	PROPN
iajs-3010	49	14	et	et	PROPN
iajs-3010	49	15	al	al	PROPN
iajs-3010	49	16	.	.	PUNCT
iajs-3010	50	1	[	[	X
iajs-3010	50	2	12	12	NUM
iajs-3010	50	3	]	]	PUNCT
iajs-3010	50	4	report	report	NOUN
iajs-3010	50	5	that	that	SCONJ
iajs-3010	50	6	the	the	DET
iajs-3010	50	7	rates	rate	NOUN
iajs-3010	50	8	of	of	ADP
iajs-3010	50	9	chronic	chronic	ADJ
iajs-3010	50	10	spontaneous	spontaneous	ADJ
iajs-3010	50	11	urticaria	urticaria	NOUN
iajs-3010	50	12	that	that	PRON
iajs-3010	50	13	varies	vary	VERB
iajs-3010	50	14	across	across	ADP
iajs-3010	50	15	europe	europe	PROPN
iajs-3010	50	16	central	central	ADJ
iajs-3010	50	17	and	and	CCONJ
iajs-3010	50	18	south	south	PROPN
iajs-3010	50	19	america	america	PROPN
iajs-3010	50	20	,	,	PUNCT
iajs-3010	50	21	with	with	ADP
iajs-3010	50	22	a	a	DET
iajs-3010	50	23	greater	great	ADJ
iajs-3010	50	24	rate	rate	NOUN
iajs-3010	50	25	of	of	ADP
iajs-3010	50	26	females	female	NOUN
iajs-3010	50	27	and	and	CCONJ
iajs-3010	50	28	a	a	DET
iajs-3010	50	29	statistically	statistically	ADV
iajs-3010	50	30	significant	significant	ADJ
iajs-3010	50	31	difference	difference	NOUN
iajs-3010	50	32	.	.	PUNCT
iajs-3010	51	1	with	with	ADP
iajs-3010	51	2	an	an	DET
iajs-3010	51	3	average	average	ADJ
iajs-3010	51	4	female	female	NOUN
iajs-3010	51	5	to	to	ADP
iajs-3010	51	6	male	male	ADJ
iajs-3010	51	7	ratio	ratio	NOUN
iajs-3010	51	8	of	of	ADP
iajs-3010	51	9	about	about	ADV
iajs-3010	51	10	2	2	NUM
iajs-3010	51	11	-	-	SYM
iajs-3010	51	12	1/4	1/4	NUM
iajs-3010	51	13	,	,	PUNCT
iajs-3010	51	14	cu	cu	PROPN
iajs-3010	51	15	is	be	AUX
iajs-3010	51	16	one	one	NUM
iajs-3010	51	17	of	of	ADP
iajs-3010	51	18	the	the	DET
iajs-3010	51	19	skin	skin	NOUN
iajs-3010	51	20	conditions	condition	NOUN
iajs-3010	51	21	with	with	ADP
iajs-3010	51	22	a	a	DET
iajs-3010	51	23	notable	notable	ADJ
iajs-3010	51	24	female	female	ADJ
iajs-3010	51	25	prevalence	prevalence	NOUN
iajs-3010	51	26	[	[	X
iajs-3010	51	27	13	13	NUM
iajs-3010	51	28	]	]	PUNCT
iajs-3010	51	29	.	.	PUNCT
iajs-3010	52	1	vascular	vascular	ADJ
iajs-3010	52	2	hyperpermeability	hyperpermeability	NOUN
iajs-3010	52	3	has	have	AUX
iajs-3010	52	4	been	be	AUX
iajs-3010	52	5	linked	link	VERB
iajs-3010	52	6	to	to	ADP
iajs-3010	52	7	this	this	DET
iajs-3010	52	8	phenomenon	phenomenon	NOUN
iajs-3010	52	9	,	,	PUNCT
iajs-3010	52	10	which	which	PRON
iajs-3010	52	11	is	be	AUX
iajs-3010	52	12	caused	cause	VERB
iajs-3010	52	13	by	by	ADP
iajs-3010	52	14	estrogenihjpas	estrogenihjpa	NOUN
iajs-3010	52	15	.	.	PUNCT
iajs-3010	53	1	36(2)2023	36(2)2023	NUM
iajs-3010	53	2	36	36	NUM
iajs-3010	53	3	induced	induce	VERB
iajs-3010	53	4	enhanced	enhanced	ADJ
iajs-3010	53	5	tissue	tissue	NOUN
iajs-3010	53	6	expression	expression	NOUN
iajs-3010	53	7	of	of	ADP
iajs-3010	53	8	endothelial	endothelial	ADJ
iajs-3010	53	9	nitric	nitric	ADJ
iajs-3010	53	10	oxide	oxide	NOUN
iajs-3010	53	11	synthase	synthase	NOUN
iajs-3010	53	12	.	.	PUNCT
iajs-3010	54	1	it	it	PRON
iajs-3010	54	2	is	be	AUX
iajs-3010	54	3	well	well	ADV
iajs-3010	54	4	-	-	PUNCT
iajs-3010	54	5	known	know	VERB
iajs-3010	54	6	that	that	SCONJ
iajs-3010	54	7	androgens	androgen	NOUN
iajs-3010	54	8	typically	typically	ADV
iajs-3010	54	9	have	have	VERB
iajs-3010	54	10	an	an	DET
iajs-3010	54	11	immunosuppressive	immunosuppressive	ADJ
iajs-3010	54	12	activity	activity	NOUN
iajs-3010	54	13	through	through	ADP
iajs-3010	54	14	a	a	DET
iajs-3010	54	15	variety	variety	NOUN
iajs-3010	54	16	of	of	ADP
iajs-3010	54	17	mechanisms	mechanism	NOUN
iajs-3010	54	18	,	,	PUNCT
iajs-3010	54	19	and	and	CCONJ
iajs-3010	54	20	progesterone	progesterone	NOUN
iajs-3010	54	21	similarly	similarly	ADV
iajs-3010	54	22	appears	appear	VERB
iajs-3010	54	23	to	to	PART
iajs-3010	54	24	suppress	suppress	VERB
iajs-3010	54	25	immunity	immunity	NOUN
iajs-3010	54	26	and	and	CCONJ
iajs-3010	54	27	inflammation	inflammation	NOUN
iajs-3010	54	28	.	.	PUNCT
iajs-3010	55	1	contrarily	contrarily	ADV
iajs-3010	55	2	,	,	PUNCT
iajs-3010	55	3	estrogens	estrogen	NOUN
iajs-3010	55	4	can	can	AUX
iajs-3010	55	5	promote	promote	VERB
iajs-3010	55	6	antibody	antibody	NOUN
iajs-3010	55	7	production	production	NOUN
iajs-3010	55	8	and	and	CCONJ
iajs-3010	55	9	humoral	humoral	ADJ
iajs-3010	55	10	immunity	immunity	NOUN
iajs-3010	55	11	[	[	X
iajs-3010	55	12	14	14	NUM
iajs-3010	55	13	]	]	PUNCT
iajs-3010	55	14	.	.	PUNCT
iajs-3010	56	1	biomarkers	biomarker	NOUN
iajs-3010	56	2	between	between	ADP
iajs-3010	56	3	csu	csu	NOUN
iajs-3010	56	4	patients	patient	NOUN
iajs-3010	56	5	and	and	CCONJ
iajs-3010	56	6	control	control	VERB
iajs-3010	56	7	subject	subject	ADJ
iajs-3010	56	8	the	the	DET
iajs-3010	56	9	results	result	NOUN
iajs-3010	56	10	showed	show	VERB
iajs-3010	56	11	there	there	PRON
iajs-3010	56	12	was	be	VERB
iajs-3010	56	13	highly	highly	ADV
iajs-3010	56	14	significant	significant	ADJ
iajs-3010	56	15	difference	difference	NOUN
iajs-3010	56	16	between	between	ADP
iajs-3010	56	17	the	the	DET
iajs-3010	56	18	patients	patient	NOUN
iajs-3010	56	19	and	and	CCONJ
iajs-3010	56	20	the	the	DET
iajs-3010	56	21	control	control	NOUN
iajs-3010	56	22	in	in	ADP
iajs-3010	56	23	wbc	wbc	PROPN
iajs-3010	56	24	,	,	PUNCT
iajs-3010	56	25	total	total	NOUN
iajs-3010	56	26	-	-	PUNCT
iajs-3010	56	27	ige	ige	NOUN
iajs-3010	56	28	,	,	PUNCT
iajs-3010	56	29	il-6	il-6	NOUN
iajs-3010	57	1	but	but	CCONJ
iajs-3010	57	2	eo	eo	PROPN
iajs-3010	57	3	was	be	AUX
iajs-3010	57	4	higher	high	ADJ
iajs-3010	57	5	than	than	ADP
iajs-3010	57	6	control	control	NOUN
iajs-3010	57	7	but	but	CCONJ
iajs-3010	57	8	no	no	DET
iajs-3010	57	9	significant	significant	ADJ
iajs-3010	57	10	differences	difference	NOUN
iajs-3010	57	11	at	at	ADP
iajs-3010	57	12	(	(	PUNCT
iajs-3010	57	13	p≤	p≤	NOUN
iajs-3010	57	14	0.05	0.05	NUM
iajs-3010	57	15	)	)	PUNCT
iajs-3010	57	16	table	table	NOUN
iajs-3010	57	17	2	2	NUM
iajs-3010	57	18	table	table	NOUN
iajs-3010	57	19	2	2	NUM
iajs-3010	57	20	.	.	PUNCT
iajs-3010	57	21	comparison	comparison	NOUN
iajs-3010	57	22	the	the	DET
iajs-3010	57	23	immunological	immunological	ADJ
iajs-3010	57	24	biomarkers	biomarker	NOUN
iajs-3010	57	25	between	between	ADP
iajs-3010	57	26	study	study	NOUN
iajs-3010	57	27	groups	group	NOUN
iajs-3010	57	28	groups	group	NOUN
iajs-3010	57	29	n	n	PRON
iajs-3010	57	30	wbc	wbc	PROPN
iajs-3010	57	31	mean±	mean±	PROPN
iajs-3010	57	32	s.e	s.e	PROPN
iajs-3010	57	33	eo	eo	PROPN
iajs-3010	57	34	mean±	mean±	PROPN
iajs-3010	58	1	s.e	s.e	PROPN
iajs-3010	58	2	total	total	PROPN
iajs-3010	58	3	-	-	PUNCT
iajs-3010	58	4	ige	ige	PROPN
iajs-3010	58	5	mean±	mean±	PROPN
iajs-3010	58	6	s.e	s.e	PROPN
iajs-3010	58	7	iu	iu	PROPN
iajs-3010	58	8	/	/	SYM
iajs-3010	58	9	ml	ml	PROPN
iajs-3010	58	10	il-6	il-6	PROPN
iajs-3010	58	11	mean±	mean±	NOUN
iajs-3010	59	1	s.e	s.e	PROPN
iajs-3010	59	2	pg	pg	PROPN
iajs-3010	59	3	/	/	SYM
iajs-3010	59	4	ml	ml	PROPN
iajs-3010	59	5	patients	patient	NOUN
iajs-3010	59	6	80	80	NUM
iajs-3010	59	7	a0.34±	a0.34±	NOUN
iajs-3010	59	8	8.14	8.14	NUM
iajs-3010	59	9	a0.27±	a0.27±	NOUN
iajs-3010	59	10	2.22	2.22	NUM
iajs-3010	59	11	a±12.6	a±12.6	NOUN
iajs-3010	59	12	198.49	198.49	NUM
iajs-3010	59	13	23.92	23.92	NUM
iajs-3010	59	14	±	±	NOUN
iajs-3010	59	15	0.75a	0.75a	NOUN
iajs-3010	59	16	controls	control	VERB
iajs-3010	59	17	40	40	NUM
iajs-3010	59	18	b0.22±	b0.22±	NOUN
iajs-3010	59	19	6.7	6.7	NUM
iajs-3010	59	20	a±0.19	a±0.19	NOUN
iajs-3010	59	21	1.89	1.89	NUM
iajs-3010	59	22	b±3.8	b±3.8	NOUN
iajs-3010	59	23	32.96	32.96	NUM
iajs-3010	59	24	8.7708	8.7708	NUM
iajs-3010	59	25	±	±	NUM
iajs-3010	59	26	0.57b	0.57b	NUM
iajs-3010	59	27	p	p	ADJ
iajs-3010	59	28	-	-	PUNCT
iajs-3010	59	29	value	value	NOUN
iajs-3010	59	30	0.011	0.011	NUM
iajs-3010	59	31	0.548	0.548	NUM
iajs-3010	59	32	0.0001	0.0001	NUM
iajs-3010	59	33	0.001	0.001	NUM
iajs-3010	59	34	the	the	DET
iajs-3010	59	35	different	different	ADJ
iajs-3010	59	36	letters	letter	NOUN
iajs-3010	59	37	mean	mean	VERB
iajs-3010	59	38	there	there	PRON
iajs-3010	59	39	was	be	VERB
iajs-3010	59	40	a	a	DET
iajs-3010	59	41	significant	significant	ADJ
iajs-3010	59	42	difference	difference	NOUN
iajs-3010	59	43	while	while	SCONJ
iajs-3010	59	44	the	the	DET
iajs-3010	59	45	similar	similar	ADJ
iajs-3010	59	46	letters	letter	NOUN
iajs-3010	59	47	mean	mean	VERB
iajs-3010	59	48	there	there	PRON
iajs-3010	59	49	was	be	VERB
iajs-3010	59	50	not	not	PART
iajs-3010	59	51	a	a	DET
iajs-3010	59	52	significant	significant	ADJ
iajs-3010	59	53	difference	difference	NOUN
iajs-3010	59	54	.	.	PUNCT
iajs-3010	60	1	the	the	DET
iajs-3010	60	2	obtained	obtain	VERB
iajs-3010	60	3	results	result	NOUN
iajs-3010	60	4	generally	generally	ADV
iajs-3010	60	5	agreed	agree	VERB
iajs-3010	60	6	with	with	ADP
iajs-3010	60	7	góra	góra	PROPN
iajs-3010	60	8	et	et	PROPN
iajs-3010	60	9	al.[15]mentioned	al.[15]mentione	VERB
iajs-3010	60	10	the	the	DET
iajs-3010	60	11	parameters	parameter	NOUN
iajs-3010	60	12	(	(	PUNCT
iajs-3010	60	13	wbc	wbc	PROPN
iajs-3010	60	14	,	,	PUNCT
iajs-3010	60	15	eo	eo	PROPN
iajs-3010	60	16	,	,	PUNCT
iajs-3010	60	17	ige	ige	PROPN
iajs-3010	60	18	,	,	PUNCT
iajs-3010	60	19	il-6	il-6	NUM
iajs-3010	60	20	)	)	PUNCT
iajs-3010	60	21	higher	high	ADJ
iajs-3010	60	22	in	in	ADP
iajs-3010	60	23	patient	patient	NOUN
iajs-3010	60	24	with	with	ADP
iajs-3010	60	25	acute	acute	ADJ
iajs-3010	60	26	and	and	CCONJ
iajs-3010	60	27	chronic	chronic	ADJ
iajs-3010	60	28	urticarial	urticarial	NOUN
iajs-3010	60	29	than	than	ADP
iajs-3010	60	30	control	control	NOUN
iajs-3010	60	31	group	group	NOUN
iajs-3010	60	32	,	,	PUNCT
iajs-3010	60	33	as	as	ADV
iajs-3010	60	34	well	well	ADV
iajs-3010	60	35	as	as	ADP
iajs-3010	60	36	agreed	agree	VERB
iajs-3010	60	37	with	with	ADP
iajs-3010	60	38	jang	jang	PROPN
iajs-3010	60	39	et	et	PROPN
iajs-3010	60	40	al	al	PROPN
iajs-3010	60	41	.	.	PUNCT
iajs-3010	61	1	[	[	X
iajs-3010	61	2	16	16	NUM
iajs-3010	61	3	]	]	PUNCT
iajs-3010	61	4	the	the	DET
iajs-3010	61	5	serum	serum	PROPN
iajs-3010	61	6	ige	ige	PROPN
iajs-3010	61	7	higher	higher	ADV
iajs-3010	61	8	in	in	ADP
iajs-3010	61	9	the	the	DET
iajs-3010	61	10	patients	patient	NOUN
iajs-3010	61	11	ige	ige	PROPN
iajs-3010	61	12	modulates	modulate	NOUN
iajs-3010	61	13	mast	mast	NOUN
iajs-3010	61	14	cell	cell	NOUN
iajs-3010	61	15	activation	activation	NOUN
iajs-3010	61	16	and	and	CCONJ
iajs-3010	61	17	releases	release	VERB
iajs-3010	61	18	histamine	histamine	NOUN
iajs-3010	61	19	,	,	PUNCT
iajs-3010	61	20	lipid	lipid	NOUN
iajs-3010	61	21	mediators	mediator	NOUN
iajs-3010	61	22	,	,	PUNCT
iajs-3010	61	23	kinins	kinin	NOUN
iajs-3010	61	24	,	,	PUNCT
iajs-3010	61	25	and	and	CCONJ
iajs-3010	61	26	cytokines	cytokine	NOUN
iajs-3010	61	27	,	,	PUNCT
iajs-3010	61	28	which	which	PRON
iajs-3010	61	29	contributes	contribute	VERB
iajs-3010	61	30	to	to	ADP
iajs-3010	61	31	the	the	DET
iajs-3010	61	32	development	development	NOUN
iajs-3010	61	33	and	and	CCONJ
iajs-3010	61	34	severity	severity	NOUN
iajs-3010	61	35	of	of	ADP
iajs-3010	61	36	csu	csu	VERB
iajs-3010	61	37	by	by	ADP
iajs-3010	61	38	interacting	interact	VERB
iajs-3010	61	39	with	with	ADP
iajs-3010	61	40	a	a	DET
iajs-3010	61	41	high	high	ADJ
iajs-3010	61	42	-	-	PUNCT
iajs-3010	61	43	affinity	affinity	NOUN
iajs-3010	61	44	ige	ige	NOUN
iajs-3010	61	45	receptor	receptor	NOUN
iajs-3010	61	46	(	(	PUNCT
iajs-3010	61	47	fcri	fcri	NOUN
iajs-3010	61	48	)	)	PUNCT
iajs-3010	61	49	found	find	VERB
iajs-3010	61	50	on	on	ADP
iajs-3010	61	51	cutaneous	cutaneous	ADJ
iajs-3010	61	52	mast	mast	NOUN
iajs-3010	61	53	cells	cell	NOUN
iajs-3010	61	54	and	and	CCONJ
iajs-3010	61	55	basophils	basophil	NOUN
iajs-3010	61	56	[	[	X
iajs-3010	61	57	17	17	NUM
iajs-3010	61	58	]	]	PUNCT
iajs-3010	61	59	.	.	PUNCT
iajs-3010	62	1	the	the	DET
iajs-3010	62	2	results	result	NOUN
iajs-3010	62	3	of	of	ADP
iajs-3010	62	4	immunological	immunological	ADJ
iajs-3010	62	5	markers	marker	NOUN
iajs-3010	62	6	and	and	CCONJ
iajs-3010	62	7	age	age	NOUN
iajs-3010	62	8	showed	show	VERB
iajs-3010	62	9	in	in	ADP
iajs-3010	62	10	table	table	NOUN
iajs-3010	62	11	(	(	PUNCT
iajs-3010	62	12	3	3	NUM
iajs-3010	62	13	)	)	PUNCT
iajs-3010	62	14	,	,	PUNCT
iajs-3010	62	15	the	the	DET
iajs-3010	62	16	patient	patient	NOUN
iajs-3010	62	17	with	with	ADP
iajs-3010	62	18	age	age	NOUN
iajs-3010	62	19	5160	5160	NUM
iajs-3010	62	20	and	and	CCONJ
iajs-3010	62	21	21	21	NUM
iajs-3010	62	22	-	-	SYM
iajs-3010	62	23	30	30	NUM
iajs-3010	62	24	year	year	NOUN
iajs-3010	62	25	had	have	VERB
iajs-3010	62	26	highest	high	ADJ
iajs-3010	62	27	eosinophils	eosinophil	NOUN
iajs-3010	62	28	count	count	NOUN
iajs-3010	62	29	while	while	SCONJ
iajs-3010	62	30	those	those	PRON
iajs-3010	62	31	with	with	ADP
iajs-3010	62	32	age	age	NOUN
iajs-3010	62	33	41	41	NUM
iajs-3010	62	34	-	-	SYM
iajs-3010	62	35	50	50	NUM
iajs-3010	62	36	and	and	CCONJ
iajs-3010	62	37	51	51	NUM
iajs-3010	62	38	-	-	SYM
iajs-3010	62	39	60	60	NUM
iajs-3010	62	40	year	year	NOUN
iajs-3010	62	41	had	have	VERB
iajs-3010	62	42	highest	high	ADJ
iajs-3010	62	43	total	total	ADJ
iajs-3010	62	44	-	-	PUNCT
iajs-3010	62	45	ige	ige	NOUN
iajs-3010	62	46	level	level	NOUN
iajs-3010	62	47	211.7	211.7	NUM
iajs-3010	62	48	±38.96	±38.96	NOUN
iajs-3010	62	49	iu	iu	PROPN
iajs-3010	62	50	/	/	SYM
iajs-3010	62	51	ml	ml	NOUN
iajs-3010	62	52	,	,	PUNCT
iajs-3010	62	53	211.69	211.69	NUM
iajs-3010	62	54	±38.71	±38.71	X
iajs-3010	62	55	iu	iu	NOUN
iajs-3010	62	56	/	/	SYM
iajs-3010	62	57	ml	ml	NOUN
iajs-3010	62	58	respectively	respectively	ADV
iajs-3010	62	59	but	but	CCONJ
iajs-3010	62	60	patients	patient	NOUN
iajs-3010	62	61	with	with	ADP
iajs-3010	62	62	21	21	NUM
iajs-3010	62	63	-	-	SYM
iajs-3010	62	64	30	30	NUM
iajs-3010	62	65	and	and	CCONJ
iajs-3010	62	66	51	51	NUM
iajs-3010	62	67	-	-	SYM
iajs-3010	62	68	60	60	NUM
iajs-3010	62	69	year	year	NOUN
iajs-3010	62	70	showed	show	VERB
iajs-3010	62	71	highest	high	ADJ
iajs-3010	62	72	il-6	il-6	NOUN
iajs-3010	62	73	level	level	NOUN
iajs-3010	62	74	26.4	26.4	NUM
iajs-3010	62	75	±1.77	±1.77	NOUN
iajs-3010	62	76	pg	pg	NOUN
iajs-3010	62	77	/	/	SYM
iajs-3010	62	78	ml	ml	NOUN
iajs-3010	62	79	,	,	PUNCT
iajs-3010	62	80	25.03±2.39pg	25.03±2.39pg	NUM
iajs-3010	62	81	/	/	SYM
iajs-3010	62	82	ml	ml	NOUN
iajs-3010	62	83	respectively	respectively	ADV
iajs-3010	62	84	however	however	ADV
iajs-3010	62	85	the	the	DET
iajs-3010	62	86	patients	patient	NOUN
iajs-3010	62	87	with	with	ADP
iajs-3010	62	88	different	different	ADJ
iajs-3010	62	89	ages	age	NOUN
iajs-3010	62	90	recorded	record	VERB
iajs-3010	62	91	high	high	ADJ
iajs-3010	62	92	value	value	NOUN
iajs-3010	62	93	levels	level	NOUN
iajs-3010	62	94	than	than	ADP
iajs-3010	62	95	the	the	DET
iajs-3010	62	96	control	control	NOUN
iajs-3010	62	97	with	with	ADP
iajs-3010	62	98	same	same	ADJ
iajs-3010	62	99	ages	age	NOUN
iajs-3010	62	100	with	with	ADP
iajs-3010	62	101	significant	significant	ADJ
iajs-3010	62	102	differences	difference	NOUN
iajs-3010	62	103	except	except	SCONJ
iajs-3010	62	104	wbc	wbc	PROPN
iajs-3010	62	105	count	count	NOUN
iajs-3010	62	106	in	in	ADP
iajs-3010	62	107	age	age	NOUN
iajs-3010	62	108	41	41	NUM
iajs-3010	62	109	-	-	SYM
iajs-3010	62	110	50	50	NUM
iajs-3010	62	111	and	and	CCONJ
iajs-3010	62	112	51	51	NUM
iajs-3010	62	113	-	-	SYM
iajs-3010	62	114	60	60	NUM
iajs-3010	62	115	year	year	NOUN
iajs-3010	62	116	showed	show	VERB
iajs-3010	62	117	highest	high	ADJ
iajs-3010	62	118	count	count	NOUN
iajs-3010	62	119	9.2	9.2	NUM
iajs-3010	62	120	±1.34	±1.34	NOUN
iajs-3010	62	121	cell	cell	NOUN
iajs-3010	62	122	/	/	SYM
iajs-3010	62	123	cm³	cm³	NOUN
iajs-3010	62	124	,	,	PUNCT
iajs-3010	62	125	9.3±1.21cell	9.3±1.21cell	NUM
iajs-3010	62	126	/	/	SYM
iajs-3010	62	127	cm³	cm³	NOUN
iajs-3010	62	128	respectively	respectively	ADV
iajs-3010	62	129	and	and	CCONJ
iajs-3010	62	130	eosinophils	eosinophil	VERB
iajs-3010	62	131	count	count	NOUN
iajs-3010	62	132	in	in	ADP
iajs-3010	62	133	age	age	NOUN
iajs-3010	62	134	51	51	NUM
iajs-3010	62	135	-	-	SYM
iajs-3010	62	136	60	60	NUM
iajs-3010	62	137	and	and	CCONJ
iajs-3010	62	138	21	21	NUM
iajs-3010	62	139	-	-	SYM
iajs-3010	62	140	30	30	NUM
iajs-3010	62	141	had	have	VERB
iajs-3010	62	142	highest	high	ADJ
iajs-3010	62	143	count	count	NOUN
iajs-3010	62	144	2.4±	2.4±	PROPN
iajs-3010	62	145	0.6	0.6	NUM
iajs-3010	62	146	,	,	PUNCT
iajs-3010	62	147	1.99	1.99	NUM
iajs-3010	62	148	±0.45	±0.45	PROPN
iajs-3010	62	149	respectively	respectively	ADV
iajs-3010	62	150	with	with	ADP
iajs-3010	62	151	no	no	DET
iajs-3010	62	152	significant	significant	ADJ
iajs-3010	62	153	difference	difference	NOUN
iajs-3010	62	154	at	at	ADP
iajs-3010	62	155	(	(	PUNCT
iajs-3010	62	156	p≤	p≤	NOUN
iajs-3010	62	157	0.05	0.05	NUM
iajs-3010	62	158	)	)	PUNCT
iajs-3010	62	159	table	table	NOUN
iajs-3010	62	160	3	3	NUM
iajs-3010	62	161	ihjpas	ihjpa	NOUN
iajs-3010	62	162	.	.	PUNCT
iajs-3010	63	1	36(2)2023	36(2)2023	NUM
iajs-3010	63	2	37	37	NUM
iajs-3010	63	3	table	table	NOUN
iajs-3010	63	4	3	3	NUM
iajs-3010	63	5	.	.	PUNCT
iajs-3010	63	6	biomarkers	biomarker	NOUN
iajs-3010	63	7	and	and	CCONJ
iajs-3010	63	8	age	age	NOUN
iajs-3010	63	9	distribution	distribution	NOUN
iajs-3010	63	10	in	in	ADP
iajs-3010	63	11	patients	patient	NOUN
iajs-3010	63	12	and	and	CCONJ
iajs-3010	63	13	control	control	NOUN
iajs-3010	63	14	groups	group	NOUN
iajs-3010	63	15	age	age	NOUN
iajs-3010	63	16	group	group	NOUN
iajs-3010	63	17	n	n	PROPN
iajs-3010	64	1	wbc	wbc	PROPN
iajs-3010	64	2	mean±	mean±	PROPN
iajs-3010	64	3	s.e	s.e	PROPN
iajs-3010	64	4	.	.	PROPN
iajs-3010	64	5	eo	eo	PROPN
iajs-3010	64	6	mean±	mean±	PROPN
iajs-3010	65	1	s.e	s.e	PROPN
iajs-3010	65	2	.	.	PROPN
iajs-3010	65	3	total	total	PROPN
iajs-3010	65	4	-	-	PUNCT
iajs-3010	65	5	ige	ige	PROPN
iajs-3010	65	6	mean±	mean±	PROPN
iajs-3010	65	7	s.e	s.e	PROPN
iajs-3010	65	8	.	.	PROPN
iajs-3010	65	9	il6	il6	PROPN
iajs-3010	65	10	mean±	mean±	PROPN
iajs-3010	65	11	s.e	s.e	PROPN
iajs-3010	65	12	.	.	PROPN
iajs-3010	65	13	patients	patient	NOUN
iajs-3010	65	14	11	11	NUM
iajs-3010	65	15	-	-	SYM
iajs-3010	65	16	20	20	NUM
iajs-3010	65	17	13	13	NUM
iajs-3010	65	18	7.9	7.9	NUM
iajs-3010	65	19	±0.6	±0.6	NOUN
iajs-3010	65	20	3.48±1.21	3.48±1.21	NOUN
iajs-3010	65	21	177.95	177.95	NUM
iajs-3010	65	22	±28.20	±28.20	NOUN
iajs-3010	65	23	23.38	23.38	NUM
iajs-3010	65	24	±1.81	±1.81	PROPN
iajs-3010	65	25	21	21	NUM
iajs-3010	65	26	-	-	SYM
iajs-3010	65	27	30	30	NUM
iajs-3010	65	28	21	21	NUM
iajs-3010	65	29	7.65±0.42	7.65±0.42	NUM
iajs-3010	65	30	1.99	1.99	NUM
iajs-3010	65	31	±0.45	±0.45	PROPN
iajs-3010	65	32	201.79	201.79	NUM
iajs-3010	65	33	±22.28	±22.28	NOUN
iajs-3010	65	34	26.4	26.4	NUM
iajs-3010	65	35	±1.77	±1.77	NOUN
iajs-3010	65	36	31	31	NUM
iajs-3010	65	37	-	-	SYM
iajs-3010	65	38	40	40	NUM
iajs-3010	65	39	22	22	NUM
iajs-3010	65	40	7.47±0.53	7.47±0.53	NUM
iajs-3010	65	41	1.87	1.87	NUM
iajs-3010	65	42	±0.28	±0.28	PROPN
iajs-3010	65	43	193.07±24.04	193.07±24.04	NUM
iajs-3010	65	44	21.38±1.12	21.38±1.12	NUM
iajs-3010	65	45	41	41	NUM
iajs-3010	65	46	-	-	SYM
iajs-3010	65	47	50	50	NUM
iajs-3010	65	48	12	12	NUM
iajs-3010	65	49	9.2	9.2	NUM
iajs-3010	65	50	±1.34	±1.34	NOUN
iajs-3010	65	51	1.67±0.43	1.67±0.43	NUM
iajs-3010	65	52	211.7	211.7	NUM
iajs-3010	65	53	±38.96	±38.96	NOUN
iajs-3010	65	54	23.63±1.126	23.63±1.126	NUM
iajs-3010	65	55	51	51	NUM
iajs-3010	65	56	-	-	SYM
iajs-3010	65	57	60	60	NUM
iajs-3010	65	58	12	12	NUM
iajs-3010	65	59	9.3±1.21	9.3±1.21	NUM
iajs-3010	65	60	2.4±	2.4±	NUM
iajs-3010	65	61	0.6	0.6	NUM
iajs-3010	65	62	211.69	211.69	NUM
iajs-3010	65	63	±38.71	±38.71	NOUN
iajs-3010	65	64	25.03±2.39	25.03±2.39	PROPN
iajs-3010	65	65	controls	control	VERB
iajs-3010	65	66	11	11	NUM
iajs-3010	65	67	-	-	SYM
iajs-3010	65	68	20	20	NUM
iajs-3010	65	69	5	5	NUM
iajs-3010	65	70	7.02±0.85	7.02±0.85	NOUN
iajs-3010	65	71	1.49±0.28	1.49±0.28	NUM
iajs-3010	65	72	29.44±8.93	29.44±8.93	NUM
iajs-3010	66	1	6.67±1.4	6.67±1.4	NUM
iajs-3010	66	2	21	21	NUM
iajs-3010	66	3	-	-	SYM
iajs-3010	66	4	30	30	NUM
iajs-3010	66	5	18	18	NUM
iajs-3010	66	6	7.028±0.33	7.028±0.33	NUM
iajs-3010	66	7	1.96	1.96	NUM
iajs-3010	66	8	±0.27	±0.27	PROPN
iajs-3010	66	9	38.63±7.36	38.63±7.36	PROPN
iajs-3010	66	10	11.09±0.78	11.09±0.78	NUM
iajs-3010	66	11	31	31	NUM
iajs-3010	66	12	-	-	SYM
iajs-3010	66	13	40	40	NUM
iajs-3010	66	14	4	4	NUM
iajs-3010	66	15	6.52±0.59	6.52±0.59	NUM
iajs-3010	66	16	2.7±1.03	2.7±1.03	NUM
iajs-3010	66	17	20.98±2.28	20.98±2.28	NUM
iajs-3010	66	18	5.53±1.11	5.53±1.11	NUM
iajs-3010	66	19	41	41	NUM
iajs-3010	66	20	-	-	SYM
iajs-3010	66	21	50	50	NUM
iajs-3010	66	22	5	5	NUM
iajs-3010	66	23	6.22±0.45	6.22±0.45	NUM
iajs-3010	66	24	1.98±0.77	1.98±0.77	NUM
iajs-3010	66	25	26.36±5.35	26.36±5.35	NUM
iajs-3010	66	26	6.5±1.50	6.5±1.50	NUM
iajs-3010	66	27	51	51	NUM
iajs-3010	66	28	-	-	SYM
iajs-3010	66	29	60	60	NUM
iajs-3010	66	30	8	8	NUM
iajs-3010	66	31	6.56±0.62	6.56±0.62	NUM
iajs-3010	66	32	1.42±0.26	1.42±0.26	NUM
iajs-3010	66	33	28.5±5.7	28.5±5.7	NUM
iajs-3010	66	34	8.01±0.87	8.01±0.87	NUM
iajs-3010	66	35	p	p	NOUN
iajs-3010	66	36	value	value	NOUN
iajs-3010	66	37	0.292	0.292	NUM
iajs-3010	66	38	0.971	0.971	NUM
iajs-3010	66	39	0.001	0.001	NUM
iajs-3010	66	40	0.001	0.001	NUM
iajs-3010	66	41	p	p	NOUN
iajs-3010	66	42	value	value	NOUN
iajs-3010	66	43	≤0.05	≤0.05	NOUN
iajs-3010	66	44	means	mean	VERB
iajs-3010	66	45	there	there	PRON
iajs-3010	66	46	was	be	VERB
iajs-3010	66	47	a	a	DET
iajs-3010	66	48	significant	significant	ADJ
iajs-3010	66	49	difference	difference	NOUN
iajs-3010	66	50	between	between	ADP
iajs-3010	66	51	the	the	DET
iajs-3010	66	52	patients	patient	NOUN
iajs-3010	66	53	and	and	CCONJ
iajs-3010	66	54	the	the	DET
iajs-3010	66	55	control	control	NOUN
iajs-3010	66	56	in	in	ADP
iajs-3010	66	57	same	same	ADJ
iajs-3010	66	58	age	age	NOUN
iajs-3010	66	59	range	range	NOUN
iajs-3010	66	60	.	.	PUNCT
iajs-3010	67	1	p	p	NOUN
iajs-3010	67	2	value	value	NOUN
iajs-3010	67	3	>	>	X
iajs-3010	67	4	0.05	0.05	NUM
iajs-3010	67	5	means	mean	VERB
iajs-3010	67	6	there	there	PRON
iajs-3010	67	7	was	be	VERB
iajs-3010	67	8	not	not	PART
iajs-3010	67	9	a	a	DET
iajs-3010	67	10	significant	significant	ADJ
iajs-3010	67	11	difference	difference	NOUN
iajs-3010	67	12	between	between	ADP
iajs-3010	67	13	the	the	DET
iajs-3010	67	14	patients	patient	NOUN
iajs-3010	67	15	and	and	CCONJ
iajs-3010	67	16	the	the	DET
iajs-3010	67	17	control	control	NOUN
iajs-3010	67	18	in	in	ADP
iajs-3010	67	19	same	same	ADJ
iajs-3010	67	20	age	age	NOUN
iajs-3010	67	21	range	range	NOUN
iajs-3010	67	22	.	.	PUNCT
iajs-3010	68	1	the	the	DET
iajs-3010	68	2	results	result	NOUN
iajs-3010	68	3	were	be	AUX
iajs-3010	68	4	in	in	ADP
iajs-3010	68	5	agreement	agreement	NOUN
iajs-3010	68	6	with	with	ADP
iajs-3010	68	7	chuamanochan	chuamanochan	PROPN
iajs-3010	68	8	et	et	PROPN
iajs-3010	68	9	al	al	PROPN
iajs-3010	68	10	.	.	PUNCT
iajs-3010	69	1	[	[	X
iajs-3010	69	2	18	18	NUM
iajs-3010	69	3	]	]	PUNCT
iajs-3010	69	4	.	.	PUNCT
iajs-3010	70	1	the	the	DET
iajs-3010	70	2	most	most	ADV
iajs-3010	70	3	frequent	frequent	ADJ
iajs-3010	70	4	cause	cause	NOUN
iajs-3010	70	5	of	of	ADP
iajs-3010	70	6	cu	cu	PROPN
iajs-3010	70	7	was	be	AUX
iajs-3010	70	8	chronic	chronic	ADJ
iajs-3010	70	9	spontaneous	spontaneous	ADJ
iajs-3010	70	10	urticaria	urticaria	NOUN
iajs-3010	70	11	in	in	ADP
iajs-3010	70	12	both	both	DET
iajs-3010	70	13	groups	group	NOUN
iajs-3010	70	14	of	of	ADP
iajs-3010	70	15	patients	patient	NOUN
iajs-3010	70	16	,	,	PUNCT
iajs-3010	70	17	those	those	PRON
iajs-3010	70	18	67	67	NUM
iajs-3010	70	19	(	(	PUNCT
iajs-3010	70	20	60	60	NUM
iajs-3010	70	21	-	-	SYM
iajs-3010	70	22	83	83	NUM
iajs-3010	70	23	)	)	PUNCT
iajs-3010	70	24	years	year	NOUN
iajs-3010	70	25	old	old	ADJ
iajs-3010	70	26	and	and	CCONJ
iajs-3010	70	27	those	those	DET
iajs-3010	70	28	35.6	35.6	NUM
iajs-3010	70	29	(	(	PUNCT
iajs-3010	70	30	15	15	NUM
iajs-3010	70	31	-	-	SYM
iajs-3010	70	32	59	59	NUM
iajs-3010	70	33	)	)	PUNCT
iajs-3010	70	34	years	year	NOUN
iajs-3010	70	35	old	old	ADJ
iajs-3010	70	36	.	.	PUNCT
iajs-3010	71	1	however	however	ADV
iajs-3010	71	2	,	,	PUNCT
iajs-3010	71	3	without	without	ADP
iajs-3010	71	4	a	a	DET
iajs-3010	71	5	statistically	statistically	ADV
iajs-3010	71	6	significant	significant	ADJ
iajs-3010	71	7	difference	difference	NOUN
iajs-3010	71	8	,	,	PUNCT
iajs-3010	71	9	the	the	DET
iajs-3010	71	10	aging	age	VERB
iajs-3010	71	11	group	group	NOUN
iajs-3010	71	12	had	have	VERB
iajs-3010	71	13	higher	high	ADJ
iajs-3010	71	14	rates	rate	NOUN
iajs-3010	71	15	of	of	ADP
iajs-3010	71	16	positive	positive	ADJ
iajs-3010	71	17	autologous	autologous	ADJ
iajs-3010	71	18	serum	serum	NOUN
iajs-3010	71	19	skin	skin	NOUN
iajs-3010	71	20	tests	test	NOUN
iajs-3010	71	21	,	,	PUNCT
iajs-3010	71	22	anti	anti	ADJ
iajs-3010	71	23	-	-	NOUN
iajs-3010	71	24	thyroid	thyroid	ADJ
iajs-3010	71	25	and	and	CCONJ
iajs-3010	71	26	antinuclear	antinuclear	ADJ
iajs-3010	71	27	antibodies	antibody	NOUN
iajs-3010	71	28	,	,	PUNCT
iajs-3010	71	29	increased	increase	VERB
iajs-3010	71	30	wbc	wbc	PROPN
iajs-3010	71	31	,	,	PUNCT
iajs-3010	71	32	and	and	CCONJ
iajs-3010	71	33	eosinophils	eosinophil	NOUN
iajs-3010	71	34	than	than	SCONJ
iajs-3010	71	35	the	the	DET
iajs-3010	71	36	non	non	ADJ
iajs-3010	71	37	-	-	ADJ
iajs-3010	71	38	aging	aging	ADJ
iajs-3010	71	39	group	group	NOUN
iajs-3010	71	40	did	do	VERB
iajs-3010	71	41	.	.	PUNCT
iajs-3010	72	1	in	in	ADP
iajs-3010	72	2	addition	addition	NOUN
iajs-3010	72	3	,	,	PUNCT
iajs-3010	72	4	mast	mast	NOUN
iajs-3010	72	5	cells	cell	NOUN
iajs-3010	72	6	,	,	PUNCT
iajs-3010	72	7	basophils	basophil	NOUN
iajs-3010	72	8	,	,	PUNCT
iajs-3010	72	9	eosinophils	eosinophil	NOUN
iajs-3010	72	10	,	,	PUNCT
iajs-3010	72	11	and	and	CCONJ
iajs-3010	72	12	ige	ige	PROPN
iajs-3010	72	13	are	be	AUX
iajs-3010	72	14	crucial	crucial	ADJ
iajs-3010	72	15	elements	element	NOUN
iajs-3010	72	16	in	in	ADP
iajs-3010	72	17	allergic	allergic	ADJ
iajs-3010	72	18	inflammation	inflammation	NOUN
iajs-3010	72	19	[	[	X
iajs-3010	72	20	18	18	NUM
iajs-3010	72	21	]	]	PUNCT
iajs-3010	72	22	.	.	PUNCT
iajs-3010	73	1	additionally	additionally	ADV
iajs-3010	73	2	,	,	PUNCT
iajs-3010	73	3	hussein	hussein	PROPN
iajs-3010	73	4	et	et	PROPN
iajs-3010	73	5	al	al	PROPN
iajs-3010	73	6	.	.	PUNCT
iajs-3010	74	1	[	[	X
iajs-3010	74	2	19	19	NUM
iajs-3010	74	3	]	]	PUNCT
iajs-3010	74	4	indicated	indicate	VERB
iajs-3010	74	5	that	that	SCONJ
iajs-3010	74	6	il-17a	il-17a	PROPN
iajs-3010	74	7	may	may	AUX
iajs-3010	74	8	be	be	AUX
iajs-3010	74	9	induced	induce	VERB
iajs-3010	74	10	by	by	ADP
iajs-3010	74	11	stress	stress	NOUN
iajs-3010	74	12	and	and	CCONJ
iajs-3010	74	13	may	may	AUX
iajs-3010	74	14	have	have	VERB
iajs-3010	74	15	an	an	DET
iajs-3010	74	16	influence	influence	NOUN
iajs-3010	74	17	on	on	ADP
iajs-3010	74	18	an	an	DET
iajs-3010	74	19	increase	increase	NOUN
iajs-3010	74	20	in	in	ADP
iajs-3010	74	21	acute	acute	ADJ
iajs-3010	74	22	urticaria	urticaria	NOUN
iajs-3010	74	23	patients	patient	NOUN
iajs-3010	74	24	'	'	PART
iajs-3010	74	25	total	total	ADJ
iajs-3010	74	26	wbc	wbc	PROPN
iajs-3010	74	27	.	.	PUNCT
iajs-3010	75	1	immediate	immediate	ADJ
iajs-3010	75	2	hypersensitivity	hypersensitivity	NOUN
iajs-3010	75	3	responses	response	NOUN
iajs-3010	75	4	are	be	AUX
iajs-3010	75	5	started	start	VERB
iajs-3010	75	6	and	and	CCONJ
iajs-3010	75	7	spread	spread	VERB
iajs-3010	75	8	by	by	ADP
iajs-3010	75	9	antigen	antigen	NOUN
iajs-3010	75	10	-	-	PUNCT
iajs-3010	75	11	specific	specific	ADJ
iajs-3010	75	12	ige	ige	NOUN
iajs-3010	75	13	synthesis	synthesis	NOUN
iajs-3010	75	14	,	,	PUNCT
iajs-3010	75	15	which	which	PRON
iajs-3010	75	16	is	be	AUX
iajs-3010	75	17	followed	follow	VERB
iajs-3010	75	18	by	by	ADP
iajs-3010	75	19	ige	ige	PROPN
iajs-3010	75	20	fixation	fixation	NOUN
iajs-3010	75	21	to	to	PART
iajs-3010	75	22	fc	fc	PROPN
iajs-3010	75	23	ri	ri	PROPN
iajs-3010	75	24	receptors	receptor	NOUN
iajs-3010	75	25	on	on	ADP
iajs-3010	75	26	mast	mast	NOUN
iajs-3010	75	27	cells	cell	NOUN
iajs-3010	75	28	and	and	CCONJ
iajs-3010	75	29	basophils	basophils	PROPN
iajs-3010	75	30	.	.	PUNCT
iajs-3010	76	1	mast	mast	NOUN
iajs-3010	76	2	cells	cell	NOUN
iajs-3010	76	3	,	,	PUNCT
iajs-3010	76	4	eosinophils	eosinophil	NOUN
iajs-3010	76	5	and	and	CCONJ
iajs-3010	76	6	basophils	basophil	NOUN
iajs-3010	76	7	are	be	AUX
iajs-3010	76	8	key	key	ADJ
iajs-3010	76	9	effector	effector	NOUN
iajs-3010	76	10	cells	cell	NOUN
iajs-3010	76	11	in	in	ADP
iajs-3010	76	12	both	both	CCONJ
iajs-3010	76	13	innate	innate	ADJ
iajs-3010	76	14	and	and	CCONJ
iajs-3010	76	15	adaptive	adaptive	ADJ
iajs-3010	76	16	immunity	immunity	NOUN
iajs-3010	76	17	as	as	ADV
iajs-3010	76	18	well	well	ADV
iajs-3010	76	19	as	as	ADP
iajs-3010	76	20	allergic	allergic	ADJ
iajs-3010	76	21	inflammation	inflammation	NOUN
iajs-3010	76	22	[	[	X
iajs-3010	76	23	20	20	NUM
iajs-3010	76	24	]	]	PUNCT
iajs-3010	76	25	.	.	PUNCT
iajs-3010	77	1	this	this	PRON
iajs-3010	77	2	explained	explain	VERB
iajs-3010	77	3	the	the	DET
iajs-3010	77	4	patients	patient	NOUN
iajs-3010	77	5	with	with	ADP
iajs-3010	77	6	high	high	ADJ
iajs-3010	77	7	eosinophils	eosinophil	NOUN
iajs-3010	77	8	count	count	NOUN
iajs-3010	77	9	had	have	VERB
iajs-3010	77	10	high	high	ADJ
iajs-3010	77	11	ige	ige	NOUN
iajs-3010	77	12	level	level	NOUN
iajs-3010	77	13	too	too	ADV
iajs-3010	77	14	,	,	PUNCT
iajs-3010	77	15	finally	finally	ADV
iajs-3010	77	16	same	same	ADJ
iajs-3010	77	17	result	result	NOUN
iajs-3010	77	18	between	between	ADP
iajs-3010	77	19	il6	il6	NOUN
iajs-3010	77	20	and	and	CCONJ
iajs-3010	77	21	eosinophils	eosinophil	NOUN
iajs-3010	77	22	noticed	notice	VERB
iajs-3010	77	23	in	in	ADP
iajs-3010	77	24	patient	patient	NOUN
iajs-3010	77	25	with	with	ADP
iajs-3010	77	26	same	same	ADJ
iajs-3010	77	27	age	age	NOUN
iajs-3010	77	28	due	due	ADP
iajs-3010	77	29	to	to	ADP
iajs-3010	77	30	il-6	il-6	NOUN
iajs-3010	77	31	produced	produce	VERB
iajs-3010	77	32	from	from	ADP
iajs-3010	77	33	eosinophils	eosinophil	NOUN
iajs-3010	77	34	[	[	X
iajs-3010	77	35	21	21	NUM
iajs-3010	77	36	]	]	PUNCT
iajs-3010	77	37	.	.	PUNCT
iajs-3010	78	1	the	the	DET
iajs-3010	78	2	results	result	NOUN
iajs-3010	78	3	of	of	ADP
iajs-3010	78	4	total	total	NOUN
iajs-3010	78	5	-	-	PUNCT
iajs-3010	78	6	ige	ige	NOUN
iajs-3010	78	7	between	between	ADP
iajs-3010	78	8	patients	patient	NOUN
iajs-3010	78	9	pre	pre	ADJ
iajs-3010	78	10	-	-	NOUN
iajs-3010	78	11	treatment	treatment	NOUN
iajs-3010	78	12	and	and	CCONJ
iajs-3010	78	13	post	post	ADJ
iajs-3010	78	14	-	-	ADJ
iajs-3010	78	15	treatment	treatment	NOUN
iajs-3010	78	16	showed	show	VERB
iajs-3010	78	17	various	various	ADJ
iajs-3010	78	18	results	result	NOUN
iajs-3010	78	19	,	,	PUNCT
iajs-3010	78	20	the	the	DET
iajs-3010	78	21	total	total	NOUN
iajs-3010	78	22	-	-	PUNCT
iajs-3010	78	23	ige	ige	NOUN
iajs-3010	78	24	in	in	ADP
iajs-3010	78	25	patients	patient	NOUN
iajs-3010	78	26	pre	pre	ADJ
iajs-3010	78	27	-	-	NOUN
iajs-3010	78	28	treatment	treatment	NOUN
iajs-3010	78	29	was	be	AUX
iajs-3010	78	30	higher	high	ADJ
iajs-3010	78	31	than	than	ADP
iajs-3010	78	32	patients	patient	NOUN
iajs-3010	78	33	post	post	ADJ
iajs-3010	78	34	-	-	NOUN
iajs-3010	78	35	treatment	treatment	NOUN
iajs-3010	78	36	which	which	PRON
iajs-3010	78	37	represented	represent	VERB
iajs-3010	78	38	220.80	220.80	NUM
iajs-3010	78	39	±28.80	±28.80	ADP
iajs-3010	78	40	iu	iu	ADP
iajs-3010	78	41	/	/	SYM
iajs-3010	78	42	ml	ml	NOUN
iajs-3010	78	43	and	and	CCONJ
iajs-3010	78	44	190.03	190.03	NUM
iajs-3010	78	45	±	±	NUM
iajs-3010	78	46	13.58iu	13.58iu	NUM
iajs-3010	78	47	/	/	SYM
iajs-3010	78	48	ml	ml	NOUN
iajs-3010	78	49	)	)	PUNCT
iajs-3010	78	50	respectively	respectively	ADV
iajs-3010	78	51	and	and	CCONJ
iajs-3010	78	52	higher	high	ADJ
iajs-3010	78	53	than	than	ADP
iajs-3010	78	54	the	the	DET
iajs-3010	78	55	ihjpas	ihjpa	NOUN
iajs-3010	78	56	.	.	PUNCT
iajs-3010	79	1	36(2)2023	36(2)2023	NUM
iajs-3010	79	2	38	38	NUM
iajs-3010	79	3	control	control	NOUN
iajs-3010	79	4	group	group	NOUN
iajs-3010	79	5	(	(	PUNCT
iajs-3010	79	6	32.96	32.96	NUM
iajs-3010	79	7	±3.80	±3.80	NOUN
iajs-3010	79	8	iu	iu	NOUN
iajs-3010	79	9	/	/	SYM
iajs-3010	79	10	ml	ml	NOUN
iajs-3010	79	11	)	)	PUNCT
iajs-3010	79	12	with	with	ADP
iajs-3010	79	13	significant	significant	ADJ
iajs-3010	79	14	difference	difference	NOUN
iajs-3010	79	15	between	between	ADP
iajs-3010	79	16	those	those	DET
iajs-3010	79	17	group	group	NOUN
iajs-3010	79	18	at	at	ADP
iajs-3010	79	19	(	(	PUNCT
iajs-3010	79	20	p	p	NOUN
iajs-3010	79	21	≤	≤	NOUN
iajs-3010	79	22	0.05	0.05	NUM
iajs-3010	79	23	)	)	PUNCT
iajs-3010	79	24	and	and	CCONJ
iajs-3010	79	25	il-6	il-6	NOUN
iajs-3010	79	26	between	between	ADP
iajs-3010	79	27	patients	patient	NOUN
iajs-3010	79	28	pre	pre	ADJ
iajs-3010	79	29	-	-	NOUN
iajs-3010	79	30	treatment	treatment	NOUN
iajs-3010	79	31	and	and	CCONJ
iajs-3010	79	32	patients	patient	NOUN
iajs-3010	79	33	post	post	ADJ
iajs-3010	79	34	-	-	ADJ
iajs-3010	79	35	treatment	treatment	NOUN
iajs-3010	79	36	showed	show	VERB
iajs-3010	79	37	various	various	ADJ
iajs-3010	79	38	results	result	NOUN
iajs-3010	79	39	as	as	ADV
iajs-3010	79	40	well	well	ADV
iajs-3010	79	41	as	as	ADP
iajs-3010	79	42	il-6	il-6	NOUN
iajs-3010	79	43	concentration	concentration	NOUN
iajs-3010	79	44	in	in	ADP
iajs-3010	79	45	patients	patient	NOUN
iajs-3010	79	46	pre	pre	ADJ
iajs-3010	79	47	-	-	NOUN
iajs-3010	79	48	treatment	treatment	NOUN
iajs-3010	79	49	was	be	AUX
iajs-3010	79	50	lower	low	ADJ
iajs-3010	79	51	than	than	ADP
iajs-3010	79	52	post	post	ADJ
iajs-3010	79	53	-	-	ADJ
iajs-3010	79	54	treatment	treatment	ADJ
iajs-3010	79	55	patients	patient	NOUN
iajs-3010	79	56	(	(	PUNCT
iajs-3010	79	57	22.46±1.04	22.46±1.04	NUM
iajs-3010	79	58	pg	pg	NOUN
iajs-3010	79	59	/	/	SYM
iajs-3010	79	60	ml	ml	NOUN
iajs-3010	79	61	and	and	CCONJ
iajs-3010	79	62	24.47±0.96pg	24.47±0.96pg	NUM
iajs-3010	79	63	/	/	SYM
iajs-3010	79	64	ml	ml	NOUN
iajs-3010	79	65	)	)	PUNCT
iajs-3010	79	66	respectively	respectively	ADV
iajs-3010	79	67	but	but	CCONJ
iajs-3010	79	68	higher	high	ADJ
iajs-3010	79	69	than	than	ADP
iajs-3010	79	70	the	the	DET
iajs-3010	79	71	control	control	NOUN
iajs-3010	79	72	group	group	NOUN
iajs-3010	79	73	(	(	PUNCT
iajs-3010	79	74	8.77	8.77	NUM
iajs-3010	79	75	±0.57pg	±0.57pg	NOUN
iajs-3010	79	76	/	/	SYM
iajs-3010	79	77	ml	ml	NOUN
iajs-3010	79	78	)	)	PUNCT
iajs-3010	79	79	with	with	ADP
iajs-3010	79	80	significant	significant	ADJ
iajs-3010	79	81	difference	difference	NOUN
iajs-3010	79	82	between	between	ADP
iajs-3010	79	83	those	those	DET
iajs-3010	79	84	group	group	NOUN
iajs-3010	79	85	at	at	ADP
iajs-3010	79	86	p	p	NOUN
iajs-3010	79	87	≤	≤	NUM
iajs-3010	79	88	0.05	0.05	NUM
iajs-3010	79	89	but	but	CCONJ
iajs-3010	79	90	wbc	wbc	PROPN
iajs-3010	79	91	and	and	CCONJ
iajs-3010	79	92	eo	eo	PROPN
iajs-3010	79	93	count	count	NOUN
iajs-3010	79	94	recorded	record	VERB
iajs-3010	79	95	in	in	ADP
iajs-3010	79	96	patients	patient	NOUN
iajs-3010	79	97	pre	pre	NOUN
iajs-3010	79	98	-	-	NOUN
iajs-3010	79	99	treatment	treatment	NOUN
iajs-3010	79	100	was	be	AUX
iajs-3010	79	101	lower	low	ADJ
iajs-3010	79	102	than	than	ADP
iajs-3010	79	103	patients	patient	NOUN
iajs-3010	79	104	post	post	ADJ
iajs-3010	79	105	-	-	ADJ
iajs-3010	79	106	treatment	treatment	ADJ
iajs-3010	79	107	significant	significant	ADJ
iajs-3010	79	108	difference	difference	NOUN
iajs-3010	79	109	between	between	ADP
iajs-3010	79	110	those	those	DET
iajs-3010	79	111	group	group	NOUN
iajs-3010	79	112	at	at	ADP
iajs-3010	79	113	p	p	NOUN
iajs-3010	79	114	≤	≤	NUM
iajs-3010	79	115	0.05	0.05	NUM
iajs-3010	79	116	in	in	ADP
iajs-3010	79	117	table	table	NOUN
iajs-3010	79	118	4	4	NUM
iajs-3010	79	119	table	table	NOUN
iajs-3010	79	120	4	4	NUM
iajs-3010	79	121	.	.	PUNCT
iajs-3010	80	1	the	the	DET
iajs-3010	80	2	comparison	comparison	NOUN
iajs-3010	80	3	between	between	ADP
iajs-3010	80	4	pre	pre	ADJ
iajs-3010	80	5	and	and	CCONJ
iajs-3010	80	6	post	post	VERB
iajs-3010	80	7	treatment	treatment	NOUN
iajs-3010	80	8	patients	patient	NOUN
iajs-3010	80	9	and	and	CCONJ
iajs-3010	80	10	controls	control	VERB
iajs-3010	80	11	group	group	NOUN
iajs-3010	80	12	n	n	CCONJ
iajs-3010	80	13	total	total	ADJ
iajs-3010	80	14	-	-	PUNCT
iajs-3010	80	15	ige	ige	PROPN
iajs-3010	80	16	il-6	il-6	NOUN
iajs-3010	80	17	wbc	wbc	PROPN
iajs-3010	80	18	eo	eo	PROPN
iajs-3010	80	19	count	count	PROPN
iajs-3010	80	20	patients	patient	NOUN
iajs-3010	80	21	pre	pre	VERB
iajs-3010	80	22	treatment	treatment	NOUN
iajs-3010	80	23	22	22	NUM
iajs-3010	80	24	220.80	220.80	NUM
iajs-3010	80	25	±28.80	±28.80	ADP
iajs-3010	80	26	22.46±1.04	22.46±1.04	NUM
iajs-3010	80	27	7.64±0.42	7.64±0.42	NUM
iajs-3010	80	28	2.59±	2.59±	NOUN
iajs-3010	80	29	0.36	0.36	NUM
iajs-3010	80	30	patients	patient	NOUN
iajs-3010	80	31	posttreatment	posttreatment	VERB
iajs-3010	80	32	58	58	NUM
iajs-3010	80	33	190.03	190.03	NUM
iajs-3010	80	34	±	±	NUM
iajs-3010	80	35	13.58	13.58	NUM
iajs-3010	80	36	24.47±0.96	24.47±0.96	NUM
iajs-3010	80	37	8.32±0.44	8.32±0.44	NOUN
iajs-3010	80	38	2.08±	2.08±	NUM
iajs-3010	80	39	0.34	0.34	NUM
iajs-3010	80	40	controls	control	VERB
iajs-3010	80	41	40	40	NUM
iajs-3010	80	42	32.96	32.96	NUM
iajs-3010	80	43	±3.80	±3.80	ADV
iajs-3010	80	44	8.77	8.77	NUM
iajs-3010	80	45	±0.57	±0.57	NOUN
iajs-3010	81	1	6.78±0.22	6.78±0.22	NUM
iajs-3010	81	2	1.89±0.19	1.89±0.19	NUM
iajs-3010	81	3	p	p	NOUN
iajs-3010	81	4	-	-	PUNCT
iajs-3010	81	5	value	value	NOUN
iajs-3010	81	6	a	a	NOUN
iajs-3010	81	7	,	,	PUNCT
iajs-3010	81	8	c=	c=	VERB
iajs-3010	81	9	0.001	0.001	NUM
iajs-3010	81	10	b=0.6	b=0.6	NOUN
iajs-3010	81	11	a	a	NOUN
iajs-3010	81	12	,	,	PUNCT
iajs-3010	81	13	c=	c=	VERB
iajs-3010	81	14	0.001	0.001	NUM
iajs-3010	81	15	b=0.4	b=0.4	NOUN
iajs-3010	81	16	a=	a=	PROPN
iajs-3010	81	17	0.10	0.10	NUM
iajs-3010	81	18	,	,	PUNCT
iajs-3010	81	19	b=0.62	b=0.62	VERB
iajs-3010	81	20	c=0.013	c=0.013	PUNCT
iajs-3010	81	21	a=0.1	a=0.1	NOUN
iajs-3010	81	22	b=0.029	b=0.029	NOUN
iajs-3010	81	23	,	,	PUNCT
iajs-3010	81	24	c=0.4	c=0.4	AUX
iajs-3010	81	25	a	a	DET
iajs-3010	81	26	-	-	PUNCT
iajs-3010	81	27	patient	patient	NOUN
iajs-3010	81	28	's	's	PART
iajs-3010	81	29	pre	pre	NOUN
iajs-3010	81	30	-	-	NOUN
iajs-3010	81	31	treatment	treatment	NOUN
iajs-3010	81	32	compared	compare	VERB
iajs-3010	81	33	with	with	ADP
iajs-3010	81	34	controls	control	NOUN
iajs-3010	81	35	,	,	PUNCT
iajs-3010	81	36	b	b	X
iajs-3010	81	37	-	-	PUNCT
iajs-3010	81	38	patients	patient	NOUN
iajs-3010	81	39	pre	pre	ADJ
iajs-3010	81	40	-	-	NOUN
iajs-3010	81	41	treatment	treatment	NOUN
iajs-3010	81	42	compared	compare	VERB
iajs-3010	81	43	with	with	ADP
iajs-3010	81	44	patients	patient	NOUN
iajs-3010	81	45	posttreatment	posttreatment	NOUN
iajs-3010	81	46	,	,	PUNCT
iajs-3010	81	47	c	c	NOUN
iajs-3010	81	48	=	=	NOUN
iajs-3010	81	49	parameters	parameter	NOUN
iajs-3010	81	50	level	level	VERB
iajs-3010	81	51	in	in	ADP
iajs-3010	81	52	patients	patient	NOUN
iajs-3010	81	53	post	post	ADJ
iajs-3010	81	54	-	-	NOUN
iajs-3010	81	55	treatment	treatment	NOUN
iajs-3010	81	56	compared	compare	VERB
iajs-3010	81	57	with	with	ADP
iajs-3010	81	58	controls	control	NOUN
iajs-3010	81	59	.	.	PUNCT
iajs-3010	82	1	during	during	ADP
iajs-3010	82	2	this	this	DET
iajs-3010	82	3	study	study	NOUN
iajs-3010	82	4	the	the	DET
iajs-3010	82	5	patients	patient	NOUN
iajs-3010	82	6	were	be	AUX
iajs-3010	82	7	selected	select	VERB
iajs-3010	82	8	regardless	regardless	ADV
iajs-3010	82	9	how	how	SCONJ
iajs-3010	82	10	long	long	ADJ
iajs-3010	82	11	have	have	AUX
iajs-3010	82	12	been	be	AUX
iajs-3010	82	13	on	on	ADP
iajs-3010	82	14	medicine	medicine	NOUN
iajs-3010	82	15	which	which	PRON
iajs-3010	82	16	the	the	DET
iajs-3010	82	17	section	section	NOUN
iajs-3010	82	18	below	below	ADP
iajs-3010	82	19	there	there	PRON
iajs-3010	82	20	will	will	AUX
iajs-3010	82	21	be	be	AUX
iajs-3010	82	22	disagreement	disagreement	NOUN
iajs-3010	82	23	and	and	CCONJ
iajs-3010	82	24	agreements	agreement	NOUN
iajs-3010	82	25	with	with	ADP
iajs-3010	82	26	different	different	ADJ
iajs-3010	82	27	study	study	NOUN
iajs-3010	82	28	due	due	ADP
iajs-3010	82	29	to	to	ADP
iajs-3010	82	30	the	the	DET
iajs-3010	82	31	level	level	NOUN
iajs-3010	82	32	of	of	ADP
iajs-3010	82	33	ige	ige	PROPN
iajs-3010	82	34	will	will	AUX
iajs-3010	82	35	be	be	AUX
iajs-3010	82	36	low	low	ADJ
iajs-3010	82	37	after	after	ADP
iajs-3010	82	38	treatment	treatment	NOUN
iajs-3010	82	39	in	in	ADP
iajs-3010	82	40	month	month	NOUN
iajs-3010	82	41	,	,	PUNCT
iajs-3010	82	42	the	the	DET
iajs-3010	82	43	results	result	NOUN
iajs-3010	82	44	showed	show	VERB
iajs-3010	82	45	agreement	agreement	NOUN
iajs-3010	82	46	with	with	ADP
iajs-3010	82	47	jang	jang	PROPN
iajs-3010	82	48	et	et	PROPN
iajs-3010	82	49	al	al	PROPN
iajs-3010	82	50	.	.	PUNCT
iajs-3010	83	1	[	[	X
iajs-3010	83	2	16	16	NUM
iajs-3010	83	3	]	]	PUNCT
iajs-3010	83	4	showed	show	VERB
iajs-3010	83	5	blood	blood	NOUN
iajs-3010	83	6	levels	level	NOUN
iajs-3010	83	7	of	of	ADP
iajs-3010	83	8	free	free	ADJ
iajs-3010	83	9	/	/	SYM
iajs-3010	83	10	total	total	ADJ
iajs-3010	83	11	ige	ige	PROPN
iajs-3010	83	12	were	be	AUX
iajs-3010	83	13	considerably	considerably	ADV
iajs-3010	83	14	greater	great	ADJ
iajs-3010	83	15	in	in	ADP
iajs-3010	83	16	csu	csu	PROPN
iajs-3010	83	17	patients	patient	NOUN
iajs-3010	83	18	than	than	ADP
iajs-3010	83	19	in	in	ADP
iajs-3010	83	20	healthy	healthy	ADJ
iajs-3010	83	21	subjects	subject	NOUN
iajs-3010	83	22	.	.	PUNCT
iajs-3010	84	1	serum	serum	PROPN
iajs-3010	84	2	free	free	ADJ
iajs-3010	84	3	and	and	CCONJ
iajs-3010	84	4	total	total	ADJ
iajs-3010	84	5	ige	ige	PROPN
iajs-3010	84	6	levels	level	NOUN
iajs-3010	84	7	change	change	VERB
iajs-3010	84	8	when	when	SCONJ
iajs-3010	84	9	using	use	VERB
iajs-3010	84	10	omalizumab	omalizumab	NOUN
iajs-3010	84	11	(	(	PUNCT
iajs-3010	84	12	omalizumab	omalizumab	NOUN
iajs-3010	84	13	is	be	AUX
iajs-3010	84	14	intended	intend	VERB
iajs-3010	84	15	to	to	PART
iajs-3010	84	16	be	be	AUX
iajs-3010	84	17	used	use	VERB
iajs-3010	84	18	as	as	ADP
iajs-3010	84	19	second	second	ADJ
iajs-3010	84	20	-	-	PUNCT
iajs-3010	84	21	line	line	NOUN
iajs-3010	84	22	therapy	therapy	NOUN
iajs-3010	84	23	for	for	ADP
iajs-3010	84	24	the	the	DET
iajs-3010	84	25	treatment	treatment	NOUN
iajs-3010	84	26	of	of	ADP
iajs-3010	84	27	chronic	chronic	ADJ
iajs-3010	84	28	spontaneous	spontaneous	ADJ
iajs-3010	84	29	urticaria	urticaria	NOUN
iajs-3010	84	30	that	that	PRON
iajs-3010	84	31	is	be	AUX
iajs-3010	84	32	refractory	refractory	NOUN
iajs-3010	84	33	to	to	ADP
iajs-3010	84	34	oral	oral	ADJ
iajs-3010	84	35	antihistamines	antihistamine	NOUN
iajs-3010	84	36	)	)	PUNCT
iajs-3010	84	37	.	.	PUNCT
iajs-3010	85	1	the	the	DET
iajs-3010	85	2	levels	level	NOUN
iajs-3010	85	3	of	of	ADP
iajs-3010	85	4	serum	serum	PROPN
iajs-3010	85	5	total	total	PROPN
iajs-3010	85	6	ige	ige	PROPN
iajs-3010	85	7	tended	tend	VERB
iajs-3010	85	8	to	to	PART
iajs-3010	85	9	rise	rise	VERB
iajs-3010	85	10	1	1	NUM
iajs-3010	85	11	month	month	NOUN
iajs-3010	85	12	posttreatment	posttreatment	NOUN
iajs-3010	85	13	(	(	PUNCT
iajs-3010	85	14	p	p	NOUN
iajs-3010	85	15	=	=	NOUN
iajs-3010	85	16	0.06	0.06	NUM
iajs-3010	85	17	)	)	PUNCT
iajs-3010	85	18	and	and	CCONJ
iajs-3010	85	19	gradually	gradually	ADV
iajs-3010	85	20	fall	fall	VERB
iajs-3010	85	21	throughout	throughout	ADP
iajs-3010	85	22	the	the	DET
iajs-3010	85	23	course	course	NOUN
iajs-3010	85	24	of	of	ADP
iajs-3010	85	25	the	the	DET
iajs-3010	85	26	12	12	NUM
iajs-3010	85	27	-	-	PUNCT
iajs-3010	85	28	month	month	NOUN
iajs-3010	85	29	treatment	treatment	NOUN
iajs-3010	85	30	period	period	NOUN
iajs-3010	85	31	without	without	ADP
iajs-3010	85	32	differing	differ	VERB
iajs-3010	85	33	significantly	significantly	ADV
iajs-3010	85	34	.	.	PUNCT
iajs-3010	86	1	however	however	ADV
iajs-3010	86	2	,	,	PUNCT
iajs-3010	86	3	the	the	DET
iajs-3010	86	4	serum	serum	PROPN
iajs-3010	86	5	total	total	NOUN
iajs-3010	86	6	ige	ige	PROPN
iajs-3010	86	7	level	level	NOUN
iajs-3010	86	8	after	after	ADP
iajs-3010	86	9	6	6	NUM
iajs-3010	86	10	months	month	NOUN
iajs-3010	86	11	is	be	AUX
iajs-3010	86	12	noticeably	noticeably	ADV
iajs-3010	86	13	greater	great	ADJ
iajs-3010	86	14	than	than	ADP
iajs-3010	86	15	the	the	DET
iajs-3010	86	16	baseline	baseline	NOUN
iajs-3010	86	17	level	level	NOUN
iajs-3010	86	18	,	,	PUNCT
iajs-3010	86	19	suggesting	suggest	VERB
iajs-3010	86	20	that	that	SCONJ
iajs-3010	86	21	omalizumab	omalizumab	NOUN
iajs-3010	86	22	therapy	therapy	NOUN
iajs-3010	86	23	may	may	AUX
iajs-3010	86	24	cause	cause	VERB
iajs-3010	86	25	a	a	DET
iajs-3010	86	26	rise	rise	NOUN
iajs-3010	86	27	in	in	ADP
iajs-3010	86	28	serum	serum	NOUN
iajs-3010	86	29	total	total	ADJ
iajs-3010	86	30	ige	ige	PROPN
iajs-3010	86	31	levels	level	NOUN
iajs-3010	86	32	.	.	PUNCT
iajs-3010	87	1	insignificant	insignificant	ADJ
iajs-3010	87	2	changes	change	NOUN
iajs-3010	87	3	were	be	AUX
iajs-3010	87	4	seen	see	VERB
iajs-3010	87	5	in	in	ADP
iajs-3010	87	6	serum	serum	NOUN
iajs-3010	87	7	free	free	PROPN
iajs-3010	87	8	ige	ige	PROPN
iajs-3010	87	9	levels	level	NOUN
iajs-3010	87	10	throughout	throughout	ADP
iajs-3010	87	11	the	the	DET
iajs-3010	87	12	course	course	NOUN
iajs-3010	87	13	of	of	ADP
iajs-3010	87	14	the	the	DET
iajs-3010	87	15	12	12	NUM
iajs-3010	87	16	-	-	PUNCT
iajs-3010	87	17	month	month	NOUN
iajs-3010	87	18	therapy	therapy	NOUN
iajs-3010	87	19	period	period	NOUN
iajs-3010	87	20	.	.	PUNCT
iajs-3010	88	1	the	the	DET
iajs-3010	88	2	classification	classification	NOUN
iajs-3010	88	3	of	of	ADP
iajs-3010	88	4	individuals	individual	NOUN
iajs-3010	88	5	with	with	ADP
iajs-3010	88	6	csu	csu	PROPN
iajs-3010	88	7	who	who	PRON
iajs-3010	88	8	are	be	AUX
iajs-3010	88	9	appropriate	appropriate	ADJ
iajs-3010	88	10	for	for	ADP
iajs-3010	88	11	omalizumab	omalizumab	NOUN
iajs-3010	88	12	treatment	treatment	NOUN
iajs-3010	88	13	was	be	AUX
iajs-3010	88	14	made	make	VERB
iajs-3010	88	15	easier	easy	ADJ
iajs-3010	88	16	by	by	ADP
iajs-3010	88	17	comparing	compare	VERB
iajs-3010	88	18	preand	preand	NOUN
iajs-3010	88	19	post	post	ADJ
iajs-3010	88	20	-	-	ADJ
iajs-3010	88	21	treatment	treatment	ADJ
iajs-3010	88	22	ige	ige	NOUN
iajs-3010	88	23	levels	level	NOUN
iajs-3010	88	24	and	and	CCONJ
iajs-3010	88	25	their	their	PRON
iajs-3010	88	26	ratios	ratio	NOUN
iajs-3010	88	27	[	[	X
iajs-3010	88	28	22	22	NUM
iajs-3010	88	29	]	]	PUNCT
iajs-3010	88	30	.	.	PUNCT
iajs-3010	89	1	the	the	DET
iajs-3010	89	2	higher	high	ADJ
iajs-3010	89	3	quantity	quantity	NOUN
iajs-3010	89	4	of	of	ADP
iajs-3010	89	5	allergen	allergen	NOUN
iajs-3010	89	6	-	-	PUNCT
iajs-3010	89	7	specific	specific	ADJ
iajs-3010	89	8	ige	ige	NOUN
iajs-3010	89	9	antibodies	antibody	NOUN
iajs-3010	89	10	on	on	ADP
iajs-3010	89	11	effector	effector	NOUN
iajs-3010	89	12	cells	cell	NOUN
iajs-3010	89	13	(	(	PUNCT
iajs-3010	89	14	including	include	VERB
iajs-3010	89	15	basophils	basophil	NOUN
iajs-3010	89	16	and	and	CCONJ
iajs-3010	89	17	mast	mast	NOUN
iajs-3010	89	18	cells	cell	NOUN
iajs-3010	89	19	)	)	PUNCT
iajs-3010	89	20	and	and	CCONJ
iajs-3010	89	21	the	the	DET
iajs-3010	89	22	higher	high	ADJ
iajs-3010	89	23	percentage	percentage	NOUN
iajs-3010	89	24	of	of	ADP
iajs-3010	89	25	attachment	attachment	NOUN
iajs-3010	89	26	to	to	ADP
iajs-3010	89	27	effector	effector	NOUN
iajs-3010	89	28	cells	cell	NOUN
iajs-3010	89	29	in	in	ADP
iajs-3010	89	30	csu	csu	PROPN
iajs-3010	89	31	may	may	AUX
iajs-3010	89	32	be	be	AUX
iajs-3010	89	33	indicated	indicate	VERB
iajs-3010	89	34	by	by	ADP
iajs-3010	89	35	the	the	DET
iajs-3010	89	36	higher	high	ADJ
iajs-3010	89	37	ratio	ratio	NOUN
iajs-3010	89	38	of	of	ADP
iajs-3010	89	39	specific	specific	ADJ
iajs-3010	89	40	ige	ige	PROPN
iajs-3010	89	41	to	to	PART
iajs-3010	89	42	serum	serum	VERB
iajs-3010	89	43	ige	ige	PROPN
iajs-3010	90	1	[	[	X
iajs-3010	90	2	23	23	NUM
iajs-3010	90	3	]	]	PUNCT
iajs-3010	90	4	.	.	PUNCT
iajs-3010	91	1	moreover	moreover	ADV
iajs-3010	91	2	,	,	PUNCT
iajs-3010	91	3	the	the	DET
iajs-3010	91	4	current	current	ADJ
iajs-3010	91	5	results	result	NOUN
iajs-3010	91	6	disagreed	disagree	VERB
iajs-3010	91	7	with	with	ADP
iajs-3010	91	8	recent	recent	ADJ
iajs-3010	91	9	study	study	NOUN
iajs-3010	91	10	[	[	X
iajs-3010	91	11	24	24	NUM
iajs-3010	91	12	]	]	PUNCT
iajs-3010	91	13	showed	show	VERB
iajs-3010	91	14	that	that	SCONJ
iajs-3010	91	15	the	the	DET
iajs-3010	91	16	serum	serum	NOUN
iajs-3010	91	17	levels	level	NOUN
iajs-3010	91	18	of	of	ADP
iajs-3010	91	19	il-6	il-6	NUM
iajs-3010	91	20	and	and	CCONJ
iajs-3010	91	21	ccl8	ccl8	PROPN
iajs-3010	91	22	pre	pre	NOUN
iajs-3010	91	23	-	-	NOUN
iajs-3010	91	24	treatment	treatment	NOUN
iajs-3010	91	25	were	be	AUX
iajs-3010	91	26	significantly	significantly	ADV
iajs-3010	91	27	higher	high	ADJ
iajs-3010	91	28	than	than	ADP
iajs-3010	91	29	post	post	ADJ
iajs-3010	91	30	-	-	NOUN
iajs-3010	91	31	treatment	treatment	NOUN
iajs-3010	91	32	.	.	PUNCT
iajs-3010	92	1	wang	wang	PROPN
iajs-3010	92	2	et	et	PROPN
iajs-3010	92	3	al	al	PROPN
iajs-3010	93	1	[	[	X
iajs-3010	93	2	25	25	NUM
iajs-3010	93	3	]	]	PUNCT
iajs-3010	93	4	ihjpas	ihjpa	NOUN
iajs-3010	93	5	.	.	PUNCT
iajs-3010	94	1	36(2)2023	36(2)2023	NUM
iajs-3010	94	2	39	39	NUM
iajs-3010	94	3	reoprted	reoprte	VERB
iajs-3010	94	4	the	the	DET
iajs-3010	94	5	level	level	NOUN
iajs-3010	94	6	of	of	ADP
iajs-3010	94	7	tnf	tnf	PROPN
iajs-3010	94	8	-	-	PUNCT
iajs-3010	94	9	α	α	PROPN
iajs-3010	94	10	,	,	PUNCT
iajs-3010	94	11	il-6	il-6	NOUN
iajs-3010	94	12	and	and	CCONJ
iajs-3010	94	13	il-10	il-10	NOUN
iajs-3010	94	14	in	in	ADP
iajs-3010	94	15	group	group	NOUN
iajs-3010	94	16	were	be	AUX
iajs-3010	94	17	significantly	significantly	ADV
iajs-3010	94	18	lower	low	ADJ
iajs-3010	94	19	after	after	ADP
iajs-3010	94	20	treatment	treatment	NOUN
iajs-3010	94	21	.	.	PUNCT
iajs-3010	95	1	moreover	moreover	ADV
iajs-3010	95	2	,	,	PUNCT
iajs-3010	95	3	these	these	DET
iajs-3010	95	4	findings	finding	NOUN
iajs-3010	95	5	agreed	agree	VERB
iajs-3010	95	6	with	with	ADP
iajs-3010	95	7	those	those	PRON
iajs-3010	95	8	of	of	ADP
iajs-3010	95	9	fujii	fujii	PROPN
iajs-3010	95	10	et	et	PROPN
iajs-3010	95	11	al	al	PROPN
iajs-3010	95	12	.	.	PUNCT
iajs-3010	96	1	[	[	X
iajs-3010	96	2	26	26	NUM
iajs-3010	96	3	]	]	X
iajs-3010	96	4	,	,	PUNCT
iajs-3010	96	5	who	who	PRON
iajs-3010	96	6	observed	observe	VERB
iajs-3010	96	7	that	that	SCONJ
iajs-3010	96	8	patients	patient	NOUN
iajs-3010	96	9	were	be	AUX
iajs-3010	96	10	resistant	resistant	ADJ
iajs-3010	96	11	to	to	ADP
iajs-3010	96	12	traditional	traditional	ADJ
iajs-3010	96	13	antihistamine	antihistamine	NOUN
iajs-3010	96	14	therapy	therapy	NOUN
iajs-3010	96	15	and	and	CCONJ
iajs-3010	96	16	required	require	VERB
iajs-3010	96	17	systemic	systemic	ADJ
iajs-3010	96	18	steroids	steroid	NOUN
iajs-3010	96	19	for	for	ADP
iajs-3010	96	20	full	full	ADJ
iajs-3010	96	21	wheal	wheal	ADJ
iajs-3010	96	22	suppression	suppression	NOUN
iajs-3010	96	23	.	.	PUNCT
iajs-3010	97	1	their	their	PRON
iajs-3010	97	2	increased	increase	VERB
iajs-3010	97	3	il-6	il-6	NOUN
iajs-3010	97	4	and	and	CCONJ
iajs-3010	97	5	crp	crp	PROPN
iajs-3010	97	6	levels	level	NOUN
iajs-3010	97	7	returned	return	VERB
iajs-3010	97	8	to	to	ADP
iajs-3010	97	9	normal	normal	ADJ
iajs-3010	97	10	once	once	ADV
iajs-3010	97	11	the	the	DET
iajs-3010	97	12	urticaria	urticaria	NOUN
iajs-3010	97	13	subsided	subside	VERB
iajs-3010	97	14	..	..	PUNCT
iajs-3010	97	15	as	as	ADP
iajs-3010	97	16	an	an	DET
iajs-3010	97	17	allergic	allergic	ADJ
iajs-3010	97	18	disease	disease	NOUN
iajs-3010	97	19	,	,	PUNCT
iajs-3010	97	20	chronic	chronic	ADJ
iajs-3010	97	21	urticarial	urticarial	NOUN
iajs-3010	97	22	is	be	AUX
iajs-3010	97	23	accompanied	accompany	VERB
iajs-3010	97	24	by	by	ADP
iajs-3010	97	25	an	an	DET
iajs-3010	97	26	inflammatory	inflammatory	ADJ
iajs-3010	97	27	reaction	reaction	NOUN
iajs-3010	97	28	that	that	PRON
iajs-3010	97	29	secretes	secrete	VERB
iajs-3010	97	30	a	a	DET
iajs-3010	97	31	large	large	ADJ
iajs-3010	97	32	amount	amount	NOUN
iajs-3010	97	33	of	of	ADP
iajs-3010	97	34	inflammatory	inflammatory	ADJ
iajs-3010	97	35	factors	factor	NOUN
iajs-3010	97	36	.	.	PUNCT
iajs-3010	98	1	tnf	tnf	PROPN
iajs-3010	98	2	-	-	PUNCT
iajs-3010	98	3	α	α	PROPN
iajs-3010	98	4	,	,	PUNCT
iajs-3010	98	5	il-6	il-6	NOUN
iajs-3010	98	6	and	and	CCONJ
iajs-3010	98	7	il-10	il-10	PRON
iajs-3010	98	8	are	be	AUX
iajs-3010	98	9	important	important	ADJ
iajs-3010	98	10	inflammatory	inflammatory	ADJ
iajs-3010	98	11	factors	factor	NOUN
iajs-3010	98	12	,	,	PUNCT
iajs-3010	98	13	all	all	PRON
iajs-3010	98	14	of	of	ADP
iajs-3010	98	15	which	which	PRON
iajs-3010	98	16	will	will	AUX
iajs-3010	98	17	change	change	VERB
iajs-3010	98	18	to	to	ADP
iajs-3010	98	19	varying	vary	VERB
iajs-3010	98	20	degrees	degree	NOUN
iajs-3010	98	21	after	after	ADP
iajs-3010	98	22	having	have	VERB
iajs-3010	98	23	an	an	DET
iajs-3010	98	24	inflammatory	inflammatory	ADJ
iajs-3010	98	25	response	response	NOUN
iajs-3010	98	26	[	[	X
iajs-3010	98	27	27	27	NUM
iajs-3010	98	28	]	]	PUNCT
iajs-3010	98	29	.	.	PUNCT
iajs-3010	99	1	on	on	ADP
iajs-3010	99	2	the	the	DET
iajs-3010	99	3	other	other	ADJ
iajs-3010	99	4	hands	hand	NOUN
iajs-3010	99	5	,	,	PUNCT
iajs-3010	99	6	this	this	DET
iajs-3010	99	7	outcome	outcome	NOUN
iajs-3010	99	8	was	be	AUX
iajs-3010	99	9	agreed	agree	VERB
iajs-3010	99	10	upon	upon	SCONJ
iajs-3010	99	11	by	by	ADP
iajs-3010	99	12	[	[	X
iajs-3010	99	13	28	28	NUM
iajs-3010	99	14	]	]	PUNCT
iajs-3010	99	15	.	.	PUNCT
iajs-3010	100	1	the	the	DET
iajs-3010	100	2	median	median	ADJ
iajs-3010	100	3	pre	pre	ADJ
iajs-3010	100	4	-	-	ADJ
iajs-3010	100	5	treatment	treatment	ADJ
iajs-3010	100	6	ige	ige	NOUN
iajs-3010	100	7	level	level	NOUN
iajs-3010	100	8	in	in	ADP
iajs-3010	100	9	the	the	DET
iajs-3010	100	10	patients	patient	NOUN
iajs-3010	100	11	was	be	AUX
iajs-3010	100	12	substantially	substantially	ADV
iajs-3010	100	13	lower	low	ADJ
iajs-3010	101	1	[	[	X
iajs-3010	101	2	189.0	189.0	NUM
iajs-3010	101	3	(	(	PUNCT
iajs-3010	101	4	1.0	1.0	NUM
iajs-3010	101	5	-	-	SYM
iajs-3010	101	6	1824.0	1824.0	NUM
iajs-3010	101	7	)	)	PUNCT
iajs-3010	101	8	]	]	PUNCT
iajs-3010	101	9	than	than	ADP
iajs-3010	101	10	the	the	DET
iajs-3010	101	11	post	post	ADJ
iajs-3010	101	12	-	-	ADJ
iajs-3010	101	13	treatment	treatment	ADJ
iajs-3010	101	14	level	level	NOUN
iajs-3010	101	15	[	[	X
iajs-3010	101	16	561.0	561.0	NUM
iajs-3010	101	17	(	(	PUNCT
iajs-3010	101	18	2.0	2.0	NUM
iajs-3010	101	19	-	-	SYM
iajs-3010	101	20	4301.0	4301.0	NUM
iajs-3010	101	21	)	)	PUNCT
iajs-3010	101	22	]	]	PUNCT
iajs-3010	101	23	.	.	PUNCT
iajs-3010	102	1	(	(	PUNCT
iajs-3010	102	2	p<0.001	p<0.001	PROPN
iajs-3010	102	3	)	)	PUNCT
iajs-3010	102	4	.	.	PUNCT
iajs-3010	103	1	there	there	PRON
iajs-3010	103	2	was	be	VERB
iajs-3010	103	3	no	no	DET
iajs-3010	103	4	significant	significant	ADJ
iajs-3010	103	5	difference	difference	NOUN
iajs-3010	103	6	in	in	ADP
iajs-3010	103	7	eosinophils	eosinophil	NOUN
iajs-3010	103	8	before	before	ADV
iajs-3010	103	9	and	and	CCONJ
iajs-3010	103	10	after	after	ADP
iajs-3010	103	11	omalizumab	omalizumab	NOUN
iajs-3010	103	12	therapy	therapy	NOUN
iajs-3010	103	13	.	.	PUNCT
iajs-3010	104	1	the	the	DET
iajs-3010	104	2	patients	patient	NOUN
iajs-3010	104	3	'	'	PART
iajs-3010	104	4	mean	mean	PROPN
iajs-3010	104	5	uct	uct	PROPN
iajs-3010	104	6	score	score	NOUN
iajs-3010	104	7	was	be	AUX
iajs-3010	104	8	determined	determine	VERB
iajs-3010	104	9	to	to	PART
iajs-3010	104	10	be	be	AUX
iajs-3010	104	11	11.5	11.5	NUM
iajs-3010	104	12	(	(	PUNCT
iajs-3010	104	13	3.9	3.9	NUM
iajs-3010	104	14	)	)	PUNCT
iajs-3010	104	15	.	.	PUNCT
iajs-3010	105	1	furthermore	furthermore	ADV
iajs-3010	105	2	,	,	PUNCT
iajs-3010	105	3	celik	celik	VERB
iajs-3010	105	4	et	et	NOUN
iajs-3010	105	5	al.[29	al.[29	NOUN
iajs-3010	105	6	]	]	PUNCT
iajs-3010	105	7	revealed	revealed	AUX
iajs-3010	105	8	the	the	DET
iajs-3010	105	9	eosinophil	eosinophil	ADJ
iajs-3010	105	10	count	count	NOUN
iajs-3010	105	11	was	be	AUX
iajs-3010	105	12	greater	great	ADJ
iajs-3010	105	13	in	in	ADP
iajs-3010	105	14	the	the	DET
iajs-3010	105	15	post	post	ADJ
iajs-3010	105	16	-	-	NOUN
iajs-3010	105	17	treatment	treatment	NOUN
iajs-3010	105	18	and	and	CCONJ
iajs-3010	105	19	pre	pre	ADJ
iajs-3010	105	20	-	-	ADJ
iajs-3010	105	21	treatment	treatment	ADJ
iajs-3010	105	22	groups	group	NOUN
iajs-3010	105	23	than	than	ADP
iajs-3010	105	24	in	in	ADP
iajs-3010	105	25	the	the	DET
iajs-3010	105	26	control	control	NOUN
iajs-3010	105	27	group	group	NOUN
iajs-3010	105	28	.	.	PUNCT
iajs-3010	106	1	in	in	ADP
iajs-3010	106	2	patients	patient	NOUN
iajs-3010	106	3	with	with	ADP
iajs-3010	106	4	csu	csu	PROPN
iajs-3010	106	5	who	who	PRON
iajs-3010	106	6	required	require	VERB
iajs-3010	106	7	long	long	ADJ
iajs-3010	106	8	-	-	PUNCT
iajs-3010	106	9	term	term	NOUN
iajs-3010	106	10	omalizumab	omalizumab	NOUN
iajs-3010	106	11	treatment	treatment	NOUN
iajs-3010	106	12	,	,	PUNCT
iajs-3010	106	13	the	the	DET
iajs-3010	106	14	eosinophil	eosinophil	ADJ
iajs-3010	106	15	-	-	PUNCT
iajs-3010	106	16	basophil	basophil	NOUN
iajs-3010	106	17	ratio	ratio	NOUN
iajs-3010	106	18	was	be	AUX
iajs-3010	106	19	high	high	ADJ
iajs-3010	106	20	and	and	CCONJ
iajs-3010	106	21	reduced	reduce	VERB
iajs-3010	106	22	after	after	ADP
iajs-3010	106	23	treatment	treatment	NOUN
iajs-3010	106	24	.	.	PUNCT
iajs-3010	107	1	the	the	DET
iajs-3010	107	2	only	only	ADJ
iajs-3010	107	3	statistically	statistically	ADV
iajs-3010	107	4	significant	significant	ADJ
iajs-3010	107	5	difference	difference	NOUN
iajs-3010	107	6	between	between	ADP
iajs-3010	107	7	the	the	DET
iajs-3010	107	8	two	two	NUM
iajs-3010	107	9	groups	group	NOUN
iajs-3010	107	10	that	that	PRON
iajs-3010	107	11	improved	improve	VERB
iajs-3010	107	12	with	with	ADP
iajs-3010	107	13	omalizumab	omalizumab	NOUN
iajs-3010	107	14	medication	medication	NOUN
iajs-3010	107	15	in	in	ADP
iajs-3010	107	16	a	a	DET
iajs-3010	107	17	short	short	ADJ
iajs-3010	107	18	period	period	NOUN
iajs-3010	107	19	of	of	ADP
iajs-3010	107	20	time	time	NOUN
iajs-3010	107	21	and	and	CCONJ
iajs-3010	107	22	required	require	VERB
iajs-3010	107	23	long	long	ADJ
iajs-3010	107	24	-	-	PUNCT
iajs-3010	107	25	term	term	NOUN
iajs-3010	107	26	treatment	treatment	NOUN
iajs-3010	107	27	was	be	AUX
iajs-3010	107	28	the	the	DET
iajs-3010	107	29	eosinophil	eosinophil	ADJ
iajs-3010	107	30	-	-	PUNCT
iajs-3010	107	31	basophil	basophil	NOUN
iajs-3010	107	32	ratio	ratio	NOUN
iajs-3010	107	33	.	.	PUNCT
iajs-3010	108	1	the	the	DET
iajs-3010	108	2	receiver	receiver	NOUN
iajs-3010	108	3	operating	operate	VERB
iajs-3010	108	4	characteristic	characteristic	NOUN
iajs-3010	108	5	(	(	PUNCT
iajs-3010	108	6	roc	roc	PROPN
iajs-3010	108	7	)	)	PUNCT
iajs-3010	108	8	the	the	DET
iajs-3010	108	9	roc	roc	PROPN
iajs-3010	108	10	results	result	NOUN
iajs-3010	108	11	of	of	ADP
iajs-3010	108	12	il-6	il-6	NOUN
iajs-3010	108	13	showed	show	VERB
iajs-3010	108	14	cut	cut	VERB
iajs-3010	108	15	-	-	PUNCT
iajs-3010	108	16	off	off	ADP
iajs-3010	108	17	value	value	NOUN
iajs-3010	108	18	is	be	AUX
iajs-3010	108	19	(	(	PUNCT
iajs-3010	108	20	15.0	15.0	NUM
iajs-3010	108	21	)	)	PUNCT
iajs-3010	108	22	,	,	PUNCT
iajs-3010	108	23	in	in	ADP
iajs-3010	108	24	roc	roc	PROPN
iajs-3010	108	25	curve	curve	NOUN
iajs-3010	108	26	validity	validity	NOUN
iajs-3010	108	27	test	test	NOUN
iajs-3010	108	28	for	for	ADP
iajs-3010	108	29	il-6	il-6	NOUN
iajs-3010	108	30	dependent	dependent	ADJ
iajs-3010	108	31	on	on	ADP
iajs-3010	108	32	clinical	clinical	ADJ
iajs-3010	108	33	diagnosis	diagnosis	NOUN
iajs-3010	108	34	and	and	CCONJ
iajs-3010	108	35	found	find	VERB
iajs-3010	108	36	greatest	great	ADJ
iajs-3010	108	37	sensitivity	sensitivity	NOUN
iajs-3010	108	38	(	(	PUNCT
iajs-3010	108	39	97.5	97.5	NUM
iajs-3010	108	40	%	%	NOUN
iajs-3010	108	41	)	)	PUNCT
iajs-3010	108	42	,	,	PUNCT
iajs-3010	108	43	specificity	specificity	NOUN
iajs-3010	108	44	(	(	PUNCT
iajs-3010	108	45	95.0	95.0	NUM
iajs-3010	108	46	%	%	NOUN
iajs-3010	108	47	)	)	PUNCT
iajs-3010	108	48	,	,	PUNCT
iajs-3010	108	49	ppv(97.5%)npv	ppv(97.5%)npv	X
iajs-3010	108	50	(	(	PUNCT
iajs-3010	108	51	97.4	97.4	NUM
iajs-3010	108	52	%	%	NOUN
iajs-3010	108	53	)	)	PUNCT
iajs-3010	108	54	,	,	PUNCT
iajs-3010	108	55	accuracy	accuracy	NOUN
iajs-3010	108	56	(	(	PUNCT
iajs-3010	108	57	93.7	93.7	NUM
iajs-3010	108	58	%	%	NOUN
iajs-3010	108	59	)	)	PUNCT
iajs-3010	108	60	and	and	CCONJ
iajs-3010	108	61	area	area	NOUN
iajs-3010	108	62	under	under	ADP
iajs-3010	108	63	curve	curve	NOUN
iajs-3010	108	64	(	(	PUNCT
iajs-3010	108	65	0.995	0.995	NUM
iajs-3010	108	66	)	)	PUNCT
iajs-3010	108	67	.	.	PUNCT
iajs-3010	109	1	overall	overall	ADV
iajs-3010	109	2	,	,	PUNCT
iajs-3010	109	3	there	there	PRON
iajs-3010	109	4	is	be	VERB
iajs-3010	109	5	a	a	DET
iajs-3010	109	6	highly	highly	ADV
iajs-3010	109	7	significant	significant	ADJ
iajs-3010	109	8	differences	difference	NOUN
iajs-3010	109	9	between	between	ADP
iajs-3010	109	10	studied	study	VERB
iajs-3010	109	11	groups	group	NOUN
iajs-3010	109	12	(	(	PUNCT
iajs-3010	109	13	p<0.001	p<0.001	X
iajs-3010	109	14	)	)	PUNCT
iajs-3010	109	15	as	as	ADP
iajs-3010	109	16	in	in	ADP
iajs-3010	109	17	figure	figure	NOUN
iajs-3010	109	18	1	1	NUM
iajs-3010	109	19	figure	figure	NOUN
iajs-3010	109	20	1	1	NUM
iajs-3010	109	21	.	.	PUNCT
iajs-3010	110	1	the	the	DET
iajs-3010	110	2	roc	roc	PROPN
iajs-3010	110	3	curve	curve	NOUN
iajs-3010	110	4	of	of	ADP
iajs-3010	110	5	il-6	il-6	NUM
iajs-3010	110	6	.	.	PUNCT
iajs-3010	111	1	1.00.80.60.40.20.0	1.00.80.60.40.20.0	NUM
iajs-3010	111	2	1	1	NUM
iajs-3010	111	3	specificity	specificity	NOUN
iajs-3010	111	4	1.0	1.0	NUM
iajs-3010	111	5	0.8	0.8	NUM
iajs-3010	111	6	0.6	0.6	NUM
iajs-3010	111	7	0.4	0.4	NUM
iajs-3010	111	8	0.2	0.2	NUM
iajs-3010	111	9	0.0	0.0	NUM
iajs-3010	111	10	se	se	X
iajs-3010	111	11	ns	ns	PROPN
iajs-3010	111	12	itiv	itiv	PROPN
iajs-3010	111	13	ity	ity	PROPN
iajs-3010	111	14	roc	roc	PROPN
iajs-3010	111	15	curve	curve	PROPN
iajs-3010	111	16	ihjpas	ihjpas	PROPN
iajs-3010	111	17	.	.	PUNCT
iajs-3010	112	1	36(2)2023	36(2)2023	NUM
iajs-3010	112	2	40	40	NUM
iajs-3010	112	3	the	the	DET
iajs-3010	112	4	findings	finding	NOUN
iajs-3010	112	5	were	be	AUX
iajs-3010	112	6	agreed	agree	VERB
iajs-3010	112	7	to	to	ADP
iajs-3010	112	8	[	[	X
iajs-3010	112	9	15	15	NUM
iajs-3010	112	10	]	]	PUNCT
iajs-3010	112	11	,	,	PUNCT
iajs-3010	112	12	the	the	DET
iajs-3010	112	13	largest	large	ADJ
iajs-3010	112	14	area	area	NOUN
iajs-3010	112	15	under	under	ADP
iajs-3010	112	16	the	the	DET
iajs-3010	112	17	curve	curve	NOUN
iajs-3010	112	18	(	(	PUNCT
iajs-3010	112	19	auc	auc	NOUN
iajs-3010	112	20	)	)	PUNCT
iajs-3010	112	21	was	be	AUX
iajs-3010	112	22	found	find	VERB
iajs-3010	112	23	for	for	ADP
iajs-3010	112	24	ip-10	ip-10	X
iajs-3010	112	25	(	(	PUNCT
iajs-3010	112	26	auc=	auc=	PROPN
iajs-3010	112	27	0.98	0.98	NUM
iajs-3010	112	28	;	;	PUNCT
iajs-3010	113	1	p	p	PROPN
iajs-3010	113	2	0.001	0.001	NUM
iajs-3010	113	3	)	)	PUNCT
iajs-3010	113	4	,	,	PUNCT
iajs-3010	113	5	for	for	ADP
iajs-3010	113	6	which	which	PRON
iajs-3010	113	7	the	the	DET
iajs-3010	113	8	optimal	optimal	ADJ
iajs-3010	113	9	cut	cut	NOUN
iajs-3010	113	10	-	-	PUNCT
iajs-3010	113	11	off	off	ADP
iajs-3010	113	12	value	value	NOUN
iajs-3010	113	13	determined	determine	VERB
iajs-3010	113	14	by	by	ADP
iajs-3010	113	15	the	the	DET
iajs-3010	113	16	youden	youden	PROPN
iajs-3010	113	17	index	index	NOUN
iajs-3010	113	18	was	be	AUX
iajs-3010	113	19	55.10	55.10	NUM
iajs-3010	113	20	.	.	PUNCT
iajs-3010	114	1	the	the	DET
iajs-3010	114	2	sensitivity	sensitivity	NOUN
iajs-3010	114	3	and	and	CCONJ
iajs-3010	114	4	specificity	specificity	NOUN
iajs-3010	114	5	of	of	ADP
iajs-3010	114	6	ip-10	ip-10	NOUN
iajs-3010	114	7	as	as	ADP
iajs-3010	114	8	a	a	DET
iajs-3010	114	9	biomarker	biomarker	NOUN
iajs-3010	114	10	of	of	ADP
iajs-3010	114	11	urticaria	urticaria	NOUN
iajs-3010	114	12	incidence	incidence	NOUN
iajs-3010	114	13	were	be	AUX
iajs-3010	114	14	determined	determine	VERB
iajs-3010	114	15	to	to	PART
iajs-3010	114	16	be	be	AUX
iajs-3010	114	17	92	92	NUM
iajs-3010	114	18	%	%	NOUN
iajs-3010	114	19	and	and	CCONJ
iajs-3010	114	20	100	100	NUM
iajs-3010	114	21	%	%	NOUN
iajs-3010	114	22	,	,	PUNCT
iajs-3010	114	23	respectively	respectively	ADV
iajs-3010	114	24	.	.	PUNCT
iajs-3010	115	1	at	at	ADP
iajs-3010	115	2	il-6	il-6	NOUN
iajs-3010	115	3	,	,	PUNCT
iajs-3010	115	4	whose	whose	DET
iajs-3010	115	5	auc	auc	NOUN
iajs-3010	115	6	was	be	AUX
iajs-3010	115	7	0.96	0.96	NUM
iajs-3010	115	8	(	(	PUNCT
iajs-3010	115	9	p	p	NOUN
iajs-3010	115	10	0.001	0.001	NUM
iajs-3010	115	11	)	)	PUNCT
iajs-3010	115	12	and	and	CCONJ
iajs-3010	115	13	reported	report	VERB
iajs-3010	115	14	same	same	ADJ
iajs-3010	115	15	sensitivity	sensitivity	NOUN
iajs-3010	115	16	and	and	CCONJ
iajs-3010	115	17	specificity	specificity	NOUN
iajs-3010	115	18	(	(	PUNCT
iajs-3010	115	19	92	92	NUM
iajs-3010	115	20	%	%	NOUN
iajs-3010	115	21	and	and	CCONJ
iajs-3010	115	22	100	100	NUM
iajs-3010	115	23	%	%	NOUN
iajs-3010	115	24	,	,	PUNCT
iajs-3010	115	25	respectively	respectively	ADV
iajs-3010	115	26	,	,	PUNCT
iajs-3010	115	27	for	for	ADP
iajs-3010	115	28	a	a	DET
iajs-3010	115	29	cut	cut	VERB
iajs-3010	115	30	-	-	PUNCT
iajs-3010	115	31	off	off	ADP
iajs-3010	115	32	point	point	NOUN
iajs-3010	115	33	of	of	ADP
iajs-3010	115	34	9.85	9.85	NUM
iajs-3010	115	35	)	)	PUNCT
iajs-3010	115	36	were	be	AUX
iajs-3010	115	37	demonstrated	demonstrate	VERB
iajs-3010	115	38	.	.	PUNCT
iajs-3010	116	1	according	accord	VERB
iajs-3010	116	2	to	to	ADP
iajs-3010	116	3	roc	roc	PROPN
iajs-3010	116	4	analysis	analysis	NOUN
iajs-3010	116	5	,	,	PUNCT
iajs-3010	116	6	il-6	il-6	PRON
iajs-3010	116	7	has	have	VERB
iajs-3010	116	8	a	a	DET
iajs-3010	116	9	high	high	ADJ
iajs-3010	116	10	sensitivity	sensitivity	NOUN
iajs-3010	116	11	and	and	CCONJ
iajs-3010	116	12	specificity	specificity	NOUN
iajs-3010	116	13	as	as	ADP
iajs-3010	116	14	a	a	DET
iajs-3010	116	15	predictor	predictor	NOUN
iajs-3010	116	16	of	of	ADP
iajs-3010	116	17	urticarial	urticarial	ADJ
iajs-3010	116	18	incidence	incidence	NOUN
iajs-3010	116	19	.	.	PUNCT
iajs-3010	117	1	on	on	ADP
iajs-3010	117	2	the	the	DET
iajs-3010	117	3	other	other	ADJ
iajs-3010	117	4	side	side	NOUN
iajs-3010	117	5	,	,	PUNCT
iajs-3010	117	6	the	the	DET
iajs-3010	117	7	roc	roc	PROPN
iajs-3010	117	8	results	result	NOUN
iajs-3010	117	9	of	of	ADP
iajs-3010	117	10	total	total	ADJ
iajs-3010	117	11	ige	ige	PROPN
iajs-3010	117	12	showed	show	VERB
iajs-3010	117	13	cut	cut	VERB
iajs-3010	117	14	-	-	PUNCT
iajs-3010	117	15	off	off	ADP
iajs-3010	117	16	value	value	NOUN
iajs-3010	117	17	is	be	AUX
iajs-3010	117	18	(	(	PUNCT
iajs-3010	117	19	78.58	78.58	NUM
iajs-3010	117	20	)	)	PUNCT
iajs-3010	117	21	,	,	PUNCT
iajs-3010	117	22	in	in	ADP
iajs-3010	117	23	roc	roc	PROPN
iajs-3010	117	24	curve	curve	NOUN
iajs-3010	117	25	validity	validity	NOUN
iajs-3010	117	26	test	test	NOUN
iajs-3010	117	27	for	for	ADP
iajs-3010	117	28	total	total	ADJ
iajs-3010	117	29	ige	ige	PROPN
iajs-3010	117	30	dependent	dependent	ADJ
iajs-3010	117	31	on	on	ADP
iajs-3010	117	32	clinical	clinical	ADJ
iajs-3010	117	33	diagnosis	diagnosis	NOUN
iajs-3010	117	34	and	and	CCONJ
iajs-3010	117	35	found	find	VERB
iajs-3010	117	36	greatest	great	ADJ
iajs-3010	117	37	sensitivity	sensitivity	NOUN
iajs-3010	117	38	(	(	PUNCT
iajs-3010	117	39	91.3	91.3	NUM
iajs-3010	117	40	%	%	NOUN
iajs-3010	117	41	)	)	PUNCT
iajs-3010	117	42	,	,	PUNCT
iajs-3010	117	43	specificity	specificity	NOUN
iajs-3010	117	44	(	(	PUNCT
iajs-3010	117	45	95.0	95.0	NUM
iajs-3010	117	46	%	%	NOUN
iajs-3010	117	47	)	)	PUNCT
iajs-3010	117	48	ppv	ppv	NOUN
iajs-3010	117	49	(	(	PUNCT
iajs-3010	117	50	97.3	97.3	NUM
iajs-3010	117	51	%	%	NOUN
iajs-3010	117	52	)	)	PUNCT
iajs-3010	117	53	,	,	PUNCT
iajs-3010	117	54	npv	npv	NOUN
iajs-3010	117	55	(	(	PUNCT
iajs-3010	117	56	85.4	85.4	NUM
iajs-3010	117	57	%	%	NOUN
iajs-3010	117	58	)	)	PUNCT
iajs-3010	117	59	,	,	PUNCT
iajs-3010	117	60	accuracy	accuracy	NOUN
iajs-3010	117	61	(	(	PUNCT
iajs-3010	117	62	87.4	87.4	NUM
iajs-3010	117	63	%	%	NOUN
iajs-3010	117	64	)	)	PUNCT
iajs-3010	117	65	and	and	CCONJ
iajs-3010	117	66	area	area	NOUN
iajs-3010	117	67	under	under	ADP
iajs-3010	117	68	curve	curve	NOUN
iajs-3010	117	69	(	(	PUNCT
iajs-3010	117	70	0.960	0.960	NUM
iajs-3010	117	71	)	)	PUNCT
iajs-3010	117	72	.	.	PUNCT
iajs-3010	118	1	overall	overall	ADV
iajs-3010	118	2	,	,	PUNCT
iajs-3010	118	3	there	there	PRON
iajs-3010	118	4	is	be	VERB
iajs-3010	118	5	a	a	DET
iajs-3010	118	6	highly	highly	ADV
iajs-3010	118	7	significant	significant	ADJ
iajs-3010	118	8	differences	difference	NOUN
iajs-3010	118	9	between	between	ADP
iajs-3010	118	10	studied	study	VERB
iajs-3010	118	11	groups	group	NOUN
iajs-3010	118	12	(	(	PUNCT
iajs-3010	118	13	p<0.001	p<0.001	X
iajs-3010	118	14	)	)	PUNCT
iajs-3010	118	15	as	as	ADP
iajs-3010	118	16	in	in	ADP
iajs-3010	118	17	figure	figure	NOUN
iajs-3010	118	18	2	2	NUM
iajs-3010	118	19	figure	figure	NOUN
iajs-3010	118	20	2	2	NUM
iajs-3010	118	21	.	.	PUNCT
iajs-3010	119	1	the	the	DET
iajs-3010	119	2	roc	roc	PROPN
iajs-3010	119	3	curve	curve	NOUN
iajs-3010	119	4	of	of	ADP
iajs-3010	119	5	t	t	PROPN
iajs-3010	119	6	-	-	PUNCT
iajs-3010	119	7	ige	ige	PROPN
iajs-3010	119	8	the	the	DET
iajs-3010	119	9	roc	roc	PROPN
iajs-3010	119	10	observed	observe	VERB
iajs-3010	119	11	that	that	SCONJ
iajs-3010	120	1	[	[	X
iajs-3010	120	2	16	16	NUM
iajs-3010	120	3	]	]	PUNCT
iajs-3010	120	4	in	in	ADP
iajs-3010	120	5	their	their	PRON
iajs-3010	120	6	study	study	NOUN
iajs-3010	120	7	that	that	PRON
iajs-3010	120	8	revealed	reveal	VERB
iajs-3010	120	9	et	et	PROPN
iajs-3010	120	10	al	al	PROPN
iajs-3010	120	11	.	.	PUNCT
iajs-3010	120	12	jangthe	jangthe	PROPN
iajs-3010	120	13	result	result	PROPN
iajs-3010	120	14	agreed	agree	VERB
iajs-3010	120	15	with	with	ADP
iajs-3010	120	16	the	the	DET
iajs-3010	120	17	area	area	NOUN
iajs-3010	120	18	values	value	NOUN
iajs-3010	120	19	under	under	ADP
iajs-3010	120	20	auc	auc	NOUN
iajs-3010	120	21	curve	curve	NOUN
iajs-3010	120	22	with	with	ADP
iajs-3010	120	23	optimum	optimum	ADJ
iajs-3010	120	24	specificity	specificity	NOUN
iajs-3010	120	25	and	and	CCONJ
iajs-3010	120	26	sensitivity	sensitivity	NOUN
iajs-3010	120	27	of	of	ADP
iajs-3010	120	28	serum	serum	NOUN
iajs-3010	120	29	levels	level	NOUN
iajs-3010	120	30	of	of	ADP
iajs-3010	120	31	ige	ige	PROPN
iajs-3010	120	32	for	for	ADP
iajs-3010	120	33	determining	determine	VERB
iajs-3010	120	34	atopic	atopic	NOUN
iajs-3010	120	35	case	case	NOUN
iajs-3010	120	36	in	in	ADP
iajs-3010	120	37	patients	patient	NOUN
iajs-3010	120	38	with	with	ADP
iajs-3010	120	39	csu	csu	PROPN
iajs-3010	120	40	were	be	AUX
iajs-3010	120	41	0.691	0.691	NUM
iajs-3010	120	42	and	and	CCONJ
iajs-3010	120	43	0.730	0.730	NUM
iajs-3010	120	44	with	with	ADP
iajs-3010	120	45	;	;	PUNCT
iajs-3010	120	46	-and	-and	NUM
iajs-3010	120	47	free	free	ADJ
iajs-3010	120	48	-total	-total	PROPN
iajs-3010	120	49	.specificity	.specificity	NOUN
iajs-3010	120	50	without	without	ADP
iajs-3010	120	51	considerably	considerably	ADV
iajs-3010	120	52	variations	variation	NOUN
iajs-3010	120	53	.	.	PUNCT
iajs-3010	121	1	72.7	72.7	NUM
iajs-3010	121	2	%	%	NOUN
iajs-3010	121	3	sensitivity;vs	sensitivity;vs	NOUN
iajs-3010	121	4	.	.	PUNCT
iajs-3010	122	1	100.0	100.0	NUM
iajs-3010	122	2	%	%	NOUN
iajs-3010	122	3	33.3%vs	33.3%vs	NUM
iajs-3010	122	4	64.7	64.7	NUM
iajs-3010	122	5	%	%	NOUN
iajs-3010	122	6	4.conclusion	4.conclusion	NUM
iajs-3010	122	7	the	the	DET
iajs-3010	122	8	obtained	obtain	VERB
iajs-3010	122	9	results	result	NOUN
iajs-3010	122	10	showed	show	VERB
iajs-3010	122	11	the	the	DET
iajs-3010	122	12	female	female	NOUN
iajs-3010	122	13	was	be	AUX
iajs-3010	122	14	higher	high	ADJ
iajs-3010	122	15	than	than	ADP
iajs-3010	122	16	male	male	ADJ
iajs-3010	122	17	in	in	ADP
iajs-3010	122	18	risk	risk	NOUN
iajs-3010	122	19	of	of	ADP
iajs-3010	122	20	csu	csu	NOUN
iajs-3010	122	21	which	which	PRON
iajs-3010	122	22	this	this	PRON
iajs-3010	122	23	was	be	AUX
iajs-3010	122	24	agreed	agree	VERB
iajs-3010	122	25	with	with	ADP
iajs-3010	122	26	different	different	ADJ
iajs-3010	122	27	previous	previous	ADJ
iajs-3010	122	28	studies	study	NOUN
iajs-3010	122	29	,	,	PUNCT
iajs-3010	122	30	also	also	ADV
iajs-3010	122	31	the	the	DET
iajs-3010	122	32	study	study	NOUN
iajs-3010	122	33	showed	show	VERB
iajs-3010	122	34	the	the	DET
iajs-3010	122	35	csu	csu	PROPN
iajs-3010	122	36	patient	patient	NOUN
iajs-3010	122	37	had	have	VERB
iajs-3010	122	38	high	high	ADJ
iajs-3010	122	39	hematological	hematological	ADJ
iajs-3010	122	40	and	and	CCONJ
iajs-3010	122	41	immunological	immunological	ADJ
iajs-3010	122	42	values	value	NOUN
iajs-3010	122	43	than	than	ADP
iajs-3010	122	44	patients	patient	NOUN
iajs-3010	122	45	in	in	ADP
iajs-3010	122	46	same	same	ADJ
iajs-3010	122	47	time	time	NOUN
iajs-3010	122	48	the	the	DET
iajs-3010	122	49	values	value	NOUN
iajs-3010	122	50	of	of	ADP
iajs-3010	122	51	biomarkers	biomarker	NOUN
iajs-3010	122	52	was	be	AUX
iajs-3010	122	53	various	various	ADJ
iajs-3010	122	54	between	between	ADP
iajs-3010	122	55	patients	patient	NOUN
iajs-3010	122	56	without	without	ADP
iajs-3010	122	57	treatment	treatment	NOUN
iajs-3010	122	58	and	and	CCONJ
iajs-3010	122	59	in	in	ADP
iajs-3010	122	60	patients	patient	NOUN
iajs-3010	122	61	whose	whose	DET
iajs-3010	122	62	under	under	ADP
iajs-3010	122	63	goes	go	VERB
iajs-3010	122	64	into	into	ADP
iajs-3010	122	65	treatment	treatment	NOUN
iajs-3010	122	66	1.00.80.60.40.20.0	1.00.80.60.40.20.0	NOUN
iajs-3010	122	67	1	1	NUM
iajs-3010	122	68	specificity	specificity	NOUN
iajs-3010	122	69	1.0	1.0	NUM
iajs-3010	122	70	0.8	0.8	NUM
iajs-3010	122	71	0.6	0.6	NUM
iajs-3010	122	72	0.4	0.4	NUM
iajs-3010	122	73	0.2	0.2	NUM
iajs-3010	122	74	0.0	0.0	NUM
iajs-3010	122	75	se	se	X
iajs-3010	122	76	ns	ns	PROPN
iajs-3010	122	77	itiv	itiv	PROPN
iajs-3010	122	78	ity	ity	PROPN
iajs-3010	122	79	roc	roc	PROPN
iajs-3010	122	80	curve	curve	PROPN
iajs-3010	122	81	ihjpas	ihjpas	PROPN
iajs-3010	122	82	.	.	PUNCT
iajs-3010	123	1	36(2)2023	36(2)2023	NUM
iajs-3010	123	2	41	41	NUM
iajs-3010	123	3	however	however	ADV
iajs-3010	123	4	during	during	ADP
iajs-3010	123	5	the	the	DET
iajs-3010	123	6	study	study	NOUN
iajs-3010	123	7	revealed	reveal	VERB
iajs-3010	123	8	the	the	DET
iajs-3010	123	9	age	age	NOUN
iajs-3010	123	10	from	from	ADP
iajs-3010	123	11	30	30	NUM
iajs-3010	123	12	to	to	PART
iajs-3010	123	13	60	60	NUM
iajs-3010	123	14	year	year	NOUN
iajs-3010	123	15	showed	show	VERB
iajs-3010	123	16	higher	high	ADJ
iajs-3010	123	17	value	value	NOUN
iajs-3010	123	18	in	in	ADP
iajs-3010	123	19	biomarkers	biomarker	NOUN
iajs-3010	123	20	than	than	ADP
iajs-3010	123	21	other	other	ADJ
iajs-3010	123	22	ages	age	NOUN
iajs-3010	123	23	finally	finally	ADV
iajs-3010	123	24	the	the	DET
iajs-3010	123	25	roc	roc	PROPN
iajs-3010	123	26	showed	show	VERB
iajs-3010	123	27	the	the	DET
iajs-3010	123	28	il-6	il-6	NOUN
iajs-3010	123	29	and	and	CCONJ
iajs-3010	123	30	ige	ige	PROPN
iajs-3010	123	31	were	be	AUX
iajs-3010	123	32	discriminated	discriminate	VERB
iajs-3010	123	33	as	as	ADP
iajs-3010	123	34	accurate	accurate	ADJ
iajs-3010	123	35	biomarkers	biomarker	NOUN
iajs-3010	123	36	for	for	ADP
iajs-3010	123	37	csu	csu	PROPN
iajs-3010	123	38	.	.	PUNCT
iajs-3010	124	1	references	reference	NOUN
iajs-3010	124	2	1	1	NUM
iajs-3010	124	3	.	.	PUNCT
iajs-3010	124	4	gonzalez	gonzalez	PROPN
iajs-3010	124	5	-	-	PUNCT
iajs-3010	124	6	diaz	diaz	PROPN
iajs-3010	124	7	,	,	PUNCT
iajs-3010	124	8	s.n	s.n	PROPN
iajs-3010	124	9	.	.	PROPN
iajs-3010	124	10	;	;	PUNCT
iajs-3010	124	11	sanchez	sanchez	PROPN
iajs-3010	124	12	-	-	PUNCT
iajs-3010	124	13	borges	borge	NOUN
iajs-3010	124	14	,	,	PUNCT
iajs-3010	124	15	m.	m.	NOUN
iajs-3010	124	16	;	;	PUNCT
iajs-3010	124	17	rangel	rangel	PROPN
iajs-3010	124	18	-	-	PUNCT
iajs-3010	124	19	gonzalez	gonzalez	PROPN
iajs-3010	124	20	,	,	PUNCT
iajs-3010	124	21	d.m	d.m	PROPN
iajs-3010	124	22	.	.	PROPN
iajs-3010	124	23	;	;	PUNCT
iajs-3010	124	24	guzman	guzman	NOUN
iajs-3010	124	25	-	-	PUNCT
iajs-3010	124	26	avilan	avilan	PROPN
iajs-3010	124	27	,	,	PUNCT
iajs-3010	124	28	r.i	r.i	PROPN
iajs-3010	124	29	.	.	PROPN
iajs-3010	124	30	;	;	PUNCT
iajs-3010	124	31	canseco	canseco	PROPN
iajs-3010	124	32	-	-	PUNCT
iajs-3010	124	33	villarreal	villarreal	PROPN
iajs-3010	124	34	,	,	PUNCT
iajs-3010	124	35	j.i	j.i	PROPN
iajs-3010	124	36	.	.	PROPN
iajs-3010	124	37	;	;	PUNCT
iajs-3010	124	38	arias	arias	PROPN
iajs-3010	124	39	-	-	PUNCT
iajs-3010	124	40	cruz	cruz	PROPN
iajs-3010	124	41	,	,	PUNCT
iajs-3010	124	42	a.	a.	NOUN
iajs-3010	124	43	chronic	chronic	NOUN
iajs-3010	124	44	urticaria	urticaria	NOUN
iajs-3010	124	45	and	and	CCONJ
iajs-3010	124	46	thyroid	thyroid	VERB
iajs-3010	124	47	pathology	pathology	NOUN
iajs-3010	124	48	.	.	PUNCT
iajs-3010	125	1	world	world	PROPN
iajs-3010	125	2	allergy	allergy	PROPN
iajs-3010	125	3	organ	organ	PROPN
iajs-3010	125	4	.	.	PUNCT
iajs-3010	126	1	j.	j.	PROPN
iajs-3010	126	2	2020	2020	PROPN
iajs-3010	126	3	,	,	PUNCT
iajs-3010	126	4	13	13	NUM
iajs-3010	126	5	,	,	PUNCT
iajs-3010	126	6	100101	100101	NUM
iajs-3010	126	7	.	.	PUNCT
iajs-3010	127	1	2	2	X
iajs-3010	127	2	.	.	X
iajs-3010	127	3	choi	choi	NOUN
iajs-3010	127	4	,	,	PUNCT
iajs-3010	127	5	j.-h	j.-h	PROPN
iajs-3010	127	6	.	.	PUNCT
iajs-3010	127	7	;	;	PUNCT
iajs-3010	127	8	lee	lee	PROPN
iajs-3010	127	9	,	,	PUNCT
iajs-3010	127	10	d.h	d.h	PROPN
iajs-3010	127	11	.	.	PROPN
iajs-3010	127	12	;	;	PUNCT
iajs-3010	127	13	song	song	NOUN
iajs-3010	127	14	,	,	PUNCT
iajs-3010	127	15	w.-j	w.-j	PROPN
iajs-3010	127	16	.	.	PUNCT
iajs-3010	127	17	;	;	PUNCT
iajs-3010	128	1	choi	choi	NOUN
iajs-3010	128	2	,	,	PUNCT
iajs-3010	128	3	m.	m.	NOUN
iajs-3010	128	4	;	;	PUNCT
iajs-3010	128	5	kwon	kwon	PROPN
iajs-3010	128	6	,	,	PUNCT
iajs-3010	128	7	j.-w	j.-w	PROPN
iajs-3010	128	8	.	.	PUNCT
iajs-3010	128	9	;	;	PUNCT
iajs-3010	128	10	kim	kim	PROPN
iajs-3010	128	11	,	,	PUNCT
iajs-3010	128	12	g.-w	g.-w	PROPN
iajs-3010	128	13	.	.	PUNCT
iajs-3010	128	14	;	;	PUNCT
iajs-3010	128	15	kim	kim	PROPN
iajs-3010	128	16	,	,	PUNCT
iajs-3010	128	17	m.h	m.h	PROPN
iajs-3010	128	18	.	.	PROPN
iajs-3010	128	19	;	;	PUNCT
iajs-3010	128	20	kim	kim	PROPN
iajs-3010	128	21	,	,	PUNCT
iajs-3010	128	22	m.a	m.a	PROPN
iajs-3010	128	23	.	.	PROPN
iajs-3010	128	24	;	;	PUNCT
iajs-3010	128	25	kim	kim	PROPN
iajs-3010	128	26	,	,	PUNCT
iajs-3010	128	27	m.-h	m.-h	PROPN
iajs-3010	128	28	.	.	PUNCT
iajs-3010	128	29	;	;	PUNCT
iajs-3010	128	30	kim	kim	PROPN
iajs-3010	128	31	,	,	PUNCT
iajs-3010	128	32	b.-k	b.-k	PROPN
iajs-3010	128	33	.	.	PUNCT
iajs-3010	129	1	the	the	DET
iajs-3010	129	2	kaaaci	kaaaci	NOUN
iajs-3010	129	3	/	/	SYM
iajs-3010	129	4	kda	kda	NOUN
iajs-3010	129	5	evidence	evidence	NOUN
iajs-3010	129	6	-	-	PUNCT
iajs-3010	129	7	based	base	VERB
iajs-3010	129	8	practice	practice	NOUN
iajs-3010	129	9	guidelines	guideline	NOUN
iajs-3010	129	10	for	for	ADP
iajs-3010	129	11	chronic	chronic	ADJ
iajs-3010	129	12	spontaneous	spontaneous	ADJ
iajs-3010	129	13	urticaria	urticaria	NOUN
iajs-3010	129	14	in	in	ADP
iajs-3010	129	15	korean	korean	ADJ
iajs-3010	129	16	adults	adult	NOUN
iajs-3010	129	17	and	and	CCONJ
iajs-3010	129	18	children	child	NOUN
iajs-3010	129	19	:	:	PUNCT
iajs-3010	129	20	part	part	NOUN
iajs-3010	129	21	2	2	NUM
iajs-3010	129	22	.	.	PUNCT
iajs-3010	129	23	management	management	NOUN
iajs-3010	129	24	of	of	ADP
iajs-3010	129	25	h1	h1	NOUN
iajs-3010	129	26	-	-	PUNCT
iajs-3010	129	27	antihistaminerefractory	antihistaminerefractory	ADJ
iajs-3010	129	28	chronic	chronic	ADJ
iajs-3010	129	29	urticaria	urticaria	NOUN
iajs-3010	129	30	.	.	PUNCT
iajs-3010	130	1	allergy	allergy	NOUN
iajs-3010	130	2	.	.	PUNCT
iajs-3010	131	1	asthma	asthma	PROPN
iajs-3010	131	2	immunol	immunol	PROPN
iajs-3010	131	3	.	.	PUNCT
iajs-3010	132	1	res	re	NOUN
iajs-3010	132	2	.	.	PUNCT
iajs-3010	133	1	2020	2020	NUM
iajs-3010	133	2	,	,	PUNCT
iajs-3010	133	3	12	12	NUM
iajs-3010	133	4	,	,	PUNCT
iajs-3010	133	5	750	750	NUM
iajs-3010	133	6	.	.	NOUN
iajs-3010	134	1	3	3	X
iajs-3010	134	2	.	.	X
iajs-3010	134	3	kolkhir	kolkhir	NOUN
iajs-3010	134	4	,	,	PUNCT
iajs-3010	134	5	p.	p.	NOUN
iajs-3010	134	6	;	;	PUNCT
iajs-3010	135	1	church	church	PROPN
iajs-3010	135	2	,	,	PUNCT
iajs-3010	135	3	m.k	m.k	PROPN
iajs-3010	135	4	.	.	PUNCT
iajs-3010	135	5	;	;	PUNCT
iajs-3010	135	6	altrichter	altrichter	ADV
iajs-3010	135	7	,	,	PUNCT
iajs-3010	135	8	s.	s.	PROPN
iajs-3010	135	9	;	;	PUNCT
iajs-3010	135	10	skov	skov	PROPN
iajs-3010	135	11	,	,	PUNCT
iajs-3010	135	12	p.s	p.s	PROPN
iajs-3010	135	13	.	.	PROPN
iajs-3010	135	14	;	;	PUNCT
iajs-3010	135	15	hawro	hawro	PROPN
iajs-3010	135	16	,	,	PUNCT
iajs-3010	135	17	t.	t.	PROPN
iajs-3010	135	18	;	;	PUNCT
iajs-3010	135	19	frischbutter	frischbutter	PROPN
iajs-3010	135	20	,	,	PUNCT
iajs-3010	135	21	s.	s.	PROPN
iajs-3010	135	22	;	;	PUNCT
iajs-3010	135	23	metz	metz	PROPN
iajs-3010	135	24	,	,	PUNCT
iajs-3010	135	25	m.	m.	NOUN
iajs-3010	135	26	;	;	PUNCT
iajs-3010	135	27	maurer	maurer	PROPN
iajs-3010	135	28	,	,	PUNCT
iajs-3010	135	29	m.	m.	NOUN
iajs-3010	135	30	eosinopenia	eosinopenia	PROPN
iajs-3010	135	31	,	,	PUNCT
iajs-3010	135	32	in	in	ADP
iajs-3010	135	33	chronic	chronic	ADJ
iajs-3010	135	34	spontaneous	spontaneous	ADJ
iajs-3010	135	35	urticaria	urticaria	NOUN
iajs-3010	135	36	,	,	PUNCT
iajs-3010	135	37	is	be	AUX
iajs-3010	135	38	associated	associate	VERB
iajs-3010	135	39	with	with	ADP
iajs-3010	135	40	high	high	ADJ
iajs-3010	135	41	disease	disease	NOUN
iajs-3010	135	42	activity	activity	NOUN
iajs-3010	135	43	,	,	PUNCT
iajs-3010	135	44	autoimmunity	autoimmunity	NOUN
iajs-3010	135	45	,	,	PUNCT
iajs-3010	135	46	and	and	CCONJ
iajs-3010	135	47	poor	poor	ADJ
iajs-3010	135	48	response	response	NOUN
iajs-3010	135	49	to	to	ADP
iajs-3010	135	50	treatment	treatment	NOUN
iajs-3010	135	51	.	.	PUNCT
iajs-3010	136	1	j.	j.	PROPN
iajs-3010	136	2	allergy	allergy	PROPN
iajs-3010	136	3	clin	clin	PROPN
iajs-3010	136	4	.	.	PUNCT
iajs-3010	137	1	immunol	immunol	PROPN
iajs-3010	137	2	.	.	PUNCT
iajs-3010	138	1	pract	pract	PROPN
iajs-3010	138	2	.	.	PUNCT
iajs-3010	139	1	2020	2020	NUM
iajs-3010	139	2	,	,	PUNCT
iajs-3010	139	3	8	8	NUM
iajs-3010	139	4	,	,	PUNCT
iajs-3010	139	5	318–325	318–325	NUM
iajs-3010	139	6	.	.	PUNCT
iajs-3010	140	1	4	4	NUM
iajs-3010	140	2	.	.	X
iajs-3010	140	3	lawton	lawton	PROPN
iajs-3010	140	4	,	,	PUNCT
iajs-3010	140	5	s.	s.	PROPN
iajs-3010	140	6	identifying	identifying	NOUN
iajs-3010	140	7	,	,	PUNCT
iajs-3010	140	8	diagnosing	diagnosing	NOUN
iajs-3010	140	9	and	and	CCONJ
iajs-3010	140	10	managing	manage	VERB
iajs-3010	140	11	skin	skin	NOUN
iajs-3010	140	12	allergies	allergy	NOUN
iajs-3010	140	13	.	.	PUNCT
iajs-3010	141	1	prim	prim	ADJ
iajs-3010	141	2	.	.	PUNCT
iajs-3010	142	1	heal	heal	NOUN
iajs-3010	142	2	.	.	PUNCT
iajs-3010	143	1	care	care	NOUN
iajs-3010	143	2	2016	2016	NUM
iajs-3010	143	3	,	,	PUNCT
iajs-3010	143	4	26	26	NUM
iajs-3010	143	5	.	.	NOUN
iajs-3010	143	6	5	5	NUM
iajs-3010	143	7	.	.	X
iajs-3010	143	8	rorsman	rorsman	PROPN
iajs-3010	143	9	,	,	PUNCT
iajs-3010	143	10	h.	h.	PROPN
iajs-3010	143	11	basophilic	basophilic	PROPN
iajs-3010	143	12	leucopenia	leucopenia	PROPN
iajs-3010	143	13	in	in	ADP
iajs-3010	143	14	different	different	ADJ
iajs-3010	143	15	forms	form	NOUN
iajs-3010	143	16	of	of	ADP
iajs-3010	143	17	urticaria	urticaria	NOUN
iajs-3010	143	18	.	.	PUNCT
iajs-3010	144	1	allergy	allergy	PROPN
iajs-3010	144	2	1962	1962	NUM
iajs-3010	144	3	,	,	PUNCT
iajs-3010	144	4	17	17	NUM
iajs-3010	144	5	,	,	PUNCT
iajs-3010	144	6	168	168	NUM
iajs-3010	144	7	–	–	PUNCT
iajs-3010	144	8	184	184	NUM
iajs-3010	144	9	.	.	NOUN
iajs-3010	144	10	6	6	NUM
iajs-3010	144	11	.	.	X
iajs-3010	145	1	sutton	sutton	PROPN
iajs-3010	145	2	,	,	PUNCT
iajs-3010	145	3	b.j	b.j	PROPN
iajs-3010	145	4	.	.	PROPN
iajs-3010	145	5	;	;	PUNCT
iajs-3010	145	6	davies	davy	NOUN
iajs-3010	145	7	,	,	PUNCT
iajs-3010	145	8	a.m.	a.m.	ADV
iajs-3010	145	9	;	;	PUNCT
iajs-3010	145	10	bax	bax	PROPN
iajs-3010	145	11	,	,	PUNCT
iajs-3010	145	12	h.j	h.j	PROPN
iajs-3010	145	13	.	.	PROPN
iajs-3010	145	14	;	;	PUNCT
iajs-3010	145	15	karagiannis	karagiannis	PROPN
iajs-3010	145	16	,	,	PUNCT
iajs-3010	145	17	s.n	s.n	PROPN
iajs-3010	145	18	.	.	PROPN
iajs-3010	145	19	ige	ige	PROPN
iajs-3010	145	20	antibodies	antibodie	VERB
iajs-3010	145	21	:	:	PUNCT
iajs-3010	145	22	from	from	ADP
iajs-3010	145	23	structure	structure	NOUN
iajs-3010	145	24	to	to	PART
iajs-3010	145	25	function	function	VERB
iajs-3010	145	26	and	and	CCONJ
iajs-3010	145	27	clinical	clinical	ADJ
iajs-3010	145	28	translation	translation	NOUN
iajs-3010	145	29	.	.	PUNCT
iajs-3010	146	1	antibodies	antibodie	VERB
iajs-3010	146	2	2019	2019	NUM
iajs-3010	146	3	,	,	PUNCT
iajs-3010	146	4	8	8	NUM
iajs-3010	146	5	,	,	PUNCT
iajs-3010	146	6	19	19	NUM
iajs-3010	146	7	.	.	NOUN
iajs-3010	147	1	7	7	NUM
iajs-3010	147	2	.	.	X
iajs-3010	147	3	altrichter	altrichter	PROPN
iajs-3010	147	4	,	,	PUNCT
iajs-3010	147	5	s.	s.	PROPN
iajs-3010	147	6	;	;	PUNCT
iajs-3010	147	7	zampeli	zampeli	PROPN
iajs-3010	147	8	,	,	PUNCT
iajs-3010	147	9	v.	v.	PROPN
iajs-3010	147	10	;	;	PUNCT
iajs-3010	147	11	ellrich	ellrich	ADV
iajs-3010	147	12	,	,	PUNCT
iajs-3010	147	13	a.	a.	PROPN
iajs-3010	147	14	;	;	PUNCT
iajs-3010	147	15	zhang	zhang	PROPN
iajs-3010	147	16	,	,	PUNCT
iajs-3010	147	17	k.	k.	PROPN
iajs-3010	147	18	;	;	PUNCT
iajs-3010	147	19	church	church	PROPN
iajs-3010	147	20	,	,	PUNCT
iajs-3010	147	21	m.k	m.k	PROPN
iajs-3010	147	22	.	.	PUNCT
iajs-3010	147	23	;	;	PUNCT
iajs-3010	147	24	maurer	maurer	PROPN
iajs-3010	147	25	,	,	PUNCT
iajs-3010	147	26	m.	m.	NOUN
iajs-3010	147	27	igm	igm	PROPN
iajs-3010	147	28	and	and	CCONJ
iajs-3010	147	29	iga	iga	PROPN
iajs-3010	147	30	in	in	ADP
iajs-3010	147	31	addition	addition	NOUN
iajs-3010	147	32	to	to	ADP
iajs-3010	147	33	igg	igg	NOUN
iajs-3010	147	34	autoantibodies	autoantibody	NOUN
iajs-3010	147	35	against	against	ADP
iajs-3010	147	36	fcɛriα	fcɛriα	NOUN
iajs-3010	147	37	are	be	AUX
iajs-3010	147	38	frequent	frequent	ADJ
iajs-3010	147	39	and	and	CCONJ
iajs-3010	147	40	associated	associate	VERB
iajs-3010	147	41	with	with	ADP
iajs-3010	147	42	disease	disease	NOUN
iajs-3010	147	43	markers	marker	NOUN
iajs-3010	147	44	of	of	ADP
iajs-3010	147	45	chronic	chronic	ADJ
iajs-3010	147	46	spontaneous	spontaneous	ADJ
iajs-3010	147	47	urticaria	urticaria	NOUN
iajs-3010	147	48	.	.	PUNCT
iajs-3010	148	1	allergy	allergy	PROPN
iajs-3010	148	2	2020	2020	NUM
iajs-3010	148	3	,	,	PUNCT
iajs-3010	148	4	75	75	NUM
iajs-3010	148	5	,	,	PUNCT
iajs-3010	148	6	3208–3215	3208–3215	NUM
iajs-3010	148	7	.	.	NOUN
iajs-3010	148	8	8	8	NUM
iajs-3010	148	9	.	.	X
iajs-3010	149	1	kaur	kaur	PROPN
iajs-3010	149	2	,	,	PUNCT
iajs-3010	149	3	s.	s.	PROPN
iajs-3010	149	4	;	;	PUNCT
iajs-3010	149	5	bansal	bansal	NOUN
iajs-3010	149	6	,	,	PUNCT
iajs-3010	149	7	y.	y.	PROPN
iajs-3010	149	8	;	;	PUNCT
iajs-3010	149	9	kumar	kumar	PROPN
iajs-3010	149	10	,	,	PUNCT
iajs-3010	149	11	r.	r.	PROPN
iajs-3010	149	12	;	;	PUNCT
iajs-3010	149	13	bansal	bansal	NOUN
iajs-3010	149	14	,	,	PUNCT
iajs-3010	149	15	g.	g.	PROPN
iajs-3010	149	16	a	a	DET
iajs-3010	149	17	panoramic	panoramic	ADJ
iajs-3010	149	18	review	review	NOUN
iajs-3010	149	19	of	of	ADP
iajs-3010	149	20	il-6	il-6	NUM
iajs-3010	149	21	:	:	PUNCT
iajs-3010	149	22	structure	structure	NOUN
iajs-3010	149	23	,	,	PUNCT
iajs-3010	149	24	pathophysiological	pathophysiological	ADJ
iajs-3010	149	25	roles	role	NOUN
iajs-3010	149	26	and	and	CCONJ
iajs-3010	149	27	inhibitors	inhibitor	NOUN
iajs-3010	149	28	.	.	PUNCT
iajs-3010	150	1	bioorg	bioorg	VERB
iajs-3010	150	2	.	.	PUNCT
iajs-3010	151	1	med	med	PROPN
iajs-3010	151	2	.	.	PROPN
iajs-3010	151	3	chem	chem	PROPN
iajs-3010	151	4	.	.	PUNCT
iajs-3010	152	1	2020	2020	NUM
iajs-3010	152	2	,	,	PUNCT
iajs-3010	152	3	28	28	NUM
iajs-3010	152	4	,	,	PUNCT
iajs-3010	152	5	115327	115327	NUM
iajs-3010	152	6	.	.	PUNCT
iajs-3010	153	1	9	9	X
iajs-3010	153	2	.	.	X
iajs-3010	153	3	alasandagutti	alasandagutti	VERB
iajs-3010	153	4	,	,	PUNCT
iajs-3010	153	5	m.l	m.l	PROPN
iajs-3010	153	6	.	.	PROPN
iajs-3010	153	7	;	;	PUNCT
iajs-3010	153	8	ponnana	ponnana	PROPN
iajs-3010	153	9	,	,	PUNCT
iajs-3010	153	10	m.	m.	NOUN
iajs-3010	153	11	;	;	PUNCT
iajs-3010	153	12	sivangala	sivangala	PROPN
iajs-3010	153	13	,	,	PUNCT
iajs-3010	153	14	r.	r.	PROPN
iajs-3010	153	15	;	;	PUNCT
iajs-3010	153	16	thada	thada	PROPN
iajs-3010	153	17	,	,	PUNCT
iajs-3010	153	18	s.	s.	PROPN
iajs-3010	153	19	;	;	PUNCT
iajs-3010	153	20	joshi	joshi	PROPN
iajs-3010	153	21	,	,	PUNCT
iajs-3010	153	22	l.	l.	PROPN
iajs-3010	153	23	;	;	PUNCT
iajs-3010	153	24	hussain	hussain	PROPN
iajs-3010	153	25	,	,	PUNCT
iajs-3010	153	26	h.	h.	PROPN
iajs-3010	153	27	;	;	PUNCT
iajs-3010	153	28	ansari	ansari	PROPN
iajs-3010	153	29	,	,	PUNCT
iajs-3010	153	30	s.s	s.s	PROPN
iajs-3010	153	31	.	.	PROPN
iajs-3010	153	32	;	;	PUNCT
iajs-3010	153	33	valluri	valluri	PROPN
iajs-3010	153	34	,	,	PUNCT
iajs-3010	153	35	v.	v.	PROPN
iajs-3010	153	36	;	;	PUNCT
iajs-3010	153	37	gaddam	gaddam	PROPN
iajs-3010	153	38	,	,	PUNCT
iajs-3010	153	39	s.l	s.l	PROPN
iajs-3010	153	40	.	.	NOUN
iajs-3010	153	41	role	role	NOUN
iajs-3010	153	42	of	of	ADP
iajs-3010	153	43	ifn	ifn	PROPN
iajs-3010	153	44	-	-	PUNCT
iajs-3010	153	45	γ	γ	NOUN
iajs-3010	153	46	and	and	CCONJ
iajs-3010	153	47	il-6	il-6	NOUN
iajs-3010	153	48	cytokines	cytokine	NOUN
iajs-3010	153	49	and	and	CCONJ
iajs-3010	153	50	their	their	PRON
iajs-3010	153	51	association	association	NOUN
iajs-3010	153	52	in	in	ADP
iajs-3010	153	53	determining	determine	VERB
iajs-3010	153	54	susceptibility	susceptibility	NOUN
iajs-3010	153	55	to	to	PART
iajs-3010	153	56	chronic	chronic	VERB
iajs-3010	153	57	idiopathic	idiopathic	ADJ
iajs-3010	153	58	urticaria	urticaria	NOUN
iajs-3010	153	59	.	.	PUNCT
iajs-3010	154	1	genet	genet	NOUN
iajs-3010	154	2	.	.	PUNCT
iajs-3010	155	1	test	test	NOUN
iajs-3010	155	2	.	.	PUNCT
iajs-3010	156	1	mol	mol	PROPN
iajs-3010	156	2	.	.	PUNCT
iajs-3010	157	1	biomarkers	biomarker	NOUN
iajs-3010	157	2	2014	2014	NUM
iajs-3010	157	3	,	,	PUNCT
iajs-3010	157	4	18	18	NUM
iajs-3010	157	5	,	,	PUNCT
iajs-3010	157	6	804–809	804–809	NUM
iajs-3010	157	7	.	.	PROPN
iajs-3010	157	8	10	10	NUM
iajs-3010	157	9	.	.	PUNCT
iajs-3010	158	1	uysal	uysal	ADJ
iajs-3010	158	2	,	,	PUNCT
iajs-3010	158	3	p.i̇.	p.i̇.	PROPN
iajs-3010	158	4	;	;	PUNCT
iajs-3010	158	5	hayran	hayran	NOUN
iajs-3010	158	6	,	,	PUNCT
iajs-3010	158	7	y.	y.	PROPN
iajs-3010	158	8	;	;	PUNCT
iajs-3010	158	9	akdoğan	akdoğan	NOUN
iajs-3010	158	10	,	,	PUNCT
iajs-3010	158	11	n.	n.	PROPN
iajs-3010	158	12	;	;	PUNCT
iajs-3010	158	13	öktem	öktem	PROPN
iajs-3010	158	14	,	,	PUNCT
iajs-3010	158	15	a.	a.	NOUN
iajs-3010	158	16	;	;	PUNCT
iajs-3010	158	17	atılan	atılan	PROPN
iajs-3010	158	18	,	,	PUNCT
iajs-3010	158	19	a.	a.	NOUN
iajs-3010	158	20	;	;	PUNCT
iajs-3010	158	21	aksoy	aksoy	PROPN
iajs-3010	158	22	,	,	PUNCT
iajs-3010	158	23	g.g	g.g	PROPN
iajs-3010	158	24	.	.	PROPN
iajs-3010	158	25	;	;	PUNCT
iajs-3010	158	26	yalçın	yalçın	VERB
iajs-3010	158	27	,	,	PUNCT
iajs-3010	158	28	b.	b.	PROPN
iajs-3010	158	29	effect	effect	NOUN
iajs-3010	158	30	of	of	ADP
iajs-3010	158	31	omalizumab	omalizumab	NOUN
iajs-3010	158	32	therapy	therapy	NOUN
iajs-3010	158	33	on	on	ADP
iajs-3010	158	34	coagulation	coagulation	NOUN
iajs-3010	158	35	parameters	parameter	NOUN
iajs-3010	158	36	and	and	CCONJ
iajs-3010	158	37	total	total	ADJ
iajs-3010	158	38	immunoglobulin	immunoglobulin	NOUN
iajs-3010	158	39	e	e	PROPN
iajs-3010	158	40	levels	level	NOUN
iajs-3010	158	41	in	in	ADP
iajs-3010	158	42	patients	patient	NOUN
iajs-3010	158	43	with	with	ADP
iajs-3010	158	44	chronic	chronic	ADJ
iajs-3010	158	45	idiopathic	idiopathic	ADJ
iajs-3010	158	46	urticaria	urticaria	NOUN
iajs-3010	158	47	and	and	CCONJ
iajs-3010	158	48	bullous	bullous	ADJ
iajs-3010	158	49	pemphigoid	pemphigoid	NOUN
iajs-3010	158	50	.	.	PUNCT
iajs-3010	159	1	turk	turk	PROPN
iajs-3010	159	2	dermatoloji	dermatoloji	PROPN
iajs-3010	159	3	derg	derg	PROPN
iajs-3010	159	4	.	.	PUNCT
iajs-3010	160	1	2018	2018	NUM
iajs-3010	160	2	,	,	PUNCT
iajs-3010	160	3	12	12	NUM
iajs-3010	160	4	,	,	PUNCT
iajs-3010	160	5	159	159	NUM
iajs-3010	160	6	.	.	NOUN
iajs-3010	160	7	11	11	NUM
iajs-3010	160	8	.	.	PUNCT
iajs-3010	161	1	hatif	hatif	PROPN
iajs-3010	161	2	st	st	PROPN
iajs-3010	161	3	,	,	PUNCT
iajs-3010	161	4	;	;	PUNCT
iajs-3010	161	5	hussein	hussein	PROPN
iajs-3010	161	6	ta	ta	PROPN
iajs-3010	161	7	,	,	PUNCT
iajs-3010	161	8	;	;	PUNCT
iajs-3010	161	9	muhieldden	muhieldden	ADJ
iajs-3010	161	10	aa	aa	NOUN
iajs-3010	161	11	.	.	PUNCT
iajs-3010	161	12	;	;	PUNCT
iajs-3010	161	13	evaluation	evaluation	NOUN
iajs-3010	161	14	of	of	ADP
iajs-3010	161	15	il17	il17	PROPN
iajs-3010	161	16	-	-	PUNCT
iajs-3010	161	17	a	a	DET
iajs-3010	161	18	serum	serum	NOUN
iajs-3010	161	19	levels	level	NOUN
iajs-3010	161	20	in	in	ADP
iajs-3010	161	21	iraqi	iraqi	ADJ
iajs-3010	161	22	patients	patient	NOUN
iajs-3010	161	23	with	with	ADP
iajs-3010	161	24	alopecia	alopecia	NOUN
iajs-3010	161	25	areata	areata	ADJ
iajs-3010	161	26	and	and	CCONJ
iajs-3010	161	27	alopecia	alopecia	NOUN
iajs-3010	161	28	universalis	universali	VERB
iajs-3010	161	29	.	.	PUNCT
iajs-3010	162	1	biochem	biochem	PROPN
iajs-3010	162	2	.	.	PUNCT
iajs-3010	163	1	cell	cell	NOUN
iajs-3010	163	2	arch	arch	NOUN
iajs-3010	163	3	.	.	PUNCT
iajs-3010	164	1	2020	2020	NUM
iajs-3010	164	2	,	,	PUNCT
iajs-3010	164	3	20,6419	20,6419	NUM
iajs-3010	164	4	-	-	SYM
iajs-3010	164	5	25	25	NUM
iajs-3010	164	6	.	.	PUNCT
iajs-3010	164	7	12	12	NUM
iajs-3010	164	8	.	.	PUNCT
iajs-3010	165	1	maurer	maurer	PROPN
iajs-3010	165	2	,	,	PUNCT
iajs-3010	165	3	m.	m.	NOUN
iajs-3010	165	4	;	;	PUNCT
iajs-3010	165	5	houghton	houghton	PROPN
iajs-3010	165	6	,	,	PUNCT
iajs-3010	165	7	k.	k.	PROPN
iajs-3010	165	8	;	;	PUNCT
iajs-3010	165	9	costa	costa	PROPN
iajs-3010	165	10	,	,	PUNCT
iajs-3010	165	11	c.	c.	PROPN
iajs-3010	165	12	;	;	PUNCT
iajs-3010	165	13	dabove	dabove	VERB
iajs-3010	165	14	,	,	PUNCT
iajs-3010	165	15	f.	f.	PROPN
iajs-3010	165	16	;	;	PUNCT
iajs-3010	165	17	ensina	ensina	PROPN
iajs-3010	165	18	,	,	PUNCT
iajs-3010	165	19	l.f	l.f	PROPN
iajs-3010	165	20	.	.	PROPN
iajs-3010	165	21	;	;	PUNCT
iajs-3010	165	22	giménez	giménez	PROPN
iajs-3010	165	23	-	-	PUNCT
iajs-3010	165	24	arnau	arnau	PROPN
iajs-3010	165	25	,	,	PUNCT
iajs-3010	165	26	a.	a.	NOUN
iajs-3010	165	27	;	;	PUNCT
iajs-3010	165	28	guillet	guillet	VERB
iajs-3010	165	29	,	,	PUNCT
iajs-3010	165	30	g.	g.	PROPN
iajs-3010	165	31	;	;	PUNCT
iajs-3010	165	32	konstantinou	konstantinou	PROPN
iajs-3010	165	33	,	,	PUNCT
iajs-3010	165	34	g.n	g.n	PROPN
iajs-3010	165	35	.	.	PROPN
iajs-3010	165	36	;	;	PUNCT
iajs-3010	165	37	labrador	labrador	NOUN
iajs-3010	165	38	-	-	PUNCT
iajs-3010	165	39	horrillo	horrillo	ADV
iajs-3010	165	40	,	,	PUNCT
iajs-3010	165	41	m.	m.	NOUN
iajs-3010	165	42	;	;	PUNCT
iajs-3010	165	43	lapeere	lapeere	ADV
iajs-3010	165	44	,	,	PUNCT
iajs-3010	165	45	h.	h.	PROPN
iajs-3010	165	46	differences	difference	NOUN
iajs-3010	165	47	in	in	ADP
iajs-3010	165	48	chronic	chronic	ADJ
iajs-3010	165	49	spontaneous	spontaneous	ADJ
iajs-3010	165	50	urticaria	urticaria	NOUN
iajs-3010	165	51	between	between	ADP
iajs-3010	165	52	europe	europe	PROPN
iajs-3010	165	53	and	and	CCONJ
iajs-3010	165	54	central	central	ADJ
iajs-3010	165	55	/	/	SYM
iajs-3010	165	56	south	south	PROPN
iajs-3010	165	57	america	america	PROPN
iajs-3010	165	58	:	:	PUNCT
iajs-3010	165	59	results	result	NOUN
iajs-3010	165	60	of	of	ADP
iajs-3010	165	61	the	the	DET
iajs-3010	165	62	multi	multi	ADJ
iajs-3010	165	63	-	-	ADJ
iajs-3010	165	64	center	center	ADJ
iajs-3010	165	65	real	real	ADJ
iajs-3010	165	66	world	world	NOUN
iajs-3010	165	67	aware	aware	ADJ
iajs-3010	165	68	study	study	NOUN
iajs-3010	165	69	.	.	PUNCT
iajs-3010	166	1	world	world	NOUN
iajs-3010	166	2	allergy	allergy	PROPN
iajs-3010	166	3	organ	organ	PROPN
iajs-3010	166	4	.	.	PUNCT
iajs-3010	167	1	j.	j.	PROPN
iajs-3010	167	2	2018	2018	PROPN
iajs-3010	167	3	,	,	PUNCT
iajs-3010	167	4	11	11	NUM
iajs-3010	167	5	,	,	PUNCT
iajs-3010	167	6	32	32	NUM
iajs-3010	167	7	.	.	NOUN
iajs-3010	167	8	13	13	NUM
iajs-3010	167	9	.	.	X
iajs-3010	167	10	cassano	cassano	PROPN
iajs-3010	167	11	,	,	PUNCT
iajs-3010	167	12	n.	n.	NOUN
iajs-3010	167	13	;	;	PUNCT
iajs-3010	167	14	colombo	colombo	NOUN
iajs-3010	167	15	,	,	PUNCT
iajs-3010	167	16	d.	d.	PROPN
iajs-3010	167	17	;	;	PUNCT
iajs-3010	167	18	bellia	bellia	PROPN
iajs-3010	167	19	,	,	PUNCT
iajs-3010	167	20	g.	g.	PROPN
iajs-3010	167	21	;	;	PUNCT
iajs-3010	167	22	zagni	zagni	PROPN
iajs-3010	167	23	,	,	PUNCT
iajs-3010	167	24	e.	e.	PROPN
iajs-3010	167	25	;	;	PUNCT
iajs-3010	167	26	vena	vena	PROPN
iajs-3010	167	27	,	,	PUNCT
iajs-3010	167	28	g.a	g.a	PROPN
iajs-3010	167	29	.	.	PROPN
iajs-3010	167	30	gender	gender	NOUN
iajs-3010	167	31	-	-	PUNCT
iajs-3010	167	32	related	relate	VERB
iajs-3010	167	33	differences	difference	NOUN
iajs-3010	167	34	in	in	ADP
iajs-3010	167	35	chronic	chronic	ADJ
iajs-3010	167	36	urticaria	urticaria	NOUN
iajs-3010	167	37	.	.	PUNCT
iajs-3010	168	1	g.	g.	PROPN
iajs-3010	168	2	ital	ital	PROPN
iajs-3010	168	3	.	.	PUNCT
iajs-3010	169	1	di	di	PROPN
iajs-3010	169	2	dermatologia	dermatologia	PROPN
iajs-3010	169	3	e	e	PROPN
iajs-3010	169	4	venereol	venereol	PROPN
iajs-3010	169	5	.	.	PUNCT
iajs-3010	170	1	organo	organo	PROPN
iajs-3010	170	2	uff	uff	PROPN
iajs-3010	170	3	.	.	PUNCT
iajs-3010	170	4	soc	soc	PROPN
iajs-3010	170	5	.	.	PUNCT
iajs-3010	171	1	ital	ital	PROPN
iajs-3010	171	2	.	.	PUNCT
iajs-3010	171	3	di	di	PROPN
iajs-3010	171	4	dermatologia	dermatologia	PROPN
iajs-3010	171	5	e	e	PROPN
iajs-3010	171	6	sifilogr	sifilogr	PROPN
iajs-3010	171	7	.	.	PUNCT
iajs-3010	172	1	2015	2015	NUM
iajs-3010	172	2	,	,	PUNCT
iajs-3010	172	3	151	151	NUM
iajs-3010	172	4	,	,	PUNCT
iajs-3010	172	5	544–552	544–552	NUM
iajs-3010	172	6	.	.	NOUN
iajs-3010	173	1	14	14	NUM
iajs-3010	173	2	.	.	X
iajs-3010	173	3	hox	hox	PROPN
iajs-3010	173	4	,	,	PUNCT
iajs-3010	173	5	v.	v.	PROPN
iajs-3010	173	6	;	;	PUNCT
iajs-3010	173	7	desai	desai	PROPN
iajs-3010	173	8	,	,	PUNCT
iajs-3010	173	9	a.	a.	PROPN
iajs-3010	173	10	;	;	PUNCT
iajs-3010	173	11	bandara	bandara	PROPN
iajs-3010	173	12	,	,	PUNCT
iajs-3010	173	13	g.	g.	PROPN
iajs-3010	173	14	;	;	PUNCT
iajs-3010	173	15	gilfillan	gilfillan	NOUN
iajs-3010	173	16	,	,	PUNCT
iajs-3010	173	17	a.m.	a.m.	ADV
iajs-3010	173	18	;	;	PUNCT
iajs-3010	173	19	metcalfe	metcalfe	PROPN
iajs-3010	173	20	,	,	PUNCT
iajs-3010	173	21	d.d	d.d	PROPN
iajs-3010	173	22	.	.	PROPN
iajs-3010	173	23	;	;	PUNCT
iajs-3010	173	24	olivera	olivera	PROPN
iajs-3010	173	25	,	,	PUNCT
iajs-3010	173	26	a.	a.	NOUN
iajs-3010	173	27	estrogen	estrogen	NOUN
iajs-3010	173	28	increases	increase	VERB
iajs-3010	173	29	the	the	DET
iajs-3010	173	30	severity	severity	NOUN
iajs-3010	173	31	of	of	ADP
iajs-3010	173	32	anaphylaxis	anaphylaxis	NOUN
iajs-3010	173	33	in	in	ADP
iajs-3010	173	34	female	female	ADJ
iajs-3010	173	35	mice	mouse	NOUN
iajs-3010	173	36	through	through	ADP
iajs-3010	173	37	enhanced	enhance	VERB
iajs-3010	173	38	endothelial	endothelial	ADJ
iajs-3010	173	39	nitric	nitric	ADJ
iajs-3010	173	40	oxide	oxide	NOUN
iajs-3010	173	41	synthase	synthase	NOUN
iajs-3010	173	42	expression	expression	NOUN
iajs-3010	173	43	and	and	CCONJ
iajs-3010	173	44	nitric	nitric	ADJ
iajs-3010	173	45	oxide	oxide	NOUN
iajs-3010	173	46	production	production	NOUN
iajs-3010	173	47	.	.	PUNCT
iajs-3010	174	1	j.	j.	PROPN
iajs-3010	174	2	allergy	allergy	PROPN
iajs-3010	174	3	clin	clin	PROPN
iajs-3010	174	4	.	.	PUNCT
iajs-3010	175	1	immunol	immunol	PROPN
iajs-3010	175	2	.	.	PUNCT
iajs-3010	176	1	2015	2015	NUM
iajs-3010	176	2	,	,	PUNCT
iajs-3010	176	3	135	135	NUM
iajs-3010	176	4	,	,	PUNCT
iajs-3010	176	5	729–736	729–736	NUM
iajs-3010	176	6	.	.	PUNCT
iajs-3010	177	1	15	15	NUM
iajs-3010	177	2	.	.	PUNCT
iajs-3010	178	1	góra	góra	PROPN
iajs-3010	178	2	,	,	PUNCT
iajs-3010	178	3	a.	a.	NOUN
iajs-3010	178	4	;	;	PUNCT
iajs-3010	178	5	przybył	przybył	ADJ
iajs-3010	178	6	,	,	PUNCT
iajs-3010	178	7	m.	m.	NOUN
iajs-3010	178	8	;	;	PUNCT
iajs-3010	178	9	świętochowska	świętochowska	NUM
iajs-3010	178	10	,	,	PUNCT
iajs-3010	178	11	e.	e.	PROPN
iajs-3010	178	12	;	;	PUNCT
iajs-3010	178	13	machura	machura	PROPN
iajs-3010	178	14	,	,	PUNCT
iajs-3010	178	15	e.	e.	PROPN
iajs-3010	178	16	assessment	assessment	NOUN
iajs-3010	178	17	of	of	ADP
iajs-3010	178	18	selected	select	VERB
iajs-3010	178	19	interleukins	interleukin	NOUN
iajs-3010	178	20	(	(	PUNCT
iajs-3010	178	21	il-6	il-6	NOUN
iajs-3010	178	22	,	,	PUNCT
iajs-3010	178	23	il-17a	il-17a	PROPN
iajs-3010	178	24	,	,	PUNCT
iajs-3010	178	25	il-18	il-18	ADP
iajs-3010	178	26	,	,	PUNCT
iajs-3010	178	27	il-23	il-23	NOUN
iajs-3010	178	28	)	)	PUNCT
iajs-3010	178	29	and	and	CCONJ
iajs-3010	178	30	chemokines	chemokine	NOUN
iajs-3010	178	31	(	(	PUNCT
iajs-3010	178	32	rantes	rante	NOUN
iajs-3010	178	33	,	,	PUNCT
iajs-3010	178	34	ip-10	ip-10	PRON
iajs-3010	178	35	)	)	PUNCT
iajs-3010	178	36	in	in	ADP
iajs-3010	178	37	children	child	NOUN
iajs-3010	178	38	with	with	ADP
iajs-3010	178	39	acute	acute	ADJ
iajs-3010	178	40	and	and	CCONJ
iajs-3010	178	41	chronic	chronic	ADJ
iajs-3010	178	42	urticaria	urticaria	NOUN
iajs-3010	178	43	.	.	PUNCT
iajs-3010	179	1	2022	2022	NUM
iajs-3010	179	2	.	.	PUNCT
iajs-3010	180	1	ihjpas	ihjpas	PROPN
iajs-3010	180	2	.	.	PUNCT
iajs-3010	181	1	36(2)2023	36(2)2023	NUM
iajs-3010	181	2	42	42	NUM
iajs-3010	181	3	16	16	NUM
iajs-3010	181	4	.	.	PUNCT
iajs-3010	182	1	jang	jang	PROPN
iajs-3010	182	2	,	,	PUNCT
iajs-3010	182	3	j.-h	j.-h	PROPN
iajs-3010	182	4	.	.	PUNCT
iajs-3010	182	5	;	;	PUNCT
iajs-3010	182	6	yang	yang	PROPN
iajs-3010	182	7	,	,	PUNCT
iajs-3010	182	8	e.-m	e.-m	PROPN
iajs-3010	182	9	.	.	PUNCT
iajs-3010	182	10	;	;	PUNCT
iajs-3010	182	11	lee	lee	PROPN
iajs-3010	182	12	,	,	PUNCT
iajs-3010	182	13	y.	y.	PROPN
iajs-3010	182	14	;	;	PUNCT
iajs-3010	182	15	ye	ye	NOUN
iajs-3010	182	16	,	,	PUNCT
iajs-3010	182	17	y.-m	y.-m	NOUN
iajs-3010	182	18	.	.	PUNCT
iajs-3010	182	19	;	;	PUNCT
iajs-3010	182	20	moon	moon	PROPN
iajs-3010	182	21	,	,	PUNCT
iajs-3010	182	22	j.	j.	PROPN
iajs-3010	182	23	;	;	PUNCT
iajs-3010	182	24	ryu	ryu	PROPN
iajs-3010	182	25	,	,	PUNCT
iajs-3010	182	26	m.s	m.s	PROPN
iajs-3010	182	27	.	.	PROPN
iajs-3010	182	28	;	;	PUNCT
iajs-3010	182	29	park	park	NOUN
iajs-3010	182	30	,	,	PUNCT
iajs-3010	182	31	h.-s	h.-s	PROPN
iajs-3010	182	32	.	.	PUNCT
iajs-3010	182	33	increased	increase	VERB
iajs-3010	182	34	serum	serum	PROPN
iajs-3010	182	35	free	free	PROPN
iajs-3010	182	36	ige	ige	PROPN
iajs-3010	182	37	levels	level	NOUN
iajs-3010	182	38	in	in	ADP
iajs-3010	182	39	patients	patient	NOUN
iajs-3010	182	40	with	with	ADP
iajs-3010	182	41	chronic	chronic	ADJ
iajs-3010	182	42	spontaneous	spontaneous	ADJ
iajs-3010	182	43	urticaria	urticaria	NOUN
iajs-3010	182	44	(	(	PUNCT
iajs-3010	182	45	csu)	csu)	NOUN
iajs-3010	182	46	☆	☆	NOUN
iajs-3010	182	47	.	.	PUNCT
iajs-3010	183	1	world	world	PROPN
iajs-3010	183	2	allergy	allergy	PROPN
iajs-3010	183	3	organ	organ	PROPN
iajs-3010	183	4	.	.	PUNCT
iajs-3010	184	1	j.	j.	PROPN
iajs-3010	184	2	2022	2022	PROPN
iajs-3010	184	3	,	,	PUNCT
iajs-3010	184	4	15	15	NUM
iajs-3010	184	5	,	,	PUNCT
iajs-3010	184	6	100629	100629	NUM
iajs-3010	184	7	.	.	PUNCT
iajs-3010	185	1	17	17	NUM
iajs-3010	185	2	.	.	X
iajs-3010	185	3	yu	yu	PROPN
iajs-3010	185	4	,	,	PUNCT
iajs-3010	185	5	y.	y.	PROPN
iajs-3010	185	6	;	;	PUNCT
iajs-3010	185	7	blokhuis	blokhuis	NOUN
iajs-3010	185	8	,	,	PUNCT
iajs-3010	185	9	b.r.j	b.r.j	NOUN
iajs-3010	185	10	.	.	PUNCT
iajs-3010	185	11	;	;	PUNCT
iajs-3010	185	12	diks	dik	NOUN
iajs-3010	185	13	,	,	PUNCT
iajs-3010	185	14	m.a.p	m.a.p	NOUN
iajs-3010	185	15	.	.	PUNCT
iajs-3010	185	16	;	;	PUNCT
iajs-3010	185	17	keshavarzian	keshavarzian	PROPN
iajs-3010	185	18	,	,	PUNCT
iajs-3010	185	19	a.	a.	NOUN
iajs-3010	185	20	;	;	PUNCT
iajs-3010	185	21	garssen	garssen	NOUN
iajs-3010	185	22	,	,	PUNCT
iajs-3010	185	23	j.	j.	PROPN
iajs-3010	185	24	;	;	PUNCT
iajs-3010	185	25	redegeld	redegeld	VERB
iajs-3010	185	26	,	,	PUNCT
iajs-3010	185	27	f.a	f.a	PROPN
iajs-3010	185	28	.	.	PROPN
iajs-3010	185	29	functional	functional	ADJ
iajs-3010	185	30	inhibitory	inhibitory	NOUN
iajs-3010	185	31	siglec-6	siglec-6	PRON
iajs-3010	185	32	is	be	AUX
iajs-3010	185	33	upregulated	upregulate	VERB
iajs-3010	185	34	in	in	ADP
iajs-3010	185	35	human	human	ADJ
iajs-3010	185	36	colorectal	colorectal	ADJ
iajs-3010	185	37	cancer	cancer	NOUN
iajs-3010	185	38	-	-	PUNCT
iajs-3010	185	39	associated	associate	VERB
iajs-3010	185	40	mast	mast	NOUN
iajs-3010	185	41	cells	cell	NOUN
iajs-3010	185	42	.	.	PUNCT
iajs-3010	186	1	front	front	ADJ
iajs-3010	186	2	.	.	PUNCT
iajs-3010	187	1	immunol	immunol	NOUN
iajs-3010	187	2	.	.	PUNCT
iajs-3010	188	1	2018	2018	NUM
iajs-3010	188	2	,	,	PUNCT
iajs-3010	188	3	9	9	NUM
iajs-3010	188	4	,	,	PUNCT
iajs-3010	188	5	2138	2138	NUM
iajs-3010	188	6	.	.	PUNCT
iajs-3010	189	1	18	18	NUM
iajs-3010	189	2	.	.	X
iajs-3010	189	3	chuamanochan	chuamanochan	PROPN
iajs-3010	189	4	,	,	PUNCT
iajs-3010	189	5	m.	m.	NOUN
iajs-3010	189	6	;	;	PUNCT
iajs-3010	189	7	kulthanan	kulthanan	PROPN
iajs-3010	189	8	,	,	PUNCT
iajs-3010	189	9	k.	k.	PROPN
iajs-3010	189	10	;	;	PUNCT
iajs-3010	189	11	tuchinda	tuchinda	PROPN
iajs-3010	189	12	,	,	PUNCT
iajs-3010	189	13	p.	p.	NOUN
iajs-3010	189	14	;	;	PUNCT
iajs-3010	189	15	chularojanamontri	chularojanamontri	PROPN
iajs-3010	189	16	,	,	PUNCT
iajs-3010	189	17	l.	l.	PROPN
iajs-3010	189	18	;	;	PUNCT
iajs-3010	189	19	nuchkull	nuchkull	NOUN
iajs-3010	189	20	,	,	PUNCT
iajs-3010	189	21	p.	p.	NOUN
iajs-3010	189	22	clinical	clinical	ADJ
iajs-3010	189	23	features	feature	NOUN
iajs-3010	189	24	of	of	ADP
iajs-3010	189	25	chronic	chronic	ADJ
iajs-3010	189	26	urticaria	urticaria	NOUN
iajs-3010	189	27	in	in	ADP
iajs-3010	189	28	aging	age	VERB
iajs-3010	189	29	population	population	NOUN
iajs-3010	189	30	.	.	PUNCT
iajs-3010	190	1	asian	asian	PROPN
iajs-3010	190	2	pacific	pacific	PROPN
iajs-3010	190	3	j.	j.	PROPN
iajs-3010	190	4	allergy	allergy	PROPN
iajs-3010	190	5	immunol	immunol	NOUN
iajs-3010	190	6	.	.	PUNCT
iajs-3010	191	1	2016	2016	NUM
iajs-3010	191	2	,	,	PUNCT
iajs-3010	191	3	34	34	NUM
iajs-3010	191	4	.	.	NOUN
iajs-3010	191	5	19	19	NUM
iajs-3010	191	6	.	.	PUNCT
iajs-3010	192	1	hussein	hussein	PROPN
iajs-3010	192	2	ta	ta	PROPN
iajs-3010	192	3	,	,	PUNCT
iajs-3010	192	4	brakhas	brakhas	PROPN
iajs-3010	192	5	sa	sa	PROPN
iajs-3010	192	6	,	,	PUNCT
iajs-3010	193	1	dawood	dawood	PROPN
iajs-3010	193	2	sm	sm	PROPN
iajs-3010	193	3	.	.	PUNCT
iajs-3010	193	4	immunological	immunological	ADJ
iajs-3010	193	5	study	study	NOUN
iajs-3010	193	6	in	in	ADP
iajs-3010	193	7	patients	patient	NOUN
iajs-3010	193	8	with	with	ADP
iajs-3010	193	9	allergic	allergic	ADJ
iajs-3010	193	10	asthma	asthma	NOUN
iajs-3010	193	11	.	.	PUNCT
iajs-3010	194	1	research	research	NOUN
iajs-3010	194	2	journal	journal	PROPN
iajs-3010	194	3	of	of	ADP
iajs-3010	194	4	pharmaceutical	pharmaceutical	ADJ
iajs-3010	194	5	biological	biological	ADJ
iajs-3010	194	6	and	and	CCONJ
iajs-3010	194	7	chemical	chemical	NOUN
iajs-3010	194	8	sciences	science	NOUN
iajs-3010	194	9	.	.	PUNCT
iajs-3010	194	10	2018	2018	NUM
iajs-3010	194	11	,	,	PUNCT
iajs-3010	194	12	1,9(1),421	1,9(1),421	PROPN
iajs-3010	194	13	-	-	SYM
iajs-3010	194	14	7	7	NUM
iajs-3010	194	15	.	.	NOUN
iajs-3010	194	16	20	20	NUM
iajs-3010	194	17	.	.	PUNCT
iajs-3010	195	1	stone	stone	NOUN
iajs-3010	195	2	,	,	PUNCT
iajs-3010	195	3	k.d	k.d	PROPN
iajs-3010	195	4	.	.	PROPN
iajs-3010	195	5	;	;	PUNCT
iajs-3010	195	6	prussin	prussin	PROPN
iajs-3010	195	7	,	,	PUNCT
iajs-3010	195	8	c.	c.	PROPN
iajs-3010	195	9	;	;	PUNCT
iajs-3010	195	10	metcalfe	metcalfe	PROPN
iajs-3010	195	11	,	,	PUNCT
iajs-3010	195	12	d.d	d.d	PROPN
iajs-3010	195	13	.	.	PROPN
iajs-3010	195	14	ige	ige	PROPN
iajs-3010	195	15	,	,	PUNCT
iajs-3010	195	16	mast	mast	NOUN
iajs-3010	195	17	cells	cell	NOUN
iajs-3010	195	18	,	,	PUNCT
iajs-3010	195	19	basophils	basophils	PROPN
iajs-3010	195	20	,	,	PUNCT
iajs-3010	195	21	and	and	CCONJ
iajs-3010	195	22	eosinophils	eosinophil	VERB
iajs-3010	195	23	.	.	PUNCT
iajs-3010	196	1	j.	j.	PROPN
iajs-3010	196	2	allergy	allergy	PROPN
iajs-3010	196	3	clin	clin	PROPN
iajs-3010	196	4	.	.	PUNCT
iajs-3010	197	1	immunol	immunol	PROPN
iajs-3010	197	2	.	.	PUNCT
iajs-3010	198	1	2010	2010	NUM
iajs-3010	198	2	,	,	PUNCT
iajs-3010	198	3	125	125	NUM
iajs-3010	198	4	,	,	PUNCT
iajs-3010	198	5	s73	s73	NOUN
iajs-3010	198	6	–	–	PUNCT
iajs-3010	198	7	s80	s80	NOUN
iajs-3010	198	8	.	.	PUNCT
iajs-3010	199	1	21	21	NUM
iajs-3010	199	2	.	.	PUNCT
iajs-3010	200	1	ghaffar	ghaffar	PROPN
iajs-3010	200	2	,	,	PUNCT
iajs-3010	200	3	o.	o.	PROPN
iajs-3010	200	4	;	;	PUNCT
iajs-3010	200	5	lavigne	lavigne	PROPN
iajs-3010	200	6	,	,	PUNCT
iajs-3010	200	7	f.	f.	PROPN
iajs-3010	200	8	;	;	PUNCT
iajs-3010	200	9	kamil	kamil	PROPN
iajs-3010	200	10	,	,	PUNCT
iajs-3010	200	11	a.	a.	PROPN
iajs-3010	200	12	;	;	PUNCT
iajs-3010	200	13	renzi	renzi	PROPN
iajs-3010	200	14	,	,	PUNCT
iajs-3010	200	15	p.	p.	PROPN
iajs-3010	200	16	;	;	PUNCT
iajs-3010	200	17	hamid	hamid	PROPN
iajs-3010	200	18	,	,	PUNCT
iajs-3010	200	19	q.	q.	NOUN
iajs-3010	200	20	interleukin-6	interleukin-6	NUM
iajs-3010	200	21	expression	expression	NOUN
iajs-3010	200	22	in	in	ADP
iajs-3010	200	23	chronic	chronic	ADJ
iajs-3010	200	24	sinusitis	sinusitis	NOUN
iajs-3010	200	25	:	:	PUNCT
iajs-3010	200	26	colocalization	colocalization	NOUN
iajs-3010	200	27	of	of	ADP
iajs-3010	200	28	gene	gene	NOUN
iajs-3010	200	29	transcripts	transcript	NOUN
iajs-3010	200	30	to	to	AUX
iajs-3010	200	31	eosinophils	eosinophil	NOUN
iajs-3010	200	32	,	,	PUNCT
iajs-3010	200	33	macrophages	macrophage	NOUN
iajs-3010	200	34	,	,	PUNCT
iajs-3010	200	35	t	t	PROPN
iajs-3010	200	36	lymphocytes	lymphocyte	VERB
iajs-3010	200	37	,	,	PUNCT
iajs-3010	200	38	and	and	CCONJ
iajs-3010	200	39	mast	mast	NOUN
iajs-3010	200	40	cells	cell	NOUN
iajs-3010	200	41	.	.	PUNCT
iajs-3010	201	1	otolaryngol	otolaryngol	PROPN
iajs-3010	201	2	.	.	PUNCT
iajs-3010	202	1	neck	neck	NOUN
iajs-3010	202	2	surg	surg	PROPN
iajs-3010	202	3	.	.	PUNCT
iajs-3010	203	1	1998	1998	NUM
iajs-3010	203	2	,	,	PUNCT
iajs-3010	203	3	118	118	NUM
iajs-3010	203	4	,	,	PUNCT
iajs-3010	203	5	504–511	504–511	NUM
iajs-3010	203	6	.	.	PUNCT
iajs-3010	204	1	22	22	NUM
iajs-3010	204	2	.	.	PUNCT
iajs-3010	204	3	ertas	ertas	PROPN
iajs-3010	204	4	,	,	PUNCT
iajs-3010	204	5	r.	r.	PROPN
iajs-3010	204	6	;	;	PUNCT
iajs-3010	204	7	ozyurt	ozyurt	PROPN
iajs-3010	204	8	,	,	PUNCT
iajs-3010	204	9	k.	k.	PROPN
iajs-3010	204	10	;	;	PUNCT
iajs-3010	204	11	atasoy	atasoy	NOUN
iajs-3010	204	12	,	,	PUNCT
iajs-3010	204	13	m.	m.	NOUN
iajs-3010	204	14	;	;	PUNCT
iajs-3010	204	15	hawro	hawro	PROPN
iajs-3010	204	16	,	,	PUNCT
iajs-3010	204	17	t.	t.	PROPN
iajs-3010	204	18	;	;	PUNCT
iajs-3010	204	19	maurer	maurer	PROPN
iajs-3010	204	20	,	,	PUNCT
iajs-3010	204	21	m.	m.	VERB
iajs-3010	204	22	the	the	DET
iajs-3010	204	23	clinical	clinical	ADJ
iajs-3010	204	24	response	response	NOUN
iajs-3010	204	25	to	to	ADP
iajs-3010	204	26	omalizumab	omalizumab	NOUN
iajs-3010	204	27	in	in	ADP
iajs-3010	204	28	chronic	chronic	ADJ
iajs-3010	204	29	spontaneous	spontaneous	ADJ
iajs-3010	204	30	urticaria	urticaria	NOUN
iajs-3010	204	31	patients	patient	NOUN
iajs-3010	204	32	is	be	AUX
iajs-3010	204	33	linked	link	VERB
iajs-3010	204	34	to	to	ADP
iajs-3010	204	35	and	and	CCONJ
iajs-3010	204	36	predicted	predict	VERB
iajs-3010	204	37	by	by	ADP
iajs-3010	204	38	ige	ige	PROPN
iajs-3010	204	39	levels	level	NOUN
iajs-3010	204	40	and	and	CCONJ
iajs-3010	204	41	their	their	PRON
iajs-3010	204	42	change	change	NOUN
iajs-3010	204	43	.	.	PUNCT
iajs-3010	205	1	allergy	allergy	NOUN
iajs-3010	205	2	2018	2018	NUM
iajs-3010	205	3	,	,	PUNCT
iajs-3010	205	4	73	73	NUM
iajs-3010	205	5	,	,	PUNCT
iajs-3010	205	6	705–712	705–712	NUM
iajs-3010	205	7	.	.	NOUN
iajs-3010	205	8	23	23	NUM
iajs-3010	205	9	.	.	PUNCT
iajs-3010	206	1	di	di	PROPN
iajs-3010	206	2	lorenzo	lorenzo	PROPN
iajs-3010	206	3	,	,	PUNCT
iajs-3010	206	4	g.	g.	PROPN
iajs-3010	206	5	;	;	PUNCT
iajs-3010	206	6	mansueto	mansueto	VERB
iajs-3010	206	7	,	,	PUNCT
iajs-3010	206	8	p.	p.	NOUN
iajs-3010	206	9	;	;	PUNCT
iajs-3010	206	10	pacor	pacor	PROPN
iajs-3010	206	11	,	,	PUNCT
iajs-3010	206	12	m.l	m.l	PROPN
iajs-3010	206	13	.	.	PROPN
iajs-3010	206	14	;	;	PUNCT
iajs-3010	206	15	rizzo	rizzo	PROPN
iajs-3010	206	16	,	,	PUNCT
iajs-3010	206	17	m.	m.	NOUN
iajs-3010	206	18	;	;	PUNCT
iajs-3010	206	19	castello	castello	PROPN
iajs-3010	206	20	,	,	PUNCT
iajs-3010	206	21	f.	f.	PROPN
iajs-3010	206	22	;	;	PUNCT
iajs-3010	206	23	martinelli	martinelli	PROPN
iajs-3010	206	24	,	,	PUNCT
iajs-3010	206	25	n.	n.	PROPN
iajs-3010	206	26	;	;	PUNCT
iajs-3010	206	27	ditta	ditta	PROPN
iajs-3010	206	28	,	,	PUNCT
iajs-3010	206	29	v.	v.	PROPN
iajs-3010	206	30	;	;	PUNCT
iajs-3010	206	31	bianco	bianco	PROPN
iajs-3010	206	32	,	,	PUNCT
iajs-3010	206	33	c.	c.	PROPN
iajs-3010	206	34	lo	lo	PROPN
iajs-3010	206	35	;	;	PUNCT
iajs-3010	206	36	leto	leto	NOUN
iajs-3010	206	37	-	-	PUNCT
iajs-3010	206	38	barone	barone	PROPN
iajs-3010	206	39	,	,	PUNCT
iajs-3010	206	40	m.s	m.s	PROPN
iajs-3010	206	41	.	.	PROPN
iajs-3010	206	42	;	;	PUNCT
iajs-3010	206	43	d’alcamo	d’alcamo	PROPN
iajs-3010	206	44	,	,	PUNCT
iajs-3010	206	45	a.	a.	NOUN
iajs-3010	206	46	evaluation	evaluation	NOUN
iajs-3010	206	47	of	of	ADP
iajs-3010	206	48	serum	serum	NOUN
iajs-3010	206	49	s	s	PROPN
iajs-3010	206	50	-	-	PUNCT
iajs-3010	206	51	ige	ige	ADJ
iajs-3010	206	52	/	/	SYM
iajs-3010	206	53	total	total	ADJ
iajs-3010	206	54	ige	ige	PROPN
iajs-3010	206	55	ratio	ratio	NOUN
iajs-3010	206	56	in	in	ADP
iajs-3010	206	57	predicting	predict	VERB
iajs-3010	206	58	clinical	clinical	ADJ
iajs-3010	206	59	response	response	NOUN
iajs-3010	206	60	to	to	ADP
iajs-3010	206	61	allergen	allergen	NOUN
iajs-3010	206	62	-	-	PUNCT
iajs-3010	206	63	specific	specific	ADJ
iajs-3010	206	64	immunotherapy	immunotherapy	NOUN
iajs-3010	206	65	.	.	PUNCT
iajs-3010	207	1	j.	j.	PROPN
iajs-3010	207	2	allergy	allergy	PROPN
iajs-3010	207	3	clin	clin	PROPN
iajs-3010	207	4	.	.	PUNCT
iajs-3010	208	1	immunol	immunol	PROPN
iajs-3010	208	2	.	.	PUNCT
iajs-3010	209	1	2009	2009	NUM
iajs-3010	209	2	,	,	PUNCT
iajs-3010	209	3	123	123	NUM
iajs-3010	209	4	,	,	PUNCT
iajs-3010	209	5	1103–1110	1103–1110	NUM
iajs-3010	209	6	.	.	PUNCT
iajs-3010	210	1	24	24	NUM
iajs-3010	210	2	.	.	PUNCT
iajs-3010	211	1	liu	liu	PROPN
iajs-3010	211	2	,	,	PUNCT
iajs-3010	211	3	z.	z.	PROPN
iajs-3010	211	4	;	;	PUNCT
iajs-3010	211	5	al	al	PROPN
iajs-3010	211	6	-	-	PUNCT
iajs-3010	211	7	quran	quran	PROPN
iajs-3010	211	8	,	,	PUNCT
iajs-3010	211	9	l.	l.	PROPN
iajs-3010	211	10	;	;	PUNCT
iajs-3010	211	11	tong	tong	PROPN
iajs-3010	211	12	,	,	PUNCT
iajs-3010	211	13	j.	j.	PROPN
iajs-3010	211	14	;	;	PUNCT
iajs-3010	211	15	cao	cao	PROPN
iajs-3010	211	16	,	,	PUNCT
iajs-3010	211	17	x.	x.	NOUN
iajs-3010	211	18	analysis	analysis	NOUN
iajs-3010	211	19	of	of	ADP
iajs-3010	211	20	clinical	clinical	ADJ
iajs-3010	211	21	features	feature	NOUN
iajs-3010	211	22	and	and	CCONJ
iajs-3010	211	23	inflammatory	inflammatory	ADJ
iajs-3010	211	24	related	related	ADJ
iajs-3010	211	25	molecules	molecule	NOUN
iajs-3010	211	26	with	with	ADP
iajs-3010	211	27	the	the	DET
iajs-3010	211	28	disease	disease	NOUN
iajs-3010	211	29	in	in	ADP
iajs-3010	211	30	acute	acute	ADJ
iajs-3010	211	31	infectious	infectious	ADJ
iajs-3010	211	32	urticaria	urticaria	NOUN
iajs-3010	211	33	.	.	PUNCT
iajs-3010	212	1	2022	2022	NUM
iajs-3010	212	2	.	.	PUNCT
iajs-3010	213	1	25	25	NUM
iajs-3010	213	2	.	.	PUNCT
iajs-3010	213	3	wang	wang	PROPN
iajs-3010	213	4	,	,	PUNCT
iajs-3010	213	5	s.	s.	PROPN
iajs-3010	213	6	;	;	PUNCT
iajs-3010	213	7	liu	liu	PROPN
iajs-3010	213	8	,	,	PUNCT
iajs-3010	213	9	y.	y.	PROPN
iajs-3010	213	10	;	;	PUNCT
iajs-3010	213	11	wang	wang	PROPN
iajs-3010	213	12	,	,	PUNCT
iajs-3010	213	13	j.	j.	PROPN
iajs-3010	213	14	;	;	PUNCT
iajs-3010	213	15	zhang	zhang	PROPN
iajs-3010	213	16	,	,	PUNCT
iajs-3010	213	17	j.	j.	PROPN
iajs-3010	213	18	clinical	clinical	PROPN
iajs-3010	213	19	efficacy	efficacy	PROPN
iajs-3010	213	20	of	of	ADP
iajs-3010	213	21	levocetirizine	levocetirizine	NOUN
iajs-3010	213	22	combined	combine	VERB
iajs-3010	213	23	with	with	ADP
iajs-3010	213	24	ebastine	ebastine	NOUN
iajs-3010	213	25	in	in	ADP
iajs-3010	213	26	the	the	DET
iajs-3010	213	27	treatment	treatment	NOUN
iajs-3010	213	28	of	of	ADP
iajs-3010	213	29	chronic	chronic	ADJ
iajs-3010	213	30	urticaria	urticaria	NOUN
iajs-3010	213	31	and	and	CCONJ
iajs-3010	213	32	their	their	PRON
iajs-3010	213	33	effect	effect	NOUN
iajs-3010	213	34	on	on	ADP
iajs-3010	213	35	serum	serum	NOUN
iajs-3010	213	36	cytokines	cytokine	NOUN
iajs-3010	213	37	.	.	PUNCT
iajs-3010	214	1	int	int	NOUN
iajs-3010	215	1	j	j	PROPN
iajs-3010	215	2	clin	clin	PROPN
iajs-3010	215	3	exp	exp	PROPN
iajs-3010	215	4	med	med	PROPN
iajs-3010	215	5	2019	2019	NUM
iajs-3010	215	6	,	,	PUNCT
iajs-3010	215	7	12	12	NUM
iajs-3010	215	8	,	,	PUNCT
iajs-3010	215	9	11675–11683	11675–11683	NUM
iajs-3010	215	10	.	.	PUNCT
iajs-3010	216	1	26	26	NUM
iajs-3010	216	2	.	.	PUNCT
iajs-3010	216	3	fujii	fujii	PROPN
iajs-3010	216	4	,	,	PUNCT
iajs-3010	216	5	k.	k.	PROPN
iajs-3010	216	6	;	;	PUNCT
iajs-3010	216	7	konishi	konishi	PROPN
iajs-3010	216	8	,	,	PUNCT
iajs-3010	216	9	k.	k.	PROPN
iajs-3010	216	10	;	;	PUNCT
iajs-3010	216	11	kanno	kanno	PROPN
iajs-3010	216	12	,	,	PUNCT
iajs-3010	216	13	y.	y.	PROPN
iajs-3010	216	14	;	;	PUNCT
iajs-3010	216	15	ohgou	ohgou	PROPN
iajs-3010	216	16	,	,	PUNCT
iajs-3010	216	17	n.	n.	NOUN
iajs-3010	216	18	acute	acute	PROPN
iajs-3010	216	19	urticaria	urticaria	NOUN
iajs-3010	216	20	with	with	ADP
iajs-3010	216	21	elevated	elevated	ADJ
iajs-3010	216	22	circulating	circulate	VERB
iajs-3010	216	23	interleukin‐6	interleukin‐6	NOUN
iajs-3010	216	24	is	be	AUX
iajs-3010	216	25	resistant	resistant	ADJ
iajs-3010	216	26	to	to	ADP
iajs-3010	216	27	anti‐histamine	anti‐histamine	NOUN
iajs-3010	216	28	treatment	treatment	NOUN
iajs-3010	216	29	.	.	PUNCT
iajs-3010	217	1	j.	j.	PROPN
iajs-3010	217	2	dermatol	dermatol	PROPN
iajs-3010	217	3	.	.	PUNCT
iajs-3010	218	1	2001	2001	NUM
iajs-3010	218	2	,	,	PUNCT
iajs-3010	218	3	28	28	NUM
iajs-3010	218	4	,	,	PUNCT
iajs-3010	218	5	248–250	248–250	NUM
iajs-3010	218	6	.	.	PUNCT
iajs-3010	219	1	27	27	NUM
iajs-3010	219	2	.	.	PUNCT
iajs-3010	220	1	papadopoulos	papadopoulos	PROPN
iajs-3010	220	2	,	,	PUNCT
iajs-3010	220	3	j.	j.	PROPN
iajs-3010	220	4	;	;	PUNCT
iajs-3010	220	5	karpouzis	karpouzi	NOUN
iajs-3010	220	6	,	,	PUNCT
iajs-3010	220	7	a.	a.	NOUN
iajs-3010	220	8	;	;	PUNCT
iajs-3010	220	9	tentes	tente	NOUN
iajs-3010	220	10	,	,	PUNCT
iajs-3010	220	11	j.	j.	PROPN
iajs-3010	220	12	;	;	PUNCT
iajs-3010	220	13	kouskoukis	kouskoukis	PROPN
iajs-3010	220	14	,	,	PUNCT
iajs-3010	220	15	c.	c.	PROPN
iajs-3010	220	16	assessment	assessment	NOUN
iajs-3010	220	17	of	of	ADP
iajs-3010	220	18	interleukins	interleukin	NOUN
iajs-3010	220	19	il-4	il-4	PROPN
iajs-3010	220	20	,	,	PUNCT
iajs-3010	220	21	il-6	il-6	NOUN
iajs-3010	220	22	,	,	PUNCT
iajs-3010	220	23	il-8	il-8	NOUN
iajs-3010	220	24	,	,	PUNCT
iajs-3010	220	25	il-10	il-10	NOUN
iajs-3010	220	26	in	in	ADP
iajs-3010	220	27	acute	acute	ADJ
iajs-3010	220	28	urticaria	urticaria	NOUN
iajs-3010	220	29	.	.	PUNCT
iajs-3010	221	1	j.	j.	PROPN
iajs-3010	221	2	clin	clin	PROPN
iajs-3010	221	3	.	.	PUNCT
iajs-3010	222	1	med	med	PROPN
iajs-3010	222	2	.	.	PUNCT
iajs-3010	223	1	res	re	NOUN
iajs-3010	223	2	.	.	PROPN
iajs-3010	223	3	2014	2014	NUM
iajs-3010	223	4	,	,	PUNCT
iajs-3010	223	5	6	6	NUM
iajs-3010	223	6	,	,	PUNCT
iajs-3010	223	7	133	133	NUM
iajs-3010	223	8	.	.	PUNCT
iajs-3010	223	9	28	28	NUM
iajs-3010	223	10	.	.	PUNCT
iajs-3010	224	1	gokcek	gokcek	PROPN
iajs-3010	224	2	ge	ge	PROPN
iajs-3010	224	3	,	,	PUNCT
iajs-3010	224	4	solak	solak	ADJ
iajs-3010	224	5	eö	eö	NOUN
iajs-3010	224	6	,	,	PUNCT
iajs-3010	224	7	çölgeçen	çölgeçen	PROPN
iajs-3010	224	8	e.	e.	PROPN
iajs-3010	225	1	the	the	DET
iajs-3010	225	2	effect	effect	NOUN
iajs-3010	225	3	of	of	ADP
iajs-3010	225	4	omalizumab	omalizumab	NOUN
iajs-3010	225	5	treatment	treatment	NOUN
iajs-3010	225	6	on	on	ADP
iajs-3010	225	7	hematological	hematological	ADJ
iajs-3010	225	8	inflammatory	inflammatory	ADJ
iajs-3010	225	9	parameters	parameter	NOUN
iajs-3010	225	10	and	and	CCONJ
iajs-3010	225	11	immunoglobulin	immunoglobulin	NOUN
iajs-3010	225	12	e	e	PROPN
iajs-3010	225	13	levels	level	NOUN
iajs-3010	225	14	in	in	ADP
iajs-3010	225	15	patients	patient	NOUN
iajs-3010	225	16	with	with	ADP
iajs-3010	225	17	chronic	chronic	ADJ
iajs-3010	225	18	spontaneous	spontaneous	ADJ
iajs-3010	225	19	urticaria	urticaria	NOUN
iajs-3010	225	20	.	.	PUNCT
iajs-3010	226	1	turkish	turkish	ADJ
iajs-3010	226	2	journal	journal	NOUN
iajs-3010	226	3	of	of	ADP
iajs-3010	226	4	dermatology	dermatology	NOUN
iajs-3010	226	5	.	.	PUNCT
iajs-3010	227	1	2021	2021	NUM
iajs-3010	227	2	,	,	PUNCT
iajs-3010	227	3	1;15(4):95	1;15(4):95	NUM
iajs-3010	227	4	.	.	NOUN
iajs-3010	227	5	29	29	NUM
iajs-3010	227	6	.	.	PUNCT
iajs-3010	228	1	celik	celik	VERB
iajs-3010	228	2	e	e	PROPN
iajs-3010	228	3	,	,	PUNCT
iajs-3010	228	4	;	;	PUNCT
iajs-3010	228	5	dirican	dirican	PROPN
iajs-3010	228	6	e.	e.	PROPN
iajs-3010	228	7	;	;	PUNCT
iajs-3010	228	8	can	can	AUX
iajs-3010	228	9	we	we	PRON
iajs-3010	228	10	predict	predict	VERB
iajs-3010	228	11	the	the	DET
iajs-3010	228	12	duration	duration	NOUN
iajs-3010	228	13	of	of	ADP
iajs-3010	228	14	treatment	treatment	NOUN
iajs-3010	228	15	requirement	requirement	NOUN
iajs-3010	228	16	by	by	ADP
iajs-3010	228	17	complete	complete	ADJ
iajs-3010	228	18	blood	blood	NOUN
iajs-3010	228	19	count	count	NOUN
iajs-3010	228	20	in	in	ADP
iajs-3010	228	21	chronic	chronic	ADJ
iajs-3010	228	22	spontaneous	spontaneous	ADJ
iajs-3010	228	23	urticaria	urticaria	NOUN
iajs-3010	228	24	patients	patient	NOUN
iajs-3010	228	25	receiving	receive	VERB
iajs-3010	228	26	omalizumab	omalizumab	NOUN
iajs-3010	228	27	?	?	PUNCT
iajs-3010	228	28	.	.	PUNCT
iajs-3010	229	1	dicle	dicle	PROPN
iajs-3010	229	2	tıp	tıp	PROPN
iajs-3010	229	3	dergisi	dergisi	PROPN
iajs-3010	229	4	.	.	PROPN
iajs-3010	230	1	2020	2020	NUM
iajs-3010	230	2	,	,	PUNCT
iajs-3010	230	3	1;47(3),568	1;47(3),568	NUM
iajs-3010	230	4	-	-	SYM
iajs-3010	230	5	77	77	NUM
iajs-3010	230	6	.	.	PUNCT